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ABSTRACT 
A large sub-family of cytokine proteins, termed chemokines, are important mediators of 
immune cell communication and primarily function to direct the migration of cells 
during immune responses. The murine homologue of the human chemokine interferon-
inducible T cell alpha fhemoattractant (I-TAC) was isolated by a cDNA subtraction 
technique from a dendritic cell line differentiated with IFN-y and TNF-a. Murine I-
T AC is 67% homologous to Hul-TAC and ~35% homologous to the murine 
chemokines Crg-2 and MuMig respectively. There are four cysteine residues with the 
first two being separated by one amino acid, and as a result is a member of the non-ELR 
CXC chemokine family. The open reading frame is 100 amino acids long with a 
predicted 21 amino acid leader sequence. The predicted leader sequence coincides with 
the leader sequence for Hul-TAC and suggests murine I-TAC is a 79 amino acid residue 
mature protein. By using a baculovirus protein expression system, it was demonstrated 
that the isolated murine I-TAC cDNA is functional and attracts activated splenocytes. 
Using semi-quantitative RT-PCR analysis of two cytokine-stimulated murine dendritic 
cell lines, MTHC-D2 and JAWS II, as well as Con A activated splenocytes from a panel 
.of knockout mice, it was elucidated that IFN-y and anti-CD40 Ab separately, and in 
synergy, enhance murine I-TAC expression. IFN-y-regulated I-TAC expression is 
primarily mediated through IRF-1 activation and IFN-al~ pathway down regulates 
murine I-TAC mRNA levels. Expression of I-TAC was reduced in the DC lines when 
exposed to the cytokine, IL-4. This suggests that I-TAC is primarily involved in cell 
mediated immune responses. 
Since I-TAC is secreted from IFN-y stimulated DCs the level of murine I-TAC mRNA 
expression was assessed by RT-PCR in different disease models. Expression levels of I-
T AC increased in correlation with respiratory syncytial viremia and influenza viremia 
during infection. The expression of I-TAC after IFN-y stimulation and expression 
during viral infection further verifies that I-TAC has a function in cell mediated immune 
responses, probably by recruiting CXCR3+ T cells. In contrast however, expression of I-
T AC was not detected by RT-PCR during a vaccinia virus infection, whereas 
previously, expression of the homologous chemokines Mig and Crg-2 have been 
. 
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detected (Mahalingam et al., 2000; Mahalingam and Karupiah, 2000). This suggests 
that vaccinia virus may have a mechanism to inhibit I-TAC expression. 
The expression of I-TAC was also assessed in the CNS of wild type and IFN-y R-1- mice 
during the myelin oligodendrocyte (MOG35_55) peptide autoimmune disease model, 
experimental autoimmune encephalomyelitis (EAE). Peak I-TAC expression was 
detected in wild type mice on day 14 when the mice begin to recover, whereas no 
increase in I-TAC expression was detected in IFN-y R-1- mice which develop severe 
EAE and die. These expression studies do not provide an understanding to the 
functional role of I-TAC during EAE, however, previously it has been shown that 
antibodies to a functional domain of CXCR3 protect mice from EAE (Arimilli et al., 
2000). It is therefore likely that murine I-TAC may act to enhance neuroinflammatory 
processes and exacerbate EAE disease. 
The last disease models investigated were two forms of rejected and non-rejected 
transplantation grafts. Murine I-TAC was expressed early during both rejected and non-
rejected allograft transplants, indicating that I-TAC may be expressed as a result of 
general damage following transplantation surgery rather than as a direct result of 
specific allograft rejection. The study analyzing tissues from rejected xenograft 
transplantation showed varying results throughout the time course, which may indicate 
differing levels of inflammation and cellular recruitment in different mice. Although the 
result does not appear to show a clear trend of I-TAC expression in the xenograft 
transplantation model it does show that cells expressing I-TAC migrate into the graft. 
These cells may be DCs or other APCs, which then express I-TAC in order to recruit T 
cells. 
To investigate the biological role of I-TAC in vivo a recombinant vacc1n1a virus 
encoding this chemokine (rVV I-TAC) was constructed. The recombinant virus was 
attenuated in vivo compared to the control virus (VV-WR). The recruitment of 
mononuclear cells into the site of infection was higher and occurred earlier in mice 
challenged with rVV I-TAC than those infected with the control virus. Subsequently, 
both C57BL/6 and athymic Swiss nude mice inoculated with rVV I-TAC were able to 
resolve infection significantly more successfully than those infected with VV-WR. 
.. 
VII 
The characteristics of murine I-TAC suggest it is an important mediator of immune cell 
communication. The research presented here has extended the know ledge about this 
potent chemokine and may subsequently augment the development of vaccines and 
therapeutics containing chemokines such as I-TAC to improve their effectiveness. 
... 
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CHAPTER 1. INTRODUCTION AND LITERATURE REVIEW. 
1.1 General overview 
There are many cells of the immune system, each carrying out different functions to 
overcome infection and keep the host in a healthy state. Host defense mechanisms are 
numerous and range from relatively primitive, constitutively expressed, non-specific 
defenses, to sophisticated adaptive mechanisms that are specifically induced in response 
to foreign antigen (invading pathogens). The process of immune cell activation requires 
recognition of invariant molecular structures common to a variety of pathogens by 
innate immune cells; these are called pathogen-associated molecular patterns (PAMPs). 
Well known examples of PAMPs include lipopolysaccharides and teichoic acids, both 
shared by a variety of bacteria, and unmethylated CpG motifs found in microbial but not 
mammalian DNA. Host organisms have evolved cellular receptors with broad 
specificities that can recognize P AMPs from infectious microbes (Kopp and Medzhitov, 
1999; Muzio and Mantovani, 2000). The result of P AMP recognition is the activation of 
the innate, non-specific immune cells such as natural killer cells (NKs), mast cells, 
macrophages, eosinophils, neutrophils and dendritic cells (DCs). Although the role of 
innate immunity was originally considered to primarily defend the host early in 
infection, it is now clear that there is an important reciprocal relationship between innate 
and adaptive immune responses throughout an infection. Antigen presenting cells 
(APCs), primarily DCs, as well as cell to cell communication mediators, including 
cytokine and chemokine proteins, have an essential role in orchestrating this process as 
well as determining the type of effector response that is ultimately generated towards a 
pathogen. These cytokines and chemokines are produced at sites of infection following 
the pathogens interaction with innate immune cells or from damaged tissues. The 
production of cytokines and chemokines not only further activates the innate immune 
cell population but also drives the recruitment and activation of adaptive immune cells 
to eliminate the invading pathogen (reviewed in Banyer et al., 2000). The adaptive 
immune response consists of pathogen-specific T- and B- lymphocyte responses that are 
stimulated through their interactions with APCs like macrophages and DCs. 
The nature of the immune response that develops is determined by the nature of the 
invading pathogen and its affect on the infected tissue and innate immune cells. This 
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interaction determines the type of cytokines, chemokines and other mediators that are 
released into the microenvironment situated around the site of infection. In turn, these 
released factors stimulate innate immune cells, including immature DCs, to develop 
specific immunoregulatory properties that reflect the identity and state of infection, and 
subsequently direct the adaptive immune response towards the invading pathogen 
(reviewed in Baggiolini et al., 1997; Rollins, 1997). Thus, both cytokines and 
chemokines are crucial elements in the progression and regulation of the immune 
response. 
1.2 Cytokines - an overview 
Cytokines are small protein messengers that regulate the development and expression of 
a wide range of immune responses. A subfamily of cytokines, termed chemokines, 
specifically control trafficking of immune cells. As such, both cytokines and 
chemokines are critical in the regulation of cells that participate in both innate and 
adaptive immune responses. Cytokines and chemokines may act both in highly 
localized environments but also in a systemic manner, and they may, themselves, 
directly mediate anti-pathogen effects (reviewed in Banyer et al., 2000). 
Cytokines may be grouped into two broad categories, firstly, those that act to stimulate 
T helper cell (Th) type one (Thl), cell mediated immune (CMI) responses, which 
mainly protect against intracellular viral, bacterial, fungal and protozoan pathogens, 
(e.g. interleukin-12, IL-12, and interferon gamma, IFN-y, cytokines). The second group 
of cytokines stimulate type two (Th2) , humoral immune (HI) responses involved in 
protection against extra cellular infections such as parasites and extracellular bacteria 
(including interleukins 4, 5, 6, 10 and 13). 
The cytokine microenvironment initiated at the site of infection also influences innate 
cell populations, including macrophages, natural killer cells (NKs), and DCs, which 
subsequently influence the CMI or HI adaptive immune responses. This cytokine 
microenvironment is therefore a key determinant for developmental pathway of the 
precursor cells and the overall immune response (O'Garra, 1998). For example, viral 
pathogens usually stimulate innate immune cells to produce factors that promote 
development of Thl cells. Thus, DC and macrophages commonly secrete large 
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amounts of IL-12, and subsequently NK cells produce IFN-y, the effect of which is to 
drive Th0 cells to differentiate into Th 1 cells. Conversely, the early production of IL-4 
for example, by a variety of innate cell types in response to extracellular pathogens such 
as helminths, directs Th2 cell development (Seder and Paul, 1994; Bendelac et al., 
1997). 
To ensure inflammatory cytokine-mediated immune responses do not unintentionally 
damage the host, the immune system has protective mechanisms. An example of this is 
the reciprocal cross-regulatory effects of Thl and Th2 effector cytokines, such as IFN-y 
and IL-4 respectively. In addition to this, Thl and Th2 cytokines can have down 
regulatory effects on cells of the innate immune system. As a result the innate and 
adaptive immune responses are intimately linked and controlled by sets of cytokines 
and their respective receptors which act to generate the most effective form of immunity 
suitable for protection against each given pathogen (Banyer et al., 2000). 
1.2.1 IFN-y 
The interferon (IFN) cytokines were initially associated with antiviral activity and are a 
key element in CMI (reviewed in Stark et al., 1998). They are also associated with a 
multitude of other functions including the inhibition of cell growth and proliferation and 
regulation of cell apoptosis, and numerous effects on the immune system. In addition, 
IFNs regulate protein expression and processing necessary for encoding the major 
histocompatibility complex (MHC), induction of CD4+ T helper cell phenotype 
development, macrophage activation, and also chemokine and cytokine induction and 
inhibition. The IFN s are subdivided into two main families, type I IFNs (also known as 
IFN-cx/~) and type II IFN (IFN-y). The type I IFNs have four subfamilies, these being 
IFN-cx, IFN-~, IFN-co, and IFN-"r whereas there is only IFN-)' in the type II family 
(Vilcek and Oliveira, 1994; Stark et al., 1998; Platanias and Fish, 1999). Although both 
classes of IFNs exhibit antiviral activity, the IFN-cx/~ class are more widely expressed 
and play an important role in the innate immune response. IFN-)', however, tends to 
have an important role in the activity of the NK cell, innate immune responses and the 
Thl type adaptive immune response (Schindler, 1999). 
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1.2.2 IL-12 
The predominant role of IL-12 as a determinant of Th 1 cell development is now well 
established (reviewed in Hsieh et al., l 993; Trinchieri, 1995). IL-12 signals primarily 
through the transcription factors, signal transducer and activator of transcription-3 
(ST A T3) and ST AT 4 (Jacobson et al., l 995; Szabo et al., 1995), although the recent 
discovery of T-bet provides clear evidence for further important lineage-specific 
transcription factors in Thl cell development (Szabo et al., 2000). T-bet, which belongs 
to the T-box family of transcription factors, is rapidly and selectively induced in 
developing Thl cells (but not Th2 cells). This in turn, upregulates the expression of 
IFN-y. This factor is inducible by IL-12, a process enhanced by IL-18 and diverts naive 
T cells into the Thl differentiation pathway. T-bet may even convert committed Th2 
cells into Thl cells, at least partly via repression of IL-4 and IL-5 gene expression 
(Szabo et al., 2000). 
Functional receptors for IL-12 are expressed on recently activated and committed naive 
T cells and Thl cells, but are lost during Th2 cell differentiation. The unresponsiveness 
of Th2 cells to IL-12 may thus be explained by down regulation of the IL-12 receptor 
~2 chain (IL-12R~2) by IL-4. Conversely, IFN-y acts to upregulate IL-12R~2 
expression by Thl cells and counteracts the activity of IL-4 in this respect (Rogge et al., 
1997; Szabo et al., 1997). This shows that once the immune response pathway has been 
determined, T cells subsequently act to amplify the cytokine signals that enhance the 
required immune cells while also down regulating the other, unnecessary arm of the T 
cell immune response. 
1.2.3 IL-4 
Just as IL-12 is a key factor in Thl cell lineage commitment, IL-4 appears to play a 
similar role in initiating Th2 cell development (reviewed in Nelms et al., 1999). Indeed, 
the influence of IL-4 on naive Th cells appears to be dominant over that of IL-12, such 
that threshold levels of IL-4 at the point of induction of an immune response will lead to 
Th2 cell development and up-regulated IL-4 production (Le Gros et al., l 990; Seder and 
Paul, 1994 ). IL-4 signals through the transcription factor ST AT6 to upregulate its own 
expression. However, STAT activation is a transient event and is unlikely, by itself, to 
determine Th cell phenotype development as this is a process which takes several days 
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(Abbas et al., 1996; Lederer et al., 1996; O'Garra, 1998). Additional lineage-specific 
transcription factors also appear to be required; c-Maf increases IL-4 expression (Ho et 
al., 1996), whilst GATA-3 induces expression of several Th2 factors in both developing 
and committed T cells and may inhibit IFN-"{ secretion (Zhang et al., 1997; Zheng and 
Flavell, 1997). The source of IL-4 early in the immune response, which is important for 
Th2 cell differentiation, remains controversial. N on-T cells, including DCs, mast cells, 
basophils and eosinophils are prime candidates, as are CD4+ and CD4-CD8- T cells of 
the NKl + subset and LACK (Leishmania homologue of receptors for activated kinase 
C)-specific CD4+ T cells expressing V~4 and V~8 TCR (Seder and Paul, 1994; Julia et 
al., 1996; Bendelac et al., 1997). Recently, it has been found that certain pathogens 
trigger IL-4 secretion from DCs themselves (d'Ostiani et al., 2000). In addition to this, 
a key role for NKl + cells in Th2 cell development was suggested by their capacity to 
produce large amounts of IL-4 immediately following activation (Bendelac et al., 
1997). However, mice deficient in CD 1, the selecting antigen for NKl + cells, were able 
to mount Th2-type responses in the absence of this cell subset (Smiley et al., 1997). 
Whilst IL-4 is a clearly a critical mediator of Th2 differentiation, the mechanisms 
underlying its activity are yet to be fully understood. 
1.2.4 Tumour necrosis factor (TNF) 
There are four major TNF family members, TNF-a, LT-a, LT-~ and LIGHT, which 
interact with four receptors termed p55 TNF receptor, p75 TNF receptor, the 
lymphotoxin ~ receptor (LT-~R) and the herpes virus entry mediator (HVEM) 
(reviewed in Wallach et al., 1999). The members of the TNF family have a wide range 
of functions during both innate and adaptive immune responses including regulating of 
inflammatory responses and induction of apoptosis (reviewed in Wallach et al., 1999). 
Dramatic increases of TNF-a have been observed after brain injury, such as a stroke or 
head trauma (Bruce et al., 1996). By using TNF-cx receptor knockout mice, it was 
demonstrated that TNF protects neurons by stimulating antioxidant pathways, especially 
the antioxidant enzyme superoxide dismutase (Bruce et al., 1996). In contrast TNF-cx 
has been demonstrated to be critical in inducing neuronal apoptosis during endotoxic 
shock (de Bock et al., 1998). In this latter study the presence of oxygen radicals, 
normally inhibited by antioxidant factors, were also necessary for cell death. These 
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studies indicate that the interaction between TNF and antioxidant pathway activity is an 
essential determinant of neuronal apoptosis. 
There are many more cytokines expressed throughout the body (e.g. IL-1 through to IL-
18, TGF-a, TGF-~ and GM-CSF) and while the role of many of these have been well 
characterised, the exact roles of the more recently identified cytokines are still being 
established. Many can act in concert with each other or function antagonistically. The 
importance of each cytokine may vary depending on specific diseases, for example IL-5 
appears to be important during asthma and lung allergies. 
1.3 Chemokines; A subfamily of cytokines 
Cells of the immune system need to identify and migrate to sites of infection. A large 
sub-family of cytokine proteins, termed chemokines, function to direct the migration of 
cells during immune responses. This occurs by the release of chemokines from infected 
cells and activated bystander cells, which disperse and interact with receptors expressed 
on immune cells in the vicinity. The first chemokine to be identified was during the 
mid- l 960s and is now termed platelet factor 4 (PF4 ). However, it was not until studies 
examining inflammation and cell migration that the second chemokine, interleukin-8 
(IL-8), was cloned and the chemokine family established (Schmid and Weissmann, 
1987; Walz et al., 1987; Gale and McColl, 1999). Research into chemokines, moreover, 
still did not develop momentum for another eight years. In 1995 Cocchi et al., 
demonstrated that three chemokines, known as RANTES, MIP-1 a, and MIP-1 ~' could 
inhibit the human immuno-deficiency virus (HIV) which causes the Acquired Immune 
Deficiency Syndrome, or AIDS (Cocchi et al., 1995). Shortly after, it was demonstrated 
that HIV required the presence of a chemokine receptor to gain entry into host cells to 
initiate infection which significantly increased chemokine research (Alkhatib et al., 
1996; Bates, 1996; Bleul et al., 1996; Dragic et al., 1996; Feng et al., 1996; Oberlin et 
al., 1996). Since then, a large number of chemokines have been identified and 
characterised which function throughout the body. Approximately 55 distinct human 
chemokines have been identified to date. Mouse and rat homologues have also been 
identified for many of these, enabling the function of chemokines to be examined in 
convenient animal models. 
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1.4 Chemokine classification 
Most chemokines are small proteins being only 92 to 125 amino acids in length (8-12 
kDa) with leader sequences of 20 to 25 amino acids directing the chemokine to be 
secreted extracellularly. The chemokine family is generally divided into four 
subfamilies based on the presence and location of the first conserved cysteine residues 
and are termed CXC (a), CC CP), C (y), and CX3C (8) chemokines, with the X 
denominating any other amino acid (Fig 1. 1). Due to the rapidly growing number of 
chemokines being identified, research groups have often reported the same protein 
under different names. Recently a new chemokine classification has been suggested for 
consideration as an internationally approved nomenclature (Zlotnik and Yoshie, 2000). 
A summary of the known human chemokines and mouse homologues, with their new 
and old nomenclature, as well as the receptor for which they bind, is shown in table 1.1. 
1.4.1 CXC chemokines 
The CXC chemokines can be further subdivided based on the presence or absence of an 
N-terminal region sequence ELR (glutamine-leucine-arginine amino acids), which lies 
between the N-terminus and the first cysteine residue and is necessary for binding to IL-
8 receptors on the surface of neutrophils (Fig 1.1 ). Hence those chemokines which 
contain ELR sequences function as neutrophil chemoattractants (reviewed in Mackay, 
1997; Rollins, 1997; Rossi and Zlotnik, 2000). In humans, the genes of nearly all CXC 
chemokines are clustered on chromosome 4 (predominantly 4q12-ql3) (reviewed in 
Baggiolini et al., 1997; Rollins, 1997). 
Chemokine family 
cc 
C C C C 
CXC 
C :x I C I IC I IC I 
ELRC :X C 
lclxxx c IC I IC I 
C 
C IC I 
Figure 1.1: Schematic diagram showing the relationship between the four chemokine 
subfamilies. The dark blue regions indicate the leader sequence and the conserved 
cysteine residues are also shown. Note that the CXC chemokines are further divided 
into ELR and non-ELR subgroups. 
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Table 1.1: Known human chemokines with their new and old nomenclature, 
homologous mouse ligand, and receptor to which they bind. Adapted from Zlotnik and 
Yoshie, 2000. 
CXC chemokine family 
·• Systematic 
'Name 
·2XCLI 
Human 
· Chromosome 
~q12-q13 
2XCL2 ~q12-q13 
CXCL3 ~q12-q13 
2XCL4 J4q12-q13 
CXCL6 ~q12-q13 
2XCL7 ... ~ql2-q1I .. 
• Human Ligand 
:r, 
• uRO-cx/MGSA-a 
i GR()-~/MGSA-~ 
iPF4 
lENA-78 
•ocP-2 
.NAP-2 
lIL-8 
• Mouse Ligand 
GRO/KC? 
... ; 
GRO/KC? 
•oRO/KC? 
PF4 
,. 
•LIX? 
. CK-3 
.Unknown 
Unknown . 2XCL8 .. ~ql}-ql} .. 
. ................. .. .. ... , 
CXCL9 '. ~q21}1 .. !Mig .• Mig 
,2XCL10 ~q21.21 IP-10 Crcr-2 
.• I:, ..... 
2XCLI 1 ~q21.2) .... I-TAC •Unknown 
.. .. . . . . . . . ., ..... 
2XCL12 l0qlLl .. • SDF-1 
2XCL13 ..... ·~q21 ... BLC/BCA-1 BLC/BCA-1 
CXCL14 Unknown • BRAK .BRAK 
CXCL16 1Unknown : CXCL16 Murine CXCL16 
C chemokine family 
Systematic Human • Human Ligand : Mouse Ligand 
Name · 2hromosome 
txCLl . lq23 • Lymphotactin/SCM-la • Lymphotactin 
lATAC 
..... , ........ 
XCL2 . lq23 SCM-1~ Unknown 
CX3C chemokine family 
· Systematic •Human Human Ligand Mouse Ligand 
Name • 2hromosome 
.. . . 
•cx3CLI l~ql3 ... Fractalkine Neurotactin 
.. · 
* A recently identified chemokine (Matloubian et al., 2000). 
•chemokine 
.............. ~~~eptc:)t( ?) .. .. 
CXCR2 > CXCRI 
CXCR2 
CXCR2 
Unknown 
... ... . .. · ~ 
.• C.:?(CR~ .......................... . 
CXCRl , CXCR2 
CXCR2 
CXCRl , CXCR2 
•cxcR3 
CXCR3 
·• 2XCR3 
•2XCR4 
·· ::xcRs 
·• Unknown 
•'Unknown 
···· ··········· .. 
ICXCR6 
·• Chernokine 
·• Receptor(s) . 
D(CRl 
txCRl 
• Chernokine 
. .. 
•Recep~or(s) .. 
,CX3CR1 
Matloubian, M., David, A., Engel, S., Ryan, J.E. and Cyster, J.G. (2000). "A 
transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo." Nat Jmmunol 
1 ( 4) : 298-304. 
* 
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Table 1.1 continued: Known human chemokines with their new and old nomenclature, 
homologous mouse ligand and receptor to which they bind. Adapted from Zlotnik and 
Yoshie, 2000. 
CC chemokine family 
.· Systematic Human I Human Ligand • Mouse Ligand . ,...., . • '""'hemokme 
Name : Chromosome • Re~eptor(s) 
CCLI 17qll.2 • I-309 TCA-3, P500 ·ccRs 
CCL2 17qll.~ • MCP-1/MCAF JE? ~CCR2 
.CCL3 ·17q11'.2 ! MIP-lcx/LD78 • MIP-la ·CCRl, CCR5 
; 
•CCL4 ,17q11.2 .MIP-1~ MJP~l~····· •CCR5 .. ... . . ....................... 
•CCL5 •RANTES .• CCR 1, CCR3 , CCR5 
.. 
... . · ····· · 
l}qll.~ ············ . iIBANTES ... .. 
············ .. ·· ····· ·· --- ............................... •• • • • •• d •" .. .. . ... ................... ···········•·•··· ............ . .... . ...... ,. ............ 
. . .. ·· ······· · ·· 
. ... . . ~ 
(CCL6) :Unknown ,: Cl0, MRP-1 Unknown 
... 
·CCL7 l 7ql L2 !MCP-3 .MARC? • CCR 1, CCR2, CCR3 
. . 
CCL8 • 17ql 1) .MCP-2 MCP-2? ·CCR3 
.. ....... ••• d • • 
(CCL9/10) .Unknown MRP-2, CCF18 MIP-1 Unknown 
. . . . . . . . ...... , .. . -· ..• 
'. CCLI 1 17q11-2 .... • ! Eotaxin ; r-, • • t:otaxm ·CCR3 
(CCL12) •unknown .MCP-5 CCR2 
. . .. . . 
CCL13 ': 17qll.2 MCP-4 Unknown CCR2, CCR3 
.. 
. . . .. .... .... -· ~- . . ·• 
CCL14 17ql 1) •HCC-1 Unknown CCRl 
... ... .. 
CCL15 
. t7qll} .. HCC-2/Lkn-l/MIP- l •unknown •CCRl , CCR3 
..... ....... 
2CL16 •. 17ql 1-2 •HCC-4/LEC •LCC-1 .,....,CRl 
.'-' 
. 
2CL17 l§ql} rTARC TARC , ,...., . ....,CR4 
.... ...... 
CCL18 17qll.2 : DC-CKl/PARC AMAC- Unknown Unknown 
1 
CCL19 ·9p13 : Mifl-3~/J3LC/~)(o¢us-3 • MIP-3~/E~C/ex~dus-3 CCR7 
..... 
·ccL20 ~q33-q37 MIP-3cx/LARC/exodus-1 : MIP-3cx/LARC/exodus- CCR6 
1 
·CCL21 &p13 • 6Ckine/SLC/exodus-2 • 6Ckine/SLC/exodus- ,CCR7 
•2/TCA-4 
,._, ... 
·ccL22 
.. 
16ql3 • MDC/STCP-1 lABCD-1 ·2CR4 
CCL23 17qll.2 •MPIF-1 runknown ·2CR1 
·CCL24 7g 11.23 ! MPIF-2/Eotaxin-2 runknown ·,....,CR3 . '--' 
2CL25 _19pl3.2 •TECK •TECK ·ccR9 
.. 
CCL26 7qll.23 . .-, . 3 •Unknown ·CCR3 • totaxm-
..... . .. 
•CCL27 9p 13 ~--"'' CTACK/ILC ALP/CTACK/ILC tCRl0 ......... 
--
Y.,w•.-_-.•••-••••,••- • ' ' , ., .• ,~-, .. .. ,,. . 
. .... , .... , .. 1..·.·· ,•,,."'· .... ,....,......,..... ..~ ...... 
S10 CCL28 .. ~~-:l-nown CCL28 Mouse CCL28 
w~, 
··•-
--
.,,, .. ,.,.,_. 
* A recently identified chemokine (Wang et al., 2000). 
Wang, W., Soto, H., Oldham, E.R., Buchanan, M.E., Homey, B., Catron, D., Jenkins, 
N., Copeland, N.G., Gilbert, D.J., Nguyen, N., Abrams, J., Kershenovich, D., Smith, 
K., McClanahan, T., Vicari, A.P. and Zlotnik, A. (2000). "Identification of a novel 
chemokine (CCL28), which binds CCRl O (GPR2)." J Biol Chem 275(29): 22313-
22323. 
- * 
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1.4.1.1 GRO-aJB!y (CXCLl/2/3) 
The three members of the GRO family (GRO a, B and y) are closely related 
chemokines, sharing greater than 86%+ amino acid identity and all contain the ELR 
motif required for neutrophil recruitment (Haskill et al., 1990). All three GROs bind to 
the CXCR2 receptor, expressed on neutrophils (White et al., 1998). GRO-a, the first to 
be identified was isolated from transformed hamster cells that had lost the ability for 
growth control (Anisowicz et al., 1987). It has however, also been referred to as 
melanoma growth ~timulatory activity, or MGSA, as it has mitogenic effects on human 
melanoma cells (Richmond et al., 1988). The expression of all three GROs appears to 
be regulated by two pathways, a cytokine (TNF-cx/IL-1) induced signal and also a 
growth related pathway (Anisowicz et al., 1991). 
1.4.1.2 SDF-1 (CXCL12) 
The non-ELR CXC chemokine, ~tromal cell-derived factor-1 (SDF-1) can activate and 
recruit monocytes, peutrophils, and peripheral blood lymphocytes and binds onto the 
receptor CXCR4. SDF-1 is a powerful HIV suppressive factor which probably occurs 
due to competition with the virus for the binding to the cell surface receptor (Bleul et 
al., 1996; Oberlin et al., 1996; Baggiolini et al., 1997). SDF-1 occurs in two alternative 
splicing variants (SDF-la and SDF-1~). One of the few exceptions to the clustering of 
CXC chemokines on chromosome 4 is SDF-1, which is encoded on chromosome 10 
( 1 0q 11.1) (Shirozu et al., 1995). SDF-1 ex stimulates the proliferation of B cell 
progenitors and was also termed pre-B cell growth stimulating factor (PBSF). Human 
SDF-1 ex is the more abundant splicing variant and the mature protein consists of 68 
amino acids (Bleul et al., 1996; Oberlin et al., 1996; Baggiolini et al., 1997). 
1.4.1.3 Mig (CXCL9) 
Monokine induced by IFN-:y (Mig), like SDF-1 is a non-ELR CXC chemokine. It is 
induced from monocytes and macrophages, specifically in response to IFN)' (Rollins, 
1997). In addition to this, Mig has been observed in autoimmune lesions and some viral 
infections indicating that Mig is important during Thl responses (Baggiolini et al., 
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1997). Mig binds to the receptor CXCR3 which is found on NK cells, Thl cells and not 
surprisingly acts as a potent chemoattractant for these cells (Liao et al., 1995). 
1.4.1.4 IP-10 (CXCLlO) 
The non-ELR CXC chemokine, Jnterferon-inducible 12.rotein-l0 (IP-10, or Crg-2 in the 
mouse) is highly homologous to Mig and therefore carries many similarities in function 
including binding to the same receptor (CXCR3) and acting as a chemoattractant for 
activated CD4+ T lymphocytes, monocytes, NK cells and also B lymphocytes (Taub et 
al., 1993; Farber, 1997). The genes for human Mig and IP-10 are adjacent with a head-
to-tail orientation with their start codons only 16 kb apart (Lee and Farber, 1996). Being 
located so closely and having similar homology and function, it is possible that the 
genes for Mig and IP-10 arose from gene duplication. One might therefore expect that 
there is a redundancy in expression or function but this is not the case, since they have 
different expression patterns during infections with either Toxoplasma gondii or 
vaccinia virus (VV). MuMig was expressed at the highest level in the liver in both 
disease models whereas Crg-2 co-localized with the respective pathogen and was 
expressed at high levels in various organs throughout the animal (Amichay et al., 1996). 
1.4.1.5 Human I-TAC (CXCLll) 
Recently a new chemokine, interferon-inducible T cell alpha chemoattractant (I-TAC), 
has been isolated from a cDNA library derived from human peripheral blood 
mononuclear cells (Cole et al., 1998). This chemokine has also been isolated by others 
and referred to as H174, ~-Rl, SCYBll, IP-9 and CXCL 11 (Rani et al., 1996; Jacobs 
et al., 1997; Laich et al., 1999; Tensen et al., 1999a). Expression of human I-TAC has 
been detected in cultured primary monocytes, cultured fetal astrocytes, a microglial cell 
line, astrocytoma cells, atheroma-associated cells, bronchial epithelial cells, 
polymorphonuclear neutrophils and keratinocytes (Rani et al., 1996; Cole et al., 1998; 
Gasperini et al., 1999; Mach et al., 1999; Sauty et al., 1999; Tensen et al., 1999b). 
Moderate expression has also been detected in human CNS, pancreas, lung, thymus and 
spleen (Cole et al., 1998; Luo et al., 1998). The mature I-TAC protein is a non-ELR 
CXC chemokine and consists of 94 amino acids. In vitro studies have demonstrated that 
expression of human I-TAC appears to be up-regulated following exposure to mainly 
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IFN-a, IFN-~ and IFN-)' plus other cell regulators such as IL-1, LPS and TNF-a (Rani 
et al., 1996; Cole et al., 1998). Human I-TAC is homologous to human Mig and IP-10 
and also uses the CXCR3 receptor but is more potent than these two chemokines. (Rani 
et al., 1996; Jacobs et al., 1997; Cole et al., 1998). The variation in potency by these 
three chemokines may induce a chemical gradient which effector cells could migrate 
down to the site of infection (Cole et al., 1998 ). Human I-TAC is a potent 
chemoattractant for activated T lymphocytes, NK cells and monocyte-like cells (Cole et 
al., 1998; Luo et al., 1998; Gasperini et al., 1999). Very recently it was demonstrated 
that human I-TAC can specifically attract T cell receptor (TCR) a~+CD8+ single 
positive T cells, TCR y8+ T cells, and NK-type cells in human thymus (Romagnani et 
al., 2001 b ). One particular focus of I-TAC research is in diseases of the nervous system. 
Stimulation of astrocytes with IFN-)' and IL-1 results in a 400,000 fold increase in 
human I-TAC rnRNA expression (Cole et al., 1998). It has also been suggested that 
human I-TAC could be involved in the pathophysiology of neuro-inflammatory 
disorders such as multiple sclerosis and in the migration of Thl cells during IFN-
dominated immune responses (Cole et al., 1998). 
1.4.2 CC chemokines 
The largest group of chemokines is the CC family of which there are 27 known human 
members. The genes of the human CC family are generally all located on chromosome 
17 (predominantly 17qll.2-12) (Baggiolini et al., 1997; Rollins, 1997). Two well 
characterised CC chemokines are MIP-1 a and RANTES. 
1.4.2.1 MIP-la (CCL3) 
The chemokine MIP-1 a was originally described as a macrophage inflammatory 12rotein 
since it attracts macrophages and usually forms a homodimer or a heterodimer with 
MIP-1 ~. The mature proteins of both MIP-1 ex and MIP-1 ~ are 69 amino acids long 
(Haelens et al., 1996). It has however, also been shown to attract other cells including 
DCs, monocytes, NK cells and T-lymphocytes as well as functioning as a stem cell 
proliferation inhibitor (U guccioni et al., 1995; Hae lens et al., 1996; Rollins, 1997). It 
has been demonstrated to be an efficient Th 1 chemotactic molecule but does not attract 
Th2 cells (Siveke and Hamann, 1998). 
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1.4.2.2 RANTES (CCLS) 
RANTES is named from 'regulated upon activation, normal T ~xpressed and ~ecreted' 
and is also a CC chemokine. As this chemokine has been associated with HIV 
suppression, RANTES has been extensively characterised, although there is still 
confusion over some of the exact functions of this chemokine. RANTES is thought to 
be a chemoattractant and activator for cells including monocytes, basophils, eosinophils 
and T cells and also induces histamine release (Kaplan et al., 1995; Haelens et al., 1996; 
Rollins, 1997). It has been determined that RANTES is an efficient chemoattractant of 
Th 1 cells but not Th2 cells indicating a role in cell mediated immune responses 
(Schrum et al., 1996; Siveke and Hamann, 1998). However, Kaplan et al., argue that 
RANTES also attracts and stimulates eosinophils and basophils causing these cells to 
release substances such as histamine or eosinophil cationic protein which suggests a 
role for this chemokine also in the mediation of allergic inflammation, a Th2 response 
(Kaplan et al., 1995; Haelens et al., 1996). 
1.4.3 C chemokines 
Two exceptions to the CXC/CC rule are the chemokines ~ingle cysteine motif (SCM)-
la (also known as XCLl or lymphotactin) and SCM-1~ (XCL2), characterised by only 
having two non-adjacent cysteine residues. These two proteins are placed into a new 
family called the C-chemokines. The genes of both these chemokines map to 
chromosome 1 at position lq23 and are both expressed from T lymphocytes and NK 
cells after activation with IL-2 or IL-12. They share the same receptor, XCRl, and as 
such are both chemoattractant molecules for NK cells and T-lymphocytes, but not 
monocytes (Yoshida et al., 1996; Hedrick and Zlotnik, 1998; Hennemann et al., 1999). 
Other than acting as a chemoattract_ant during early inflammatory responses, no other 
function for these chemokines has been identified (Hedrick and Zlotnik, 1998). 
1.4.4 CX3C chemokine 
Another exception to the CXC/CC conserved cysteine rule is the CX3C-chemokine 
termed fractalkine (CX3CL1, or neurotactin in the mouse), which has 3 amino acids 
between the first two cysteines. This chemokine is unusual, as it is the first described 
chemokine that can exist either as a soluble protein or as an integral membrane bound 
protein expressed on leukocytes. Both forms of fractalkine function predominantly as an 
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adhesion molecule for leukocytes and cells expressing its receptor, CX3CR1, in much 
the same fashion as fibronectin or intracellular adhesion molecule- I (Rollins, 1997; 
Cook et al., 2001; Umehara et al., 2001). Fractalkine is also expressed at high levels in 
neurons and its' receptor is expressed on glial cells in the central nervous system 
suggesting an important role in glial cell migration. Knockout mice lacking fractalkine 
however, have no observable abnormalities and their response to various inflammatory 
stimuli were indistinguishable from those of wild type mice (Cook et al., 2001). This 
would suggest that fractalkine is not a key chemokine molecule for immune responses. 
However, it is likely that other chemokines are compensating for the lack of fractalkine 
in the knockout mice. It is also possible that inappropriate stimuli for fractalkine studies 
were used since the receptor for fractalkine has been implicated in the progression of 
AIDS in HIV positive individuals. 
1.5 Chemokine Receptors 
For chemokines to be effective they must interact with complementary receptors 
expressed on the surface immune cells. Chemokine receptors form a distinct group of 
structurally related proteins within the super family of receptors that signal through 
heterotrimeric OTP-binding proteins (Fig 1.2). All chemokine receptors are 
approximately 350 amino acids in length consisting of a 7-transmembrane spanning (7-
TMS) region and are related by a number of conserved structural motifs, mainly found 
throughout the 7 transmembrane domains. In addition, all chemokine receptors have 
two conserved cysteines, one in the NH2-terminal domain and the other in the third 
extracellular loop. These cysteines are assumed to form a disulphide bond that is critical 
for the conformation of the ligand-binding region. 
On the basis of the overall sequence identity and the subsequent chemokine for which 
they bind, four subgroups of receptors have been defined. The CXC chemokine 
receptors share 33-77% identical amino acids and the CC chemokine receptors share 46-
89% identical amino acids (Baggiolini et al., 1997; Murdoch and Finn, 2000). Eighteen 
chemokine receptors have currently been identified, five of which bind CXC 
chemokines (CXCR1-CXCR5), ten bind CC chemokines (CCRl-CCRl0), one binds 
fractalkine (CX3CR1) and one for Lymphotactin (XCRl). The last chemokine receptor 
of the eighteen is the Duffy antigen receptor for chemokines (DARC) and is expressed 
in human erythrocytes and on endothelial cells lining post capillary venules in the 
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spleen and kidneys. DARC binds numerous chemokines as well as acting as a binding 
protein for the malarial parasite Plasmodium vivax (Horuk et al., 1996; Murdoch and 
Finn, 2000): The sequence of DARC is highly conserved across animal species, and 
along with its expression on erythrocytes and promiscuous chemokine binding, is 
thought to act as a chemokine 'sink' to keep chemokine levels in the circulation low 
(Horuk et al., 1996). The signaling mechanism through which cells respond to 
chemokine stimuli is not yet well understood, although a number of factors have been 
shown to be crucial for chemokine receptor signaling. The pathways examined to date 
have been reviewed by Mellado et al, and are summarized in figure 1.2 (Mellado et al., 
2001). 
Many chemokine receptors bind to multiple chemokine ligands within each respective 
subfamily (table 1.1) indicating flexibility within the chemokine system that also 
provides a mechanism for a chemokine gradient, orchestrating complex immune cell 
movements. However, this myriad of ligand/receptor binding makes elucidating the 
mechanism whereby specific chemokine receptors and ultimately chemokines function 
and interact quite difficult (Rollins, 1997). Complexity is also added by the fact that 
several receptors can be expressed on the same cell type(s) but in different ratios and 
with different affinities for the same chemokine ligand. For example, studies have been 
carried out which determined chemokine receptor expression on human Th 1 and Th2 
cell lines. The procedure involved generating Thl and Th2 cell lines by stimulating 
human lymphocytes with either IL-12 plus IL-4 antibody (for Thl cells) or IL-4 plus 
IL-12 antibody (for Th2 cells). The Thlffh2 cell type was confirmed by detecting the 
production of IFNy and IL-4 respectively. Expression of various chemokine receptors 
was detected by mRNA northern blot analysis after activation of the T helper cell types 
(Bonecchi et al., 1998). A summary of these results can be seen on table 1.2. In a 
review by Baggiolini et al. , additional chemokines are associated with some of the 
chemokine receptors. The ligands for CCR2 include RANTES, MIP-la, MCP 1,3, and 
4 but not MCP-2. In addition to eotaxin and MCP-3, CCR3 can also bind RANTES. 
Finally both CCR4 and CCR5 can also bind MIP-1 a and RANTES (Baggiolini et al., 
1997). 
Chemokine 
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Figure 1.2: Schematic model showing the signalling pathways activated by chemokines 
binding to their receptors. Selected regulatory molecules and transcription factors are 
shown. Adapted from (Mellado et al., 2001 ). 
CHAPTER 1 19 
Table 1.2: Summary of chemokine receptor expression on Thl and Th2 cells. Modified 
from Bonecchi et al., 1998. 
Receptor Relative expression levels Points to note 
on Th 1 and Th2 cells 
CCRl Thl = Th2 
CCR2 Thl > Th2 Both cell types had 
relatively high levels of 
expression 
CCR3 Th2 only Low levels of expression 
CCR4 Thl < Th2 14.6 fold higher 
expression 
CCR5 Thl > Th2 4.9 fold higher expression 
CXCRl Not detected 
CXCR2 Not detected 
CXCR3 Thl > Th2 6.7 fold higher expression 
CXCR4 Thl = Th2 
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1.6 Diversity of chemokine function 
Chemokines have a wide variety of functions with the major purpose being involved in 
immune cell trafficking or recruitment to sites of infection. Other roles include blood 
vessel formation (both angiogenesis and angiostasis) and Thl/Th2 lymphocyte 
differentiation (Rossi and Zlotnik, 2000). As a result of their broad and pivotal roles 
throughout the body, they have been targeted as proteins with potential therapeutic 
applications for a variety of diseases. 
1.6.1 Immune cell migration 
As the name 'chemokine' suggests, derived from chemotactic cytokines, this family of 
proteins is probably best known for their ability to attract or recruit cells of the immune 
system to sites of infection. The multiple ligand and receptor binding patterns creates a 
complex mosaic model for effector cell migration. A cascade model, where chemokines 
with different affinities for the same receptor initiate a 'chemokine gradient' which cells 
can follow to the site of interest, is the favoured mechanism for effector cell migration 
(Foxman et al., 1997). The immune cell has the ability to modify and change receptor 
expression during the course of maturation and/or activation. Secondary reactions can 
be initiated by chemokines which induce the expression of cytokines from effector cells 
and in turn, these cytokines initiate further chemokine expression and activation (Fig 
1.3) (Salazar-Mather et al., 2000). Since a large number of chemokines have been 
identified, it is possible that this may ensure sufficient recruitment of effector cells even 
if genetic defects or invading pathogens disable the 'normal' migratory chemokine 
system, whereby a chemokine with an overlapping function may then act to compensate 
(Mantovani, 1999). 
The morphological changes that occur to a migrating cell after initial chemokine 
activation is reasonably well understood (Sanchez-Madrid and del Pozo, 1999; Mellado 
et al., 2001 ). One of the first events to occur when chemokines initially interact with 
their receptor is receptor dimerization and cellular polarization resulting in two 
differentiated areas of the cell. There is a redistribution of chemokine receptors to the 
leading edge of the cell, which is triggered by chemotactic factors as well as cytokines 
such as IL-15 and IL-2. The redistribution of the chemokine receptors, and also cellular 
polarization, results in the orientation of the leading edge towards the chemoattractant 
source. Morphologically, the leukocyte in question will change from a spherical shape 
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to more of an amoebae-like cell (Fig 1.4) (Baggiolini, 1998). An arm, or leading edge, 
will form from the cell body followed by a tail-like formation. The cellular polarization 
causes the pseudopod-like tail to develop, termed a uropod. This represents a 
specialized structure with important motility and adhesion properties, including the 
expression of adhesion molecules such as L-selectin, ICAM, Mac-1 and CD43. These 
molecules promote binding of other cells resulting in enhanced leukocyte recruitment 
and transendothelial migration (Sanchez-Madrid and del Pozo, 1999; Mellado et al., 
2001). The rate at which cells migrate relies on the coordination of the extension and 
retraction adhesion molecules, for example fibroblasts migrate relatively slowly ( 1 
µm/min) due to a lag time between extension of the leading edge and retraction of the 
uropod. In contrast T lymphocytes can migrate relatively rapidly (7-7 .5 µm/min), due to 
the extension and retraction forces occurring in a very coordinated manner. This also 
results in the cell maintaining cell shape and size during movement (Niggemann et al., 
1997; Sanchez-Madrid and del Pozo, 1999). 
A. 1 - Immune cell migration 
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Figure 1.3: Model of migration mechanism. Part A. shows a gradient effect initiated by three different chemokines which the immune cell can 
'follow' to the site of infection. Part B. shows the secondary effect when the primary immune cell(s) become activated leading to a secondary 
release of chemokines by the infected cell and/or NK cell. 
Figure 1.4: Shape change of human neutrophils without chemokine stimulation (left 
panel) and 5 seconds after stimulation with a chemoattractant (Baggiolini, 1998). 
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1.6.1.1 DC chemokine and receptor expression 
Most cells of the body can express chemokines in order to recruit immune cells to the 
site of pathogen invasion. However, for cells such as antigen presenting cells, especially 
DCs, there is a complex interaction between pathogen-infected cells, chemokines, 
cytokines and other immune cells of the body. DCs migrate to the site of infection, then 
travel to the draining lymph nodes where they activate the appropriate arm of the 
immune system. A switch in chemokine and chemokine receptor expression is thought 
to control this multi-step response (Sallusto et al., 2000; Marguez and Martinez, 2001). 
Immature DCs express chemokine receptors such as CXCR 1, CCR 1, CCR2, and CCR5 
which bind chemokines that are expressed by infected cells under inflammatory 
conditions and include IL-8, MIP-la, RANTES, MCP-1 and MCP-4. While the DC is 
migrating up the inflammatory chemokine gradient, it is being exposed to cytokines 
such as TNF-a, IL-1 and bacterial or viral products such as LPS or dsRNA which 
initiate the maturation of the DC. Once the DC has been exposed to antigen and has 
become a mature DC, a complete alteration in chemokine receptor expression occurs. 
Receptors such as CXCR4, CCR4 and CCR7 are all up-regulated while the initial 
receptors are down-regulated. This enables the DC to then migrate to the lymph node to 
activate the adaptive immune response (Cyster, 1999; Sallusto et al., 2000; Marguez 
and Martinez, 2001 ). Along with chemokine receptor expression switching, a significant 
change in chemokine expression from DCs also alters during maturation. Moreover, 
chemokine expression differs, depending on the stimuli that the DC received to mature 
as well as the effector cells that are required for activation, i.e. a Thl or Th2 phenotype 
(Sallusto et al., 1999; Sall us to and Lanzavecchia, 2000). 
1.6.1.2 Chemokine potency: chemotaxis assays 
Determining the relative hierarchy of those chemokines that attract the same cell or bind 
to the same receptor can give an indication of a migration cascade that could occur for 
cellular movement. Chemokine potency can be measured in several ways ranging from 
intracellular calcium mobilization to cellular migration rates and chemokine ligand-
receptor displacement assays. 
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Chemokine induced cellular migration assays have traditionally been assayed using the 
Boyden chamber chemotaxis system (Falk et al., 1980). The ability for a 
chemoattractant molecule to facilitate movement using the Boyden chamber is carried 
out by adding the cells of interest into an upper chamber, which is separated by a filter 
from a lower chamber containing the chemoattractant of interest. After a period of 
incubation, the cells that have migrated through the filter are counted and compared to 
control samples (Falk et al., 1980). Different concentrations of chemokines can be 
utilized to obtain an indication of chemokine potency and efficiency. As the chemokine 
concentration increases, there is enhanced cell movement, both in number and in 
migration rate, however, there is an optimum chemokine concentration, after which 
receptors are desensitized resulting in the lowering of migration velocity (Ali et al., 
1999). 
Recently Heinemann et al., developed a sensitive flow cytometry assay to measure 
leukocyte shape change as a marker of cell responsiveness. This group examined shape 
change in basophils in response to a number of different chemokines. Their results 
showed the ranking of potency of the following chemokines; MCP-4 > eotaxin-2 = 
eotaxin-3 > eotaxin > MCP-1 = MCP-3 > MIP-la > RANTES = MCP-2 = IL-8. The 
degree of basophil shape change was chemokine concentration and time dependent. 
These chemokines can also bind to different receptors, and during these studies it was 
demonstrated that the levels of CCR2 and CCR3 receptor activity altered the chemokine 
mediated responses (Heinemann et al., 2000). Relative potency of chemokines is not 
limited to leukocyte migration rates as chemokines themselves can have other functions 
not related to cellular movement. 
1.6.2 Angiogenesis and angiostasis 
The formation of new blood vessels, . . or ang1ogenes1s, 1s very important for 
physiological processes including the development of new capillaries during wound 
repair (Belperio et al., 2000). Several CXC chemokines have been associated with the 
regulation of angiogenesis. Generally, the ELR containing CXC chemokines, such as 
IL-8, ENA-78, ORO-a, ORO-~ and GRO-')', which bind to the receptors CXCRl and/or 
CXCR2, enhance angiogenesis (Belperio et al., 2000). Their ability to enhance 
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angiogenesis appears to be a distinct function from their ability to recruit cells during 
· inflammatory responses (Belperio et al., 2000). 
In contrast to the enhancement of blood vessel formation, it has been shown that the 
chemokines PF4, IP-10 and Mig are potent inhibitors of angiogenesis (termed 
angiostatic chemokines) demonstrating yet another example of the multi-functionality 
of various chemokines (Angiolillo et al., 1995; Strieter et al., 1995a; Strieter et al., 
1995b). It has been observed recently that I-TAC can inhibit neovascularization in the 
rat corneal micropocket assay of angiogenesis indicating that all three IFN-inducible 
chemokines (Mig, IP-10 and I-TAC) are potent inhibitors of angiogenesis (Belperio et 
al., 2000). The mechanism by which these chemokines function is still unclear, 
although it is thought to involve the inhibition of endothelial cell differentiation into 
branching networks of tubular structures (Angiolillo et al., 1995). 
1.6·.3 T lymphocyte differentiation and activation 
Cytokines such as IFN-y and IL-4 have long been known to play an important role in T 
cell differentiation into Thl cells or Th2 cells respectively. There is however, emerging 
evidence that chemokines and their receptors may also have a role in T cell 
differentiation and subsequent activation from na1ve to activated T cells. For example, 
MCP-1 has been implicated in enhancing T lymphocyte differentiation in the Th2 
phenotype direction. Evidence for this is found in mice that lack MCP-1, which have 
decreased IL-4 production and increased resistance to Leishrnania infection (Gu et al., 
2000). MCP-1 also reduced production of IL-12 by macrophages in vitro (Chensue et 
al., 1996). In addition, in vitro studies show that CD4+ T cells which were activated by 
either T cell receptor cross linking or antigen-pulsed APCs while in the presence of 
MCP-1 had increased levels of IL-4 (Karpus et al., 1997). There have been two 
suggested pathways by which MCP-1 could influence T cell differentiation, the first is 
by the reduction of IL-12 expression by APCs, while the second is the enhanced 
expression of IL-4 production by activated T cells (Luther and Cyster, 2001). Other 
MCP chemokines, including MCP-2, MCP-3, and lv1CP-4 have all been found to 
decrease IL-12 production in vitro, suggesting that they too could influence Th2 
differentiation (Braun et al., 2000). With respect to enhancing Thl differentiation, the 
chemokines MIP-1 a, MIP-1 ~, and RANTES have all been implicated by either 
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enhancing IL-12 production, or by directly polarizing Th cells (Luther and Cyster, 
2001). 
In a similar fashion to DCs, the cells of adaptive immunity also express different 
chemokines and chemokine receptors depending on the type of immune response they 
are to elicit as well as their differentiation and activation state(s). For example, nai've T 
cells express CCR7 and CXCR4, whereas memory Thl cells up-regulate the expression 
of CCRl, CCR2, CCR5, and CXCR3, memory Th2 cells up-regulated CCR2, CCR3, 
and CCR4 expression. Once differentiated and activated, both these memory T cell 
subsets down-regulated expression of these receptors and up-regulated others including 
CCR7 and CXCR5 (Sallusto et al., 1999). 
1. 7 Chemokines and disease; viral infections 
As immune cells, cytokines, and chemokines are activated and released to protect the 
body from disease, it is not unexpected that chemokines and their receptors are an 
integral part of research into many different diseases. The role of chemokines and 
pathogen infections, especially viral infections, appears to be the dominant focus of 
chemokine research. Chemokines and their receptors have several different functions 
during a viral infection. Virally infected cells can express a number of different 
chemokines to activate the immune system and aid in the clearance of the virus. From 
an evolutionary perspective, it is hardly surprising that viruses themselves have 
developed methods to try and subvert the chemokine antiviral system. Viruses can 
encode chemokine or receptor homologues that can aid in their evasion of the immune 
response and, as in the case of HIV, viruses can use chemokine receptors as co-
receptors necessary for viral entry. 
1.7.1 Chemokine expression initiated by viral infections 
Cells infected with virus release a myriad of chemokines 1n order to activate the 
immune system to fight infection. Research into the expression of the chemokines 
released during infection not only aids in the understanding of viral pathogenesis, but it 
also aids the elucidation of the mechanisms the chemokine system uses to overcome 
these infections. The expression of each chemokine is dependent on the type of viral 
infection as well as the progression and state of both viral infection and immune 
response. For example, Matikainen et al., carried out a study examining chemokine 
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expression from macrophages infected with either influenza A virus or Sendai virus. 
Both viruses cause a number of different chemokines to be expressed including MIP-
1 a, RANTES, MCP-1, MCP-3, and IP-10. The levels of expression of these 
chemokines however, differ between the two viruses as well as the time points at which 
peak expression is detected. Some other chemokines are expressed in one virus model 
and not the other, for example Sendai virus induces expression of IL-8 whereas 
influenza A does not (Matikainen et al., 2000). 
Another example of two chemokines being expressed at different stages during a viral 
disease, and therefore having different functions was demonstrated by Salazar-Mather et 
al. This study demonstrated that both MIP-1 a and Mig chemokine expression is 
important in viral clearance in mice infected with murine cytomegalovirus (MCMV). 
During a MCMV infection, initial expression of the CC chemokine MIP-la promotes 
NK cell inflammation in the liver. The presence of NK cells contributes to defense 
against MCMV infections through the production of IFN-y. It was reported that peak 
liver expression of Mig is dependent upon the presence of MIP-la, NK cells, and IFN-
y. Mig then mediates an antiviral role through the recruitment of more effector cells 
such as T lymphocytes to sites of infection (Salazar-Mather et al., 1998; Salazar-Mather 
et al., 2000). 
1. 7 .2 Viral evasion mechanisms 
As cytokines and chemokines are crucial for an effective innate and adaptive immune 
response, these molecules are often the targets for immune avoidance mechanisms 
developed by many pathogens, particularly viruses (Spriggs and Sher, 1999). For 
example, several poxviruses including cowpox, variola (smallpox), EV and myxoma 
(rabbit pox) viruses encode proteins that have chemokine, cytokine and receptor 
homology (Lalani et al. , 2000). There are three common strategies that viruses have 
developed to modulate chemokine activity. These include (i) the production of 
molecules which mimic chemokine functions , (ii) the expression of chemokine receptor 
homologues, which presumably compete for chemokine binding, and (iii) the 
production of soluble chemokine-binding proteins to inhibit host chemokine activity 
(Lalani et al., 2000). 
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An example of virus encoded chemokine homologues is found in molluscum 
contagiosum virus (MCV), which is a poxvirus that causes benign tumours in the skin 
of immunocompetent children. MCV encodes a 104 amino acid genome sequence 
(MC148R) that has broad homology to the CC family of chemokines, and is most 
related to the cellular chemokine IL-11-receptor-a-locus (ILC, also known as CT AK or 
CCL27). The exact role that MC148R has in vivo is unclear, however it is secreted from 
mammalian cells in vivo, and it has been predicted that the protein is involved in 
inflammatory responses (Bugert et al., 1998; Lusso, 2000). 
Human Kaposisarcoma virus, or HHV-8, also encoded chemokine homologues, 
including vMIP-1 , vMIP-II, and vMIP-III, which act to bind the human receptors 
CCR8, CCR3, and CCR4 respectively (Boshoff et al., 1997; Dairaghi et al., 1999; Stine 
et al., 2000). As these receptors are linked to Th2 responses, it has been suggested that 
the expression of these chemokine homologues, drive the immune response towards a 
Th2 response, thereby hindering the antiviral Thl response (Lusso, 2000). 
Several viruses encode chemokine receptor homologues, which may function as 
chemokine agonists. By binding circulating chemokines without initiating intracellular 
antiviral signal, the virus causes the chemokine to be ineffective. It is however, still 
unclear how the functional mechanisms of these virus-encoded proteins operate 
(Mahalingam and Karupiah, 2000b ). Virus encoded receptor homologues generally 
have broad spectrum chemokine binding, for example, the human cytomegalovirus 
(CMV), has a gene product (US28) which binds a large variety of CC chemokines 
including MIP-la, MCP-1 and RANTES (Neote et al., 1993). Another example is the 
herpesvirus saimiri (HVS) gene product (ECRF3) which can bind multiple CXC 
chemokines, including IL-8, Gro-a, ~' and y as well as NAP-2 (Ahuja and Murphy, 
1993). 
The third strategy by which viruses use the chemokine system to evade the immune 
system is the expression of chemokine-binding proteins, which act as chemokine 
scavengers. These proteins, which are expressed by several viruses, are not related to 
chemokines or their receptors, in that they do not share any sequence similarity 
(Mahalingam and Karupiah, 2000b ). An example of a chemokine binding protein is 
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found in the Lister strain of VV, which secretes a 35 kDa protein that inhibits eotaxin 
function. This chemokine binding protein also binds other CC chemokines including 
RANTES, MIP-lcx, MCP-1, and I-309 (Alcami et al., 1998). The discovery of proteins 
such as these may be beneficial for therapeutic use. For example, the ability of this 
binding protein to block eotaxin may be used to inhibit eosinophil infiltration during 
allergic inflammatory reactions (Alcami et al., 1998). 
1. 7.3 Viral entry using chemokine receptors 
Binding of virus particles to the host cell surface initiates a cascade of events that allows 
entry of the genetic material of the virus into the cell. An example of a virus gaining 
entry into cells by using chemokine receptors is the human immuno-deficiency virus 
(HIV). It has been proposed that, for HIV-1, receptor recognition may serve as a trigger 
that initiates entry. Although CD4 was identified as the primary receptor for HIV-1, an 
additional co-receptor was necessary for infection (Bates, 1996). The co-receptor (for 
entry of T-tropic HIV-1 strains) was isolated and initially termed 'Fusin' and was 
closely related to the IL-8 receptor CXCR2 (Feng et al., 1996). Fusin was later found to 
be the receptor for the chemokine SDF-1 and renamed CXCR4 (Bleul et al., 1996; 
Oberlin et al., 1996). The receptor CCRS was also identified to be a co-receptor for 
HIV-1 CM-tropic virus strains) (Alkhatib et al., 1996; Dragic et al., 1996). Cocchi et al., 
have shown evidence that RANTES, MIP-1 ex, and MIP-1 ~ are major HIV-suppressive 
factors produced by CDS+ T cells. This is most likely due to competition for the 
chemokine receptors (Cocchi et al., 1995). 
A 32 base pair deletion in the second extracellular loop of the CCR5 gene was identified 
and was found to cause a frame-shift and premature truncation of the polypeptide (Liu 
et al., 1996). Individuals who are homozygous for the mutation are highly resistant (but 
not immune) to virus infection, while patients with heterozygous products have a slower 
progression of the disease than do normal patients (Liu et al., 1996; Samson et al., 
1996; Doms and Peiper, 1997). Interestingly the frequency of this mutation is 
surprisingly high in the western European population with about 1 % of Caucasians 
being homozygous, and 18% heterozygous (Samson et al., 1996). This suggests that 
there has been some selective pressure in the past, perhaps from another infectious 
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agent, which gave individuals with this allele a survival advantage (Doms and Peiper, 
1997). 
1.8 Chemokines and other diseases 
Not only can chemokines recruit cells to sites of pathogen infection to aid recovery, 
they can also recruit inflammatory cells to sites where their benefits are not so well 
understood and in fact, may be harmful to the host. Diseases such as multiple sclerosis, 
allogenic transplant rejection, asthma and tumour progression are all regulated by the 
presence and activity of chemokines and their receptors. 
1.8.1 Autoimmunity - Multiple sclerosis and EAE 
There have been numerous studies examining the role of several chemokines during 
autoimmune diseases such as multiple sclerosis and a similar mouse model, 
experimental autoimmune encephalomyelitis (EAE). EAE is a CNS demyelinating 
disease induced in susceptible mice, rats, guinea pigs, or non-human primates following 
immunization with myelin derived antigens, peptides or following transfer of 
autoreactive CD4+ T cell lines or clones (Willenborg et al., 1996). During the initiation 
of EAE, activated Thl autoreactive T cells appear to infiltrate the CNS by an antigen 
independent and chemokine independent process which leads to the increased 
expression of a range of proinflammatory cytokines within the CNS (Hickey et al., 
1991; Glabinski et al., 1995). These cytokines then, among other effects, upregulate the 
expression of a suite of chemokines which have been implicated in various stages of 
EAE disease. Some of the chemokines expressed during various stages of EAE include 
RANTES, MIP-lcx, MIP-1~, MCP-1 and IP-10. (Hulkower et al., 1993; Ransohoff et 
al., 1993; Glabinski et al., 1995; Godiska et al., 1995; Glabinski et al., 1997; Youssef et 
al., 1998; Glabinski and Ransohoff, 1999). Due to the overlapping roles of chemokines 
and chemokine receptors, the exact role of each chemokine in disease progression is 
unclear even when utilizing knockout mice for various receptors or chemokines (Gerard 
and Rollins, 2001). 
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1.8.2 Asthma 
Studying of the function of RANTES during allergy, predominantly thought of as a Th2 
type disease, provides an example of the difficulty in elucidating the exact function of 
various chemokines in disease. John et al., carried out a study investigating RANTES , a 
strong chemoattractant molecule for eosinophils and monocytes in human airway 
smooth muscle during allergic inflammation. This group demonstrated that, in vitro, 
RANTES mRNA expression and subsequent protein expression was induced 
independently by TNF-a but not IFN-y (both Thl cytokines). However the combination 
of IFN-y and TNF-a caused a synergistic degree of expression and release in both a 
time and dose dependent manner. RANTES production was partially inhibited by the 
Th2 derived cytokines IL-4, IL-10, and IL-13. It has been proposed that RANTES and 
possibly other chemokines may participate in chronic airway inflammation by 
interacting with both Th-1 and Th-2 derived cytokines to modulate chemoattractant 
activity for eosinophils, activated T lymphocytes, monocytes, and macrophages (John et 
al., 1997). An experiment carried out by Gonzalo et al., using mouse eotaxin (a 
chemoattractant for eosinophils during allergic reactions) demonstrated that Th 1 cell 
clones expressed eotaxin to levels similar to that of Th2 cell clones. These findings were 
further confirmed in an in vivo situation where the Th2 response is impaired. IL-4 
deficient mice (and IL-5 levels are reduced by 70-90%) are still able to express eotaxin, 
in the lungs, in similar levels to wild type mice (Ganzalo et al., 1996). 
1.8.3 Transplantation 
Chemokines have also been implicated in the rejection of transplanted grafts through 
their capacity to elicit immune cell migration. The exact mechanism by which 
transplantation rejection occurs is unclear. Migration of immune cells such as T 
lymphocytes, macrophages, NK cells, DCs and other APCs however, is thought to be 
involved as rejection occurs after those cells have migrated either to or from the 
transplant site and lymphoid organs and have recognized the material as foreign . In fact, 
the migration of DCs from the graft to secondary lymphoid organs is of primary 
significance to the rejection process (Lakkis et al. , 2000). Like EAE and other 
autoimmune diseases, numerous chemokines are expressed during the rejection process, 
and again, due to the overlapping roles of these chemokines, the exact function of each 
chemokine in the transplant process is difficult to elucidate and control (Nelson and 
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Krensky, 2001). However, Hancock et al., have demonstrated that the IFN-inducible 
chemokines, Mig and IP-10 are expressed at high levels during acute cardiac allograft 
rejection, and CXCR3 deficient mice show profound resistance in the development of 
transplant rejection (Hancock et al., 2000). 
1.8.4 Tumour progression 
One reason why the study of chemokines during angiogenesis and angiostasis 1s 
important is that many tumours require a good blood vessel network for successful 
growth (Belperio et al., 2000). Therefore, the in vivo inhibition of angiogenic 
chemokines, the ELR-CXC chemokines, or the enhancement of angiostatic chemokines, 
such as IP-10, Mig, and I-TAC, or their receptor, CXCR3, may be beneficial in the 
control of tumours. Indeed, the addition of IP-10, Mig, and/or I-TAC to primary 
cultures of human microvascular endothelial cells, which express the CXCR3 receptor 
during the S/G2-M cell cycle phase inhibit the proliferation of this cell line. This effect 
could be reversed by the addition of anti-CXCR3 antibody (Romagnani et al., 2001a). 
Sgasari et al., have carried out a study injecting human Mig into Burkitt's lymphoma 
which were growing subcutaneously in nude mice. Central and homogeneous tissue 
necrosis was observed around and within the tumour mass demonstrating antitumour 
activity of Mig (S gadari et al., 1997). The exact mechanism for this occurring is unclear 
although it is unlikely to use T cell or NK cell activity, which are recruited by Mig. It 
has been suggested that Mig enhances vascular damage associated with elastin 
destruction and intravascular thrombosis (Sgadari et al., 1997; Kanegane et al., 1998). 
1.9 Chemokines for medical use 
The multitude of chemokines and the different functions they carry out during an 
immune response has motivated researchers to question how the chemokine system can 
be utilized for therapeutic intervention. There are several potential mechanisms by 
which this could occur. Blocking chemokines or their receptors could reduce 
inflammation, which may be useful during such autoimmune diseases like multiple 
sclerosis. Enhancing expression of specific chemokines could alter the type of immune 
response, either directly or by inhibiting or enhancing other regulatory factors. 
Incorporating chemokines into vaccines could attract the correct type of immune cells to 
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fight a specific pathogen, thereby making the vaccine more efficient. Several areas are 
now being examined that can utilize these molecules in the treatment of disease. 
In a study exarmn1ng vaccinations with either a fusion protein or DNA constructs 
encoding a fusion protein between a previously non-immunogenic tumour antigen and 
either IP-10 or MCP-3 generated protection against a B cell lymphoma challenge 
(Biragyn et al., 1999). Constructs of IP-10 or MCP-3 fused to lymphoma 
immunoglobulin (lg) variable regions (sFv) were produced to form either a DNA 
vaccine or a recombinant fusion protein. The recombinant proteins retained 
conformation of the native lymphoma derived lg as well as functional chemotactic 
properties. Mice were challenged with appropriate tumour cells two weeks after their 
respective immunization regimes. The fusion protein vaccines elicited inflammatory 
responses in vivo, however mice vaccinated with the DNA constructs generated 
significant protection against large tumour challenges. This difference is most likely due 
to the ability of a DNA vaccine to enhance CD8+ mediated immune responses (Biragyn 
et al., 1999). 
An example of enhancing chemokine expression during a disease model was 
demonstrated by Narvaiza et al., who examined the anti-tumoural effect that IP-10 and 
IL-12 had on subcutaneous murine tumour nodules derived from the CT26 murine 
colorectal adenocarcinoma cell line. During this study, two adenoviruses, one encoding 
IP-10, the other IL-12, were co-localized at the same tumour nodule(s). When used 
separately, the adenoviruses did not completely clear the tumours, with IP-10 showing 
some anti-tumour activity, and IL-12 about 70% tumour clearance. However, when used 
together, 100% of tumours were eradicated by this method, showing a synergistic effect 
(Narvaiza et al., 2000). 
In addition to studies specifically targeting the chemokine system for therapeutic 
applications, some drug treatments that were previously unknown to affect the 
chemokine system are already in use. Drug treatment of the chronic inflammatory skin 
disease, psoriasis, with the use of fumaric acid esters such as dimethylfumarate (DMF) 
has been examined in human trials for several years (Nieboer et al., 1990; Kolbach and 
Nieboer, 1992; Mrowietz et al., 1998). However the mechanism by which DMF reduces 
the symptoms of disease has, until recently, remained elusive. It has been shown that 
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DMF inhibits the expression of several chemokines including, GRO-a, IL-8. Mig, IP-10 
and HuI-T AC from keratinocytes and peripheral blood mononuclear cells in a dose 
dependent manner (Stoof et al., 2001 ). This inhibition of chemokine expression 
interferes with the recruitment of T lymphocytes and other inflammatory cells in the 
dermal and epidermal compartments of the skin (Stoof et al., 2001). 
1.10 Scope of this thesis 
Identifying and characterising the chemokines expressed by the body is crucial for 
understanding the immune system as a whole, as well as the mechanisms utilized in the 
battle against disease. In addition to this, understanding chemokine function during an 
immune response will have important benefits for designing vaccine and therapeutic 
techniques to help overcome many diseases. Characterizing murine homologues of 
human chemokines is an invaluable resource to further the understanding of how 
chemokines function in vivo and during different diseases. 
The research presented here describes the characterisation of the murine homologue to 
human I-TAC, which was isolated from a dendritic cell line after stimulation with IFN-
y. Several approaches were taken to characterize this chemokine, including sequence 
analysis, in vitro and in vivo expression studies, as well as functional analysis, and using 
I-TAC itself to modify immune responses. The cDNA sequence verifies that it is a non-
ELR CXC chemokine homologous to MuMig and Crg-2. Producing the I-TAC protein 
and using it in a chemotaxis assay demonstrates that it is a functional chemoattractant 
molecule. The cytokines involved in inducing I-TAC expression was analyzed by 
stimulating two DC cell lines with various cytokines and other factors. To look at the in 
vivo mechanism for I-TAC induction, various knockout mice were utilized. After 
finding that IFN-y primarily induces I-TAC in vivo and from dendritic cells, several 
murine disease models were also examined to determine whether or not this chemokine 
is expressed during immune responses against these diseases. The different disease 
models include three virus models, these being influenza, respiratory syncytial virus 
(RSV) and VV, as well as the autoimmune disease model, experimental autoimmune 
encephalomyelitis (EAE) and two transplantation models. The potential for artificial 
manipulation of I-TAC for medical applications, such as in a vaccine situation, was also 
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assessed. A recombinant VV encoding I-TAC was constructed and various experiments 
carried out to elucidate the role of I-TAC during a rVV infection. 
CHAPTER 2. 
ISOLATION AND CHARACTERISATION OF MURINE I-TAC 
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2.1 Introduction 
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The mature human I-TAC protein is a non-ELR CXC chemokine and consists of 94 
amino acids, is homologous to human Mig and IP-10, and binds to the CXCR3 receptor. 
(Rani et al., 1996; Jacobs et al., 1997; Cole et al., 1998). Human I-TAC is a potent 
chemoattractant for activated T lymphocytes, NK cells and monocyte-like cells (Cole et 
al., 1998; Luo et al., 1998; Gasperini et al., 1999). It was demonstrated recently that 
human I-TAC specifically attracts T cell receptor (TCR) a~ +CD8+ single positive T 
cells, TCR y8+ T cells, and NK-type cells in human thymus (Romagnani et al., 2001b). 
The expression of human I-TAC has been detected in a number of different cell types 
including cultured primary monocytes, cultured fetal astrocytes, a microglial cell line, 
astrocytoma cells, atheroma-associated cells, bronchial epithelial cells, 
polymorphonuclear neutrophils and keratinocytes (Rani et al., 1996; Cole et al., 1998; 
Gasperini et al., 1999; Mach et al., 1999; Sauty et al., 1999; Tensen et al., 1999b). 
Moderate expression has also been detected in various tissues including the central 
nervous system (CNS), pancreas, lung, thymus and spleen (Cole et al., 1998; Luo et al., 
1998). In vitro studies have demonstrated that expression of human I-TAC appears to be 
up-regulated following exposure to mainly IFN-a, IFN-~ or IFN-y plus other cell 
regulators such as IL-1, LPS or TNF-a (Rani et al., 1996; Cole et al., 1998). For 
example, stimulation of astrocytes with IFN-)' and IL-1 results in a 400,000 fold 
increase in human I-TAC mRNA expression (Cole et al., 1998). The expression of this 
chemokine by antigen presenting cells (APCs) to recruit activated T cells suggests that 
human I-TAC has an important role in the integration between the innate and adaptive 
immune system. 
2.1.1 APCs; the dendritic cell 
As APCs are an important mediator between the innate and adaptive immune response, 
-
many studies examining the role of chemokines during this process have been carried 
out previously (reviewed in Cyster, 1999; Sallusto et al., 2000; Marquez and Martinez, 
2001). Fully understanding this system may enable the manipulation of the immune 
response for therapeutic applications. The most potent APC in the immune system is the 
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DC, which can present antigen as well as activate naYve CD4+ T cells in vivo (Levin et 
al., 1993). Characterisation of DC lines has an important role in the elucidation of 
intracellular activities and expression of immune molecules, including chemokines, 
which aid the study of immune cell interactions (MacKay and Moore, 1997). Producing 
an immortalized cell line has an added advantage over a non-immortalized cell line, as 
homogeneous cell populations can be continuously cultured that respond uniformly to 
given stimuli (MacKay and Moore, 1997). DC lines such as MTHC-D2 and JAWS II 
are uncommitted progenitor DCs that can be stimulated to mature, differentiate, and 
become activated when exposed to different cytokines and stimulatory factors. 
2.1.1.1 The MTHC-D2 line 
The Myb-transformed hematopoietic cell line (MTHC-D2) is a cloned cell line derived 
from 12-day fetal liver which was then transformed with a truncated form of the 
transcription factor, c-myb, which regulates cell proliferation (Gonda et al., 1993; 
Banyer and Hapel, 1999). This parental cell line was initially described as having 
characteristics of monocyte-like cells that can then differentiate into macrophage-like 
cells upon stimulation with IL-4 or dendritic-like cells after stimulation with IFN-y 
(Banyer and Hapel, 1999). However, since the discovery of different DC subtypes, this 
cell line is thought to represent a progenitor DC line that can differentiate into DCs with 
cell mediated immune response (CMI) properties after stimulation with IFN-y or DCs 
with more phagocytic properties after IL-4 simulation (Banyer et al., 2002 submitted, 
see appendix le). 
2.1.1.2 The JAWS II line 
The JAWS II DC line was developed in a different fashion from the MTHC-D2 line and 
therefore is a useful alternative in expression analysis. The JAWS II dendritic cell line 
was isolated from bone marrow tissue collected from p53 knockout mice (MacKay and 
Moore, 1997). The protein p53 is a growth suppressor factor known to be involved in 
regulating cell division and growth thereby enabling the JAWS II DC line to be 
immortalized (MacKay and Moore, 1997). The JAWS II line may be induced to mature 
by cytokine stimulation, which stimulates antigen presentation and T cell proliferation 
(MacKay and Moore, 1997). JAWS II cells have been characterised as DCs due to their 
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morphological attributes, as well as the expression of various differentiation markers 
including; Mac-1, Fey receptor, MHC class I and II, CD44 and intercellular adhesion 
molecule-1 (ICAM-1) (MacKay and Moore, 1997). 
Identifying the murine homologue of human I-TAC is crucial for further, rapid 
characterisation of this chemokine. This would enable the use of murine models to 
thoroughly investigate the role of this chemokine in vivo, as well as an opportunity to 
use I-TAC to manipulate the immune system to assess I-TACs' potential use in vaccines 
and therapies. This chapter describes the identification and preliminary characterisation 
of the murine chemokine I-TAC after being detected and isolated by a cDNA 
subtraction technique from the MTHC-D2 DC line. 
CHAPTER 2 
2.2 Materials and Methods 
2.2.1 Mice 
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Female C57BL/6 mice aged six to eight weeks were obtained from the Animal Breeding 
Establishment (ABE), John Curtin School of Medical Research (JCSMR), Canberra, 
Australia. 
2.2.2 DC Cell lines 
The semi adherent DC progenitor cell line, MTHC-D2, was subcloned from MTHC-D2 
lines described previously (Gonda et al., 1993; Banyer and Hapel, 1999). This cell line 
was maintained in Iscove's modified eagle medium (IMEM; GIBCO/BRL) 
supplemented with 10% FBS (GIBCO/BRL), 2mM glutamine (SIGMA), and 50 U/mL 
GM-CSF (Baculovirus produced, JCSMR). The adherent progenitor DC cell line, 
JAWS II (ATCC, CRL-11904), isolated from p53_1_ mice, was maintained in alpha 
minimum essential medium with ribonucleosides and deoxyribonucleosides containing 
L-glutamine (GIBCO/BRL) and supplemented with 20% fetal bovine serum (FBS) 
(Gibco/BRL), lmM sodium pyruvate and 5ng/mL murine GM-CSF (Baculovirus 
produced, JCSMR). Both the JAWS II and MTHC-D2 cell lines were stimulated for 48 
hrs with GM-CSF (5 U/mL) with or without TNF-a (500 U/mL, Baculovirus produced, 
JCSMR) and IFN-y (2 U/mL, Baculovirus produced, JCSMR). 
2.2.3 Oligonucleotide Primers 
Oligonucleotides were synthesized and supplied at a concentration of 0.2 µmole 
contained in ammonium hydroxide (Biomolecular Resource Facility, Centre for 
Molecular Structure and Function, JCSMR). To prepare primers, 1 00µL aliquots were 
added to lmL of n-butanol and centrifuged (14k rpm x 10 min). The supernatant was 
removed, pellets dried (37°C @ 10 min), resuspended in milli-Q water (MQW), and the 
concentration determined by UV absorbance at 260nm. Primer concentrations were then 
adjusted to a standard polymerase chain reaction (PCR) concentration of 20 µM. 
2.2.4 Sequencing 
. Sequencing was carried out using an ABI Prism Big Dye Terminator Cycle Sequencing 
Ready Reaction Kit (PE Applied Biosystems) and processed on an ABI Prism 377 DNA 
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automated sequencer (PE Applied Biosystems) by the biomolecular resource facility at 
JCSMR. 
2.2.5 PCR and semi-quantitative RT-PCR 
Polymerase chain reactions (PCR) were carried out using an Omnigene PCR 
thermocycler (Hybaid Limited, UK) and thermostable DNA polymerase purified from · 
bacteria which expressed T. aquatic us DNA polymerase (Taq polymerase) (Engelke et 
al., 1990). In addition to Taq polymerase ( approximately 1.5 units per 20µL reaction), 
other reaction components were, lX PCR buffer (l0mM tris[hydroxymethyl]-amino 
methane (Tris) chloride pH 8.3, 50rnM KCl, and lmg/mL gelatin), 2rnM MgCb, 
0.2rnM dNTPs (dATP, dCTP, dGTP, dTTP), primers (2µM). Reaction volumes were 
generally 1 0µL or 20µL, in 250µL thin walled tubes. PCR reactions were started (hot 
start) by the addition of Taq polymerase during the first denaturation step at 94°C. The 
thermal profile used for I-TAC was as follows: Denaturing at 94 °C for 10s, annealing at 
66°C for 20s, and extension at 72°C for 30s for 30 cycles. The oligonucleotide primers 
that amplify a 252 bp I-TAC fragment were, mITAC sense, 5'-
GAACAGGAAGGTCACAGCCATAGC-3' and mITAC antisense, 5'-
ATGAGGCGAGCCTGCTTGGATCTG-3'. All results were standardized against 
murine GAPDH by amplifying a 551 bp fragment using the primers mGAPDH sense, 
5'-ACCACAGTCCATGCCATCAC-3' and mGAPDH antisense, 5'-
TCCACCACCCTGTTGCTGTA-3 '. The thermal profile used to amplify the GAPDH 
fragment was as follows: Denaturing at 94 °C for 1 Os, annealing at 58 °C for 20s, and 
extension at 72°C for 30s for 28 cycles. RT-PCR was carried out using 1-2 µL of first 
strand cDNA (section 2.2.13) in the PCR reaction mixture (above). Prior to the actual 
assays the thermal conditions and number of cycles used were optimized for both 
primer pairs so that the PCR and RT-PCR products obtained did not proceed past the 
linear phase of the reaction nor exceed analysis limits. PCR reactions were visualized as 
described in section 2.2.6. PCRs and RT-PCRs were repeated three times to ensure 
reproducibility. 
2.2.6 Restriction Enzyme Digests and Agarose Gel Electrophoresis 
DNA was digested with commercially supplied restriction enzymes (New England 
Biolabs (NEB), USA) in the supplied buffers using the suggested protocols. Restriction 
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digests were stopped by the addition of loading buffer ( lx stain [0.025% bromophenol 
blue and 1.5% Ficoll 400 in MQW], 15mM Tris chloride pH 7.8, 50% [v/v] glycerol 
and 7mM EDT A in MQW). This buffer was also added to PCR reactions (section 2.2.5) 
prior to loading onto agarose gels. Restriction digested DNA was separated by agarose 
gel electrophoresis and visualized using UV fluorescence. Agarose gels were made with 
NuSieve GTC agarose (BioWhittaker Molecular Applications, USA), generally 3% 
[w/v] and l.25µg/ml ETBr in TAE buffer (40mM Tris acetate pH 8.5, 2mM EDTA in 
MQW). Gels were run in T AE buffer at 80 volts. DNA size standards used for agarose 
gels was Sau3AI restricted pUC18 plasmid DNA. Images were taken using the 
N ovaLines gel documentation system under UV light. 
2.2. 7 Plasmid Cloning 
DNA plasmids were constructed using a range of different restriction enzymes and 
sources of insert DNA. Briefly, plasmid vector DNA (5-l0µg) was restriction digested 
in a total volume of 1 00µL overnight at 37°C and purified by two washes of 1 00µL 
phenol/chloroform (25:24: 1 phenol, chloroform, isoamyl alcohol, Sigma), and one wash 
of 100 µL chloroform. The vector was then dephosphorylated using shrimp alkaline 
phosphatase (Boehringer Mannheim) using lµL vector per l0µL total phosphatase 
reaction, incubated at 37°C for 15 min then at 65°C for 15 min to heat inactivate the 
enzyme, as described in the supplied protocol. 
Insert DNA used for plasmid cloning was either PCR generated or isolated from other 
DNA plasmids by restriction digestion. PCR and restriction digested fragments 
separated by agarose gel (section 2.2.6) were recovered by centrifuging excised bands in 
two eppendorf tubes. The top tube had a Whatman 3MM paper cup and a hole in the 
bottom. The tubes were spun in an eppendorf centrifuge (14k rpm x 30s) with DNA 
collecting in the bottom tube. The resulting solution was used directly for ligation 
reactions. The ligation reaction contained l0µL dephosphorylated vector solution (see 
above), 7µL insert, 2µL l0x ligation buffer (NEB), and 0.5µL or 1 µL of T4 DNA 
ligase (NEB) depending on whether the fragments had cohesive or blunt ends 
respectively. Ligation reactions were incubated (l6°C x 1 hr) then 1/10 of the reaction 
mix was transformed into electrocompetent DHl0B ™ cells (GibcoBRL) using the 
supplied protocol. Transformed bacteria were incubated in 2mL L-broth (37°C x 1hr), 
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then 100 µL was spread onto L-agar plates (10g NaCl, 5g yeast extract, 10g tryptophan 
make up to final concentration of 15g/L) which generally contained the antibiotic 
ampicillin ( ~50µg/mL) and incubated (37°C) overnight. Bacterial colonies containing 
plasmid DNA were detected by one of three methods: 1) blue/white selection, which 
detects that insert DNA has been cloned into the ~-galactosidase operon of some 
plasmids (e.g., Bluescript II KS-, Stratagene, USA). The enzymatic colour reaction for 
blue/white selection required isopropylthio-B-galactoside (4µL of a l00mM stock per 
L-agar plate) and 5-bromo-4-chloro-3-indoyl-B-D-galactoside (40µL of a 2% [w/v] 
stock per L-agar plate) to be spread on L-agar plates prior to the addition of transformed 
bacteria. 2) Restriction digest of minipreped plasmid DNA (section 2.2.8) and 3) PCR 
screening which involved transferring single colonies directly into PCR reactions after 
replicaplating. Correctly cloned plasmid DNA was further checked by minipreping and 
sequencing (sections 2.2.8 and 2.2.4 ). Stocks of transformed bacteria were stored in 
glycerol stock solutions (20-30% glycerol) at -70°C. 
2.2.8 Plasmid preparation and Minipreps 
Transformed E. coli bacteria were cultured in L-broth ( 1 0g Bacto-tryptone, 5 g bacto-
yeast extract and 1 0g NaCl per L and autoclaved) overnight at 37°C. Mini prep plasmid 
DNA was prepared from overnight bacteria cultures using a modified alkaline lysis 
method (Birnboim and Doly, 1979). Briefly, 1.5 mL of culture was placed in eppendorf 
tubes, centrifuged ( 14k rpm x 1 min), and supernatant removed. Cells were then 
resuspended by vortexing in 200µ1 solution 1 ( 50m.M glucose, 1 0mM EDT A, 250rnM 
Tris, pH 8.0 made up with MQW and store at 4 °C), and left at room temperature for 5 
min. 400µL freshly made solution 2 (1 % SDS, 0.2M NaOH, made up with MQW) was 
added, tubes inverted 4 times, and left on ice (5 min). 300µL solution 3 (3M potassium, 
5M acetate, made up with MQW) was added, tubes inverted to mix thoroughly, and left 
on ice (5 min). Tubes were then centrifuged (14k rpm x 3 min) and 800µL of 
supernatant collected and placed into sterile eppendorf tubes. 500µL isopropanol was 
then added, tubes vortexed and left at RT for 5 min before centrifuging (14k rpm x 5 
min). The supernatant was removed, 500µL 70% EtOH added, and centrifuged (14k 
rpm x 3 min). The supernatant was again removed and the pellet allowed to dry (37°C x 
~20 min) before resuspending in 20µL MQW. Approximately 20µg of DNA was 
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obtained using this method. Miniprep plasmid DNA was used for PCR, sequencing, 
restriction digestion, and some plasmid cloning. 
2.2.9 Megaprep 
Megaprep plasmid DNA was prepared from 500rnL of overnight bacteria cultures, at 
37°C with the antibiotic ampicillin ( ~S0µg/rnL) and was purified using the Jetstar 2.0 
Mega plasmid purification kit (Astral) using the manufacturers protocol provided. DNA 
yield was determined by measuring a 1/100 dilution (in MQW) using UV spectrometry 
(260nm). Approximately 1-2mg of DNA was obtained using this method and stored in 
MQW at 4°C. Megaprep plasmid DNA was used for PCR, sequencing, restriction 
digestion, and plasmid cloning. 
2.2.10 Subcloning of murine I-TAC 
Sense and antisense oligonucleotide pnmers were designed to the target sequence. 
These oligonucleotides included EcoRI restriction sites to facilitate cloning. PCR 
amplification was used to amplify the target cDNA from a parental plasmid (section 
2.2.5). The oligonucleotide primers used for this were, sense pnmer, 5'-
TAGAATTCATGAACAGGAAGGTCACAGC-3' and antisense pnmer, 5'-
TAGAATTCTCACATGTTTTGACGCCTTA-3'. The amplified fragment was cloned 
into the EcoRI site of pBluescript II KS- (Stratagene) to generate the new plasmid 
(2.2.7). 
2.2.11 Baculovirus expression of murine I-TAC 
A murine I-TAC recombinant baculovirus was generated using the Bae-to-Bae™ 
Baculovirus expression system (PharMingen) using the supplied protocols. Briefly, the 
murine I-TAC ORF in pBSmI-TAC was excised and subcloned into the Xhol and Xbal 
restriction sites of the baculovirus vector plasmid, pFastBacl (PharMingen). This 
plasmid was then transformed into competent DH 1 0Bac E. coli cells that contain a wild 
type baculovirus genomic DNA bacmid. The resulting progeny were screened for 
recombinant bacmids, which were then used to transfect Sf9 insect cells (PharMingen). 
Sf9 cells were maintained in supplied media (Sf-900 II SFM, GibcoBRL) containing 
penicillin (50U/mL) and streptomycin (50µg/rnL) at 27°C, 5% CO2 according to 
suppliers protocol. On day 5, supernatant from Sf9 cells infected with either wild type 
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or recombinant baculovirus was harvested and concentrated 4 fold by centrifugation 
using the Centricon-3 microconcentrator (Amicon, USA) using the supplied protocol. 
An overview of the baculovirus expression system is illustrated. 
Baculovirus expression system (PharMingen) 
PFastBac donor plasmid 
• Clone gene of interest 
PFastBac recombinant 
E. coli colonies with recombinant bacrnid 
Verified E. coli colonies with recombinant bacmid 
Recombinant bacmid DNA 
Tran sf ect insect cells 
Recombinant B aculovirus stock 
Protein expression 
2.2.12 Splenocyte isolation and concanavalin A (Con A) blast induction 
Whole spleens were isolated from eutOOlnised mice and placed on wire mesh sieves over 
small culture dishes containing 2mL F15 MEM media (10% FCS, GibcoBRL). 
Splenocytes were isolated by gently homogenizing the spleen through the sieve using a 
5mL syringe plunger. The splenocytes were then transferred into a 1 0mL tube and 
pelleted by centrifugation (1500 rpm for 5 min in a bench-top centrifuge). Supernatant 
was removed and cells suspended in 2mL RBC lysis buffer (0.15M NIL+Cl, lmM 
KHCO3, 0. lmM Disodium EDTA, pH 7.3, sterilized by filtration) and incubated for 2 
min at RT. RBC lysis was stopped by adding 8mL F15 MEM (10% FCS), followed by 
two more washes. Splenocytes were resuspended at 5x106 cells/mL in F15 MEM (10% 
FCS). Con A (Pharmacia Biotech) was added (2 µL of a lmg/mL stock solution per mL 
cells) and the cells incubated at 37°C, 5% CO2 for 24 or 48 hrs before use. 
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2.2.13 In vitro chemotaxis assay 
Chemotaxis assays with Con A blasts were carried out using the Falcon Tissue culture 
insert system with 3 µm or 8 µm pore size 9 mm tissue culture inserts (Falcon), and 
companion tissue culture plates (Falcon), according to the manufacturers protocol. 
Briefly, the concentrated supernatant (section 2.2.11) was added (5-20µL) into Fl5 
MEM (10% FCS, GibcoBRL) in the bottom of a 24-well chemotaxis plate. Washed Con 
A blasts ( 4x 105 cells) were then added into the top of the tissue culture inserts while 
placing the inserts into the 24-well chemotaxis plate. After incubating at 37°C for 3 hrs 
the relative number of cells migrating to the lower surface was counted in five randomly 
chosen high-powered fields (magnification 1 00x) using a grid contained within a 
microscope eyepiece (Olympus). Multiple experiments were carried out to confirm the 
data. 
2.2.14 RNA isolation, cDNA synthesis and RT-PCR expression analysis in DC cell 
lines 
Messenger RNA (mRNA) was isolated from the MTHC-D2 and JAWS II DC lines 
(5xlo6 cells) using the QuickPrep Micro mRNA Purification Kit (Pharmacia Biotech). 
First strand cDNA was prepared using a Ready-To-Go ·T-Primed First Strand Kit 
(Pharmacia Biotech) according to the manufacturer's instructions. Aliquots (l-2µL) of 
the first strand cDNAs were then used directly for RT-PCR (section 2.2.5). 
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2.3 Results 
2.3.1 Identification of murine I-TAC 
Previously, a subtraction cDNA library had been generated by subtracting the cDNA 
isolated from the parental murine MTHC-D2 DC line from cDNA isolated from the 
DCs after six hrs of stimulation with IFN-y, GM-CSF and TNF-a (Banyer and Hapel, 
1999). The subtraction technique follows the protocol in the flow diagram below. 
cDNA Subtraction (CLONTECH) 
cDNA 
• Rsa I digestion to create blunt ended fragments 
• adaptor ligation to one population of cDNA fragments 
• hybridization of ligated to unligated cDNA fragments 
• selective PCR amplification of unhybridized DNA template 
• 
TI A or UDG high efficiency cloning 
• Dot blotting and sequencing 
A nucleotide blast search of partial sequences of a number of clones in this library 
identified the plasmid clone, pJB699, as having a cDNA fragment with significant 
homology to the cDNA for HuI-TAC. This murine cDNA sequence, termed murine I-
T AC, was PCR amplified. Both PCR primers encoded EcoR 1 sites enabling the 
recloning of murine I-TAC to generate the bluescript plasmid pBSmI-TAC (Fig 2.1). 
-f1 origin 
pBSI-TAC 
3.26 kb 
ColE1 ori 
I-TAC 
EcoRI 
~--EcoRV 
Hind Ill 
Clal 
Sall 
Xhol 
Apal 
Kpnl 
Figure 2.1: Plasmid n1ap of Bluescript KS- encoding the complete I-TAC cDNA ORF. 
I-TAC was inserted into the EcoRl restriction sites. 
CHAPTER2 50 
The cDNA of murine I-TAC in pBSmI-T AC was sequenced and confirmed with the 
sequence provided for pJB699. Locating the start codon (ATG) and stop codon (TGA) 
in this sequence and aligning the nucleotide sequence with HuI-TAC identified the ORF 
(Fig 2.2). By protein and nucleotide database homology analysis, it was demonstrated 
that the I-TAC protein is 100 amino acids long, six amino acids longer than HuI-TAC 
and is 67%, 37% and 32% homologous to HuI-TAC, Crg-2 (murine IP-10), and 
MuMig, respectively (Fig 2.3). Murine I-TAC, like these other chemokines, has the four 
conserved cysteine amino acid residues typical of CXC chemokines and does not 
contain an ELR motif (E-L-R refers to the amino acid motif required for recruiting 
neutrophils). Based on the hydrophobicity profile (Fig 2.4) of the ORF amino acid 
sequence and the comparisons with HuI-TAC, Crg-2 and MuMig, the signal peptide 
cleavage most likely occurs between Gly21 and Phe22 to produce a mature polypeptide 
of 79 amino acids long. 
Once the I-TAC open reading frame had been cloned and sequence analyzed, it was 
necessary to establish whether or not the murine I-TAC cDNA encoded a functional 
1 
chemokine. This was carried out by construction of a recombinant baculovirus encoding 
the isolated cDNA by PCR reamplification and recloning I-TAC from pBSmI-TAC into 
the plasmid vector pFastBac 1, using the Xbal and Xho 1 restriction enzyme sites (Fig 
2.5). The pFastBacI-TAC vector was then transformed into competent DHI0Bac E. coli 
cells containing wild type genomic baculovirus DNA ( or bacmid), that combine to form 
recombinant progeny. A recombinant baculovirus encoding I-TAC and a control virus, 
were used to infect Sf9 insect cells. Six days later the supernatants were isolated and 
concentrated before being used in an in vitro chemotaxis assays with Con A activated 
splenocytes. A control virus was used to ensure that the vin1s did not induce cell 
migration. Supernatant containing I-TAC attracted more activated splenocytes than did 
supernatant produced using the control virus, which had levels comparable to media 
only samples. Figure 2.6 shows a representative of the experiments carried out with the 
3 µm pore sized chambers. The 8 µm pore sized chambers had a higher background of 
splenocytes indicating that a number of cells were 'falling' through the pores rather than 
migrating through due to chemotaxis. At its highest level, I-TAC recruited at least 50% 
more activated splenocytes than both control samples. These findings confirmed that 
murine I-TAC had chemoattractant properties. 
1 / 1 31/11 
atg aac agg aag gtc aca gee ata gee ctg get gcg ate ate tgg gee aca get get 
M N R K V T A I A L A A I I w A T A A 
61/21 91/31 
ggc ttc ctt atg ttc aaa cag ggg cgc tgt ctt tgc ate ggc CCC ggg atg aaa gee 
G F L M F K Q G R C L C I G p G M K A 
121/41 151/51 
aaa atg gca gag gtc gag aaa get tct gta att tac ccg agt aac ggc tgc gac aaa 
K M A E V E K A s V I y p s N G C D K 
181 / 61 211/71 
gaa gtg att gtt act atg aag get cat aaa cga caa agg tgc ctg gac CCC aga tee 
E V I V T M K A H K R Q R ~ L D p R s 
241 / 81 271/91 
cag get cgc etc ata atg cag gca ata gaa aaa aag aat ttt tta agg cgt caa aac 
Q A R L I M Q A I E K K N F L R R Q N 
301 / 101 
tga 
* 
Figure 2.2: The cDNA and amino acid open reading frame sequence of the non-ELR 
CXC chemokine murine I-TAC is shown. Conserved cysteine residues are underlined. 
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Figure 2.4: Kyte and Doolittle hydrophobicity plot of murine I-TAC generated using 
DNA-Strider software. The hydrophobic signal peptide is most likely cleaved between 
Gly21 and Phe22 as shown by the dashed vertical line. 
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Figure 2.5: Plasmid map of pFastBac plasmid encoding the complete I-TAC cDNA 
ORF. I-TAC was inserted into the Xbal and Xho 1 restriction sites. 
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Figure 2.6: Baculovirus chemotaxis assay. Supernatant from a control virus or rB-I-
TAC infected 143B cells was collected and concentrated ~4 fold and used for a 
chemotaxis assay. Con A blasted splenocytes (24 hrs stimulation) from na1ve C57BL/6 
mice were used for the assay. This figure is a representative of multiple experiments 
using the 3 µm pore sized chemotaxis chambers. Standard deviation is shown and there 
is a significant difference between rB-I-TAC and control virus at the 50 µl supernatant 
amount and media only san1ples (student's t-test p<0.0002). 
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2.3.3 RT-PCR from two DC lines 
After finding that I-TAC was expressed from IFN-')' stimulated MTHC-D2 cells and 
could act as a chemoattractant molecule, a second DC cell line was examined for I-TAC 
expression. RT-PCR for murine I-TAC mRNA expression was carried out on the two 
DC cell lines, the MTHC-D2 cell line (Fig 2.7 A) and the JAWS II cell line (Fig 2.7B). 
Both parental cells (lanes 1) had no detectable I-TAC whereas in IFN-')' stimulated cell 
samples (lanes 2), I-TAC was clearly visible. The housekeeping gene, GAPDH, was 
used as a positive control and for semi-quantification, demonstrated that the expression 
levels for I-TAC were similar in both DC lines. 
A MTHC-02 
I-TAC 
1 2 
GAPDH 
B JAWS II 
I-TAC 
1 2 
GAPDH 
Figure 2.7: RT-PCR of I-TAC mRNA expression from the MTHC-2D cell line (A) and 
the JAWS II cell line (B). In both cell lines, I-TAC expression occurs after the parent 
cell line (lane 1) is stimulated with IFN-y for 48 hrs (lane 2). 
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2.4 Discussion 
The chemokine I-TAC was isolated and identified from the IFN-y stimulated MTHC-D2 
murine DC line following cDNA subtraction carried out by Dr Joanne Banyer (Banyer 
and Hapel, 1999). Murine I-TAC is 67% homologous to HuI-TAC and ~35% 
homologous to Crg-2 and MuMig respectively. There are four cysteine residues with the 
first two being separated by one amino acid, and as a result is a member of the non-ELR 
CXC chemokine family. The open reading frame is 100 amino acids long with a 
predicted 21 amino acid leader sequence. The predicted leader sequence coincides with 
the leader sequence for HuI-TAC and if cleaved at this point murine I-TAC would be a 
79 amino acid residue mature protein. 
A recombinant baculovirus encoding munne I-TAC demonstrated that the cloned 
cDNA encoded a protein that acts as a functional chemoattractant. A typical 
chemotactic response was observed with a reduction in the number of cells migrating at 
higher concentrations of I-TAC. This decrease in recruitment is a common chemokine 
regulatory mechanism caused by receptor desensitization (Ali et al., 1999). HuI-TAC, 
HuMig and IP-10 as well as MuMig ':1nd Crg-2 are all induced by IFN-y and attract 
activated T cells by binding to, and activating the human or mouse CXCR3 receptor 
respectively (Loetscher et al., 1996; Cole et al., 1998; Tamaru et al., 1998; Lu et al., 
1999). Expression of murine CXCR3 is up regulated in Con A splenocytes (Tamaro et 
al., 1998), and given the homology of the other CXCR3 binding chemokines to I-TAC, 
it is predicted that I-TAC also binds and activates the same murine receptor. 
Previously it has been demonstrated that HuI-T AC is a more potent chemokine than 
either HuMig or IP-10 (Cole et al., 1998). This was shown by several different methods, 
initially, intracellular calcium (Ca2+) mobilization in activated T cells was measured. 
Dose response curves for HuI-T AC, IP-10 and HuMig on IL-2-stimulated T cell blasts 
showed that Ca2+ mobilization was highest for HuI-TAC, followed by IP-10, and then 
HuMig. The amount of Ca2+ mobilization was chemokine concentration dependent 
(Cole et al., 1998). Following this, Cole et al., further tested chemokine potency by 
looking at the interactions with CXCR3. Cross desensitization and binding of the three 
human chemokines to the CXCR3 receptor, again demonstrated that HuI-TAC was 
clearly the more potent chemokine of the three. Maximum chemotactic migration rates 
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of CXCR3 transfected cells were observed for Hul-TAC at a concentration of 10 nM 
versus approximately 100 nM required for both IP-10 and HuMig. In addition to this, 
twice as many stable transfectants migrated in response to Hul-TAC than towards the 
other two chemokines (Cole et al., 1998). HuI-T AC was also able to displace IP-10 or 
HuMig binding to the CXCR3 receptor which again occurred in a concentration 
dependent manner (Cole et al., 1998). Interestingly, neither HuMig nor IP-10 could 
completely displace HuI-TAC suggesting that HuI-TAC has either a much higher 
affinity for CXCR3 than the other two chemokines, or that it binds to the receptor at a 
different binding region (Cole et al., 1998). The possibility of differential binding sites 
was investigated by Cox et al., by carrying out competitive binding assays. Their 
research shows evidence that HuI-TAC binds to CXCR3 in a non-overlapping region to 
IP-10 and possibly HuMig, however Hul-TAC still remains the dominant ligand for the 
receptor (Cox et al., 2001). The exact binding regions for each of these chemokines on 
the receptor are still unknown. Murine CXCR3 is highly homologous to the human 
CXCR3 receptor, with 86% identical amino acids (Lu et al., 1999). While not examined 
here, the high homologies between the human and mouse chemokines make it plausible 
that murine I-TAC is also more potent than MuMig and Crg-2. It is therefore possible 
that murine I-TAC shares a lot of similarities to Hul-TAC with regard to binding 
affinities and potency in comparison to the Mig and Crg-2. 
RT-PCR confirmed that murine I-TAC is expressed from murine progenitor DCs after 
cytokine stimulation. Together with the likelihood that murine I-TAC attracts T 
lymphocytes it is plausible that I-TAC maybe an important secondary messenger, 
linking the innate to adaptive immune systems. After DCs have been exposed to antigen 
and maturation signals (e.g. IFN-y and TNF-a), a complete alteration in chemokine 
expression occurs. Expression of both Mig and IP-10 were also isolated from the 
MTHC-D2 cDNA library containing I-TAC, and have been reported by others to be 
upregulated during this time of DC maturation (Banyer et al., 2002 submitted, see 
appendix le; Sallusto et al., 1999; Sallusto and Lanzavecchia, 2000). The expression of 
these chemokines could have several functions including recruiting T lymphocytes to 
the DC for antigen presentation and sampling in the draining lymph nodes and 
subsequent adaptive immune response activation. Detection of these chemokines from 
the MTHC-D2 cells after only 6 hrs of cytokine stimulation suggests a role early in the 
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immune response, before the DC has migrated to the 1 ymph node. Also, RT-PCR 
detection of I-TAC in MTHC-D2 cells after 48 hrs of cytokine stimulation suggests that 
this chemokine may still be functioning after the DC has reached lymph tissues (Banyer 
et al., 2002 submitted, see appendix 1 c ). Another function could be to down regulate 
receptor expression and other factors no longer required by the mature DC such as those 
receptors previously required by the immature DC for migration to the site of the 
antigen (Sallusto and Lanzavecchia, 1999; Sallusto and Lanzavecchia, 2000). A more 
thorough examination of what cytokines and other stimulatory molecules regulate 
murine I-TAC may help determine what role this chemokine has in the immune system. 
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3.1 Introduction 
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The expression of I-TAC from DC lines after stimulation with IFN-y, GM-CSF and 
TNF-cx suggests that I-TAC may be involved with CMI responses. Characterisation of 
the signalling pathway(s) responsible for the expression of I-TAC will help further 
define the role it has in the immune system. 
3.1.1 The interferon (IFN) signalling pathways 
The IFN regulatory pathway is made up of multiple cytokines, receptors and 
transcription factors, which together can effect the expression of a number of 
chemokines (Fig 3 .1) (reviewed in Stark et al., 1998; Platanias and Fish, 1999; 
Schindler, 1999). There are two main IFN receptors, the type I receptor (IFN-a/~R) and 
type II receptor (IFN-yR) which signal through related pathways. Both receptors signal 
through the binding to the Janus kinases (JAKs) which initiate signals through the signal 
transducers and activators of transcription (STATs). These JAK and STAT factors are 
not exclusive to IFN signalling but are also involved in other cytokine and growth factor 
signalling pathways. There are four known mammalian JAKs and seven known STAT 
factors (reviewed in Stark et al., 1998; Platanias and Fish, 1999; Schindler, 1999). 
Once the IFN-a/~R binds ligand it activates two JAKs, JAKl and Tyk2 which in turn, 
activate STATl and STAT2 by a tyrosine phosphorylation event. These two ST ATs 
migrate to the nucleus where they bind with p48 ( also known as Interferon response 
factor 9 - IRF9) to form the IFN-cx-stimulated gene response factor (ISGF) complex. 
ISGF then binds to the IFN-cx-stirnulated response element (ISRE) to then mediate the 
induction of target genes (reviewed in Stark et al., 1998; Platanias and Fish, 1999; 
Schindler, 1999). 
IFN-ro'P 
IFN-a/PR 
JAKl TYK2 JAK2 
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STATl 
STAT2 ___ ----------..... [D STATl 
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IRF-E IFN inducible 
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Figure 3.1: Schematic diagram of the IFN signalling pathway through the STAT-JAK 
factors (adapted from Stark et al., 1998; Schindler, 1999; Taniguchi et al., 2001). 
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IFN-)' has a similar sequence of events, however, the proteins which are activated differ 
to some extent. Once the IFN-)'R has been activated, JAKl and JAK2 are activated and 
initiate tyrosine phosphorylation of two ST AT 1 proteins. The activated ST AT 1 factors 
form a homodimer that migrates to the nucleus to bind to the gamma activation site 
(GAS), which is an IFN-)' response element that initiates the induction of target genes. 
The target genes include the interferon response factor- I (IRF-1) leading to expression 
of antiviral factors such as the IFN-)' inducible chemokines, IP-10 and Mig (reviewed in 
Stark et al. , 1998; Platanias and Fish, 1999; Schindler, 1999). IRF-1 is a major factor in 
NK cell antiviral activity as well as in the development of Thl cell differentiation. IRF-
1 physically interacts with the transcription factor NF-KB and it has been suggested that 
this binding may be important in the cytokine-induced regulation of multiple promoters 
(Baldwin, 1996). The antiviral activity of IRF-1 and subsequently NF-KB, is down 
regulated by IRF-2 through suppression of ISRE and IRF-E (Fig 3.1), (Taniguchi et al. , 
2001). 
3.1.2 TNF-a signalling 
Studies examining TNF signallinghavebeen driven by the knowledge that this cytokine 
family induces apoptosis as well having a major role in cell growth and homeostasis 
(reviewed in Lenardo et al., 1999; Wallach et al., 1999). Although these effects seem 
contradictory, the mechanism by which it operates ensures the survival of healthy, 
stable cells. TNF-a mediates its cellular responses through two distinct receptors, 
TNFR-I (p55) and TNFR-II (p75). These receptors are then able to activate numerous 
other factors, for example TNFR-I can associate with TRADD, FADD, TRAF2, I-
TRAF, RIP and FAN while TNFR-II associates with factors including TRAFl, TRAF2, 
cIAP-1 and cIAP-2 (reviewed in Damay and Aggarwal, 1997). The TNFR-I activation 
of TRADD leads to the activation of TRAF2, which can also be activated by TNFR-II 
directly. TRAF2 activation subsequently leads to the activation of several factors 
including A-20 and I-TRAF which in turn have the ability to activate NF-KB (Rothe et 
al., 1995; Hsu et al. , 1996). Synergy between TNF-a and IFN-)' to induce chemokine 
expression, including Hul-TAC and IP-10 has been reported (Ohmori and Hamilton, 
1995; Gasperini et al. , 1999; Sauty et al., 1999; Albanesi et al., 2000). The signalling 
mechanism for this synergistic effect is not entirely clear, however, both IFN-)' and 
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TNF-a can independently activate ISRE and NF-KB, both of which are involved in 
chemokine induction, including that of IP-10 (Ohmori and Hamilton, 1995). A 
schematic diagram can be seen on the previous page (Fig 3 .1 a) 
3.1.2 CD40-CD40L signalling 
Interactions between cytokines and co-stimulatory molecules can also regulate 
chemokine expression. The cell surface receptor CD40 belongs to the TNF-receptor 
(TNF-R) family and was first identified on B-lymphocytes, and has since been found to 
be expressed on monocytes, DCs and a number of nonhemopoietic cells including 
keratinocytes (reviewed in Lipsky et al., 1997; van Kooten and Banchereau, 1997; van 
Kooten and Banchereau, 2000). The major role of CD40 is in the interaction with its 
ligand, CD40L, which is expressed on activated CD4 + T cells and as a result functions 
in B cell differentiation and activation during humoral immune responses (reviewed in 
Lipsky et al., 1997; van Kooten and Banchereau, 1997; van Kooten and Banchereau, 
2000). Functional CD40 expression on DCs also appears to be critical in DC maturation 
as well as having a role in inflammatory immune responses (Mackey et al., 1998). Upon 
DC activation via CD40 a number of chemokines and cytokines are produced including 
IL-8, MIP-lcx, IL-12, IL-1 and TNF-cx. The DC CD40 induced expression of factors 
such as IL-12 and subsequent interaction and activation with T cells results in a skewing 
towards a Thl response (van Kooten and Banchereau, 1997; van Kooten and 
Banchereau, 2000). In addition to this, synergy between CD40-CD40L interactions and 
IFN-y to induce expression of several chemokines in cervical carcinoma cells has been 
observed. The chemokines upregulated include MCP-1, IP-10, and to a lesser extent 
MCP-3 and RANTES (Altenburg et al., 1999). 
The CD40 signalling pathway has been primarily studied in B cells although there 
maybe alternative pathways functioning in other cells such as in DCs (van Kooten and 
Banchereau, 1997). The intricacies of CD40 signalling are still unclear however several 
features are known. Similar to all other members of the TNF receptor family, CD40 has 
no kinase binding or activation domain, yet CD40 ligation activates protein tyrosine 
kinase including Syk, Lyn and J AK3 kinases. Several MAP kinases also appear to be 
activated by CD40 ligation. A number of TNF-R associated factors (TRAFs) have also 
found to be involved in the CD40 signalling pathway. The TRAFS can then induce 
several transcription factors, for example TRAF2 can induce NF-KB following CD40 
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cross-linking (van Kooten and Banchereau, 1997; van Kooten and Banchereau, 2000). 
Another factor that interacts with CD40 is the tumour-suppressor gene, p53, which is 
involved in cell cycle regulation. Indeed, activation of multiple myeloma cells by CD40 
induces proliferation, growth arrest or apoptosis, all of which are dependent on the 
status of p53 (Teoh et al., 2000). 
Establishing how immunologically important factors including IFN-y, TNF-cx and CD40 
ligand can influence murine I-TAC expression will help establish the role and 
importance of murine I-TAC during immune responses. 
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3.2 Materials and Methods 
3.2.1 Mice 
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Specific pathogen-free 6-8 week old female ffilCe were obtained from the Animal 
Breeding Facility, John Curtin School of Medical Research, Canberra, Australia. Single 
knockout IFN-al~R-J- and IFN-)'R_1_ mice and IFN-al~R-)'R_1_ double knockout mice 
homozygous for the disrupted gene(s) and backcrossed onto the 129/Sv background, 
were originally obtained from Dr Michel Aguet, University of Zurich (Huang et al., 
1993; Steinhoff et al., 1995; van den Broek et al., 1995). Interferon regulatory factor-I 
KO (IRF-1 _1_) mice backcrossed onto the 129/Sv background were originally obtained 
from Prof. Charles Weissman, University of Zurich (Reis et al., 1994). CD40-1- mice 
were obtained from Prof. Hitoshi Kikutani, Osaka University (Kawabe et al., 1994). 
TNF-IR-IIR_1_ double knockout mice were obtained from Dr Jacques Peschon, Irnmunex 
Research and Development Corporation (Peschon et al., 1998). Two sources of age-
matched null homozygote (C57BL/6 x 129/Sv) mice were used as controls for these 
assays (Max-Planck Institute for Immunbiologie, Freiburg, Germany and University of 
Zurich, Switzerland) as described previously (Ramshaw et al., 1997; Ruby et al., 1997). 
3.2.2 Semi-quantitative RT-PCR of DC lines exposed to cytokines and CD40 co-
stimulation 
JAWS II and MTHC-D2 cell lines were cultured as described in section 2.2.2. In 
addition, they were stimulated for 48 hrs with TNF-a (500 U/mL) and GM-CSF 
1 (5u/mL) and either IFN-y (2U/mL) or IL-4 (50U/mL), or both IFN-y plus IL-4. Some 
cell samples were activated for th~. final 16 hrs by CD40 crosslinking by adding CD40 
Ab (25µg/mL). The CD40 Ab w'as column-purified from supernatant of cultured 
FGK45.5 cells (Rolink et al., 1996). Semi-quantitative RT-PCR was carried out after 
mRNA isolation (from lx106 cells) and cDNA synthesis as described in sections 2.2.5, 
2.2.12 and 2.2.14. These analyses were carried out multiple times to confirm the data. 
3.2.3 Semi-quantitative RT-PCR of Con A blasts from knockout mice 
Semi-quantitative RT-PCR was carried out after mRNA isolation (from Ix106 cells) 
and cDNA synthesis as described in sections 2.2.5, 2.2.12 and 2.2.14. Multiple mice 
were used and R T-PCRs repeated at least three times to confirm the data. 
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3.3 Results 
3.3.1 Cytokine induced expression of murine I-TAC in DC lines 
I-TAC expression was induced in DCs matured by IFN-y and TNF-cx (chapter 2). A 
common approach used to culture and mature DCs is with IL-4 (Sallusto and 
Lanzavecchia, 1994; Banyer and Hapel, 1999). To investigate what role IL-4 may have 
on I-TAC expression, RT-PCR analysis of the MTHC-D2 and JAWS II cell lines 
exposed to TNF-cx plus IL-4, or TNF-cx plus IFN-y cytokines was carried out. These two 
cell lines are progenitor cells of DC isolated from different tissues and which have been 
transformed by two different approaches. Semi-quantitative RT-PCR analysis of both 
the MTHC-D2 (Fig 3.2A) and JAWS II (Fig 3.2B) cell lines showed that expression of 
murine I-TAC was upregulated by IFN-)'/TNF-cx (lanes 3) compared to the IL-4/TNF-cx 
(lanes 2) or untreated cells (lanes 1) both of which had no detectable murine I-TAC 
band. These data also indicate indirectly that IL-4 and TNF-q alone do not upregulate I-
T AC expression and that the key cytokine for expression appears to be IFN-)'. Indeed 
when IL-4/IFN-y/TNF-cx (lanes 7) were combined I-TAC expression was significantly 
lower than IFN-y/TNF-cx (lanes 3) treated cells indicating that IL-4 may in fact down-
regulate IFN-)' induced I-TAC expression. 
3.3.2 CD40 Ab induced expression of murine J .. TAC in DC lines 
Synergy between IFN-y and CD40 has been shown to enhance the expression of a 
number of chemokines from cervical carcinoma cells, including IP-10 and MCP-1 
(Altenburg et al., 1999). Considering the high homology between murine I-TAC and IP-
10 (chapter 2) and their induction by IFN-)', it was important to examine the effects of 
CD40 on murine I-TAC expression. Semi-quantitative RT-PCR analysis, standardized 
against GAPDH, showed, that in the absence of IFN-)', anti-CD40 Ab upregulated the 
expression of murine I-TAC in MTHC-D2 cells (Fig 3.2A lanes 1 and 2 vs lanes 4 and 
5 respectively), but not in the JAWS II cell line (Fig 3.2B lanes 1 and 2 vs lanes 4 and 5 
respectively). I-TAC expression was upregulated further in the MTHC-D2 cell line 
when exposed to both CD40Ab and IFN-)' demonstrating synergy (Fig 3.2A lane 3 vs 
lane 6) whereas synergy in the JAWS II was not detected (Fig 3.2B lane 3 vs lane 6). 
The different I-TAC expression pattern between the cell lines may be due to differences 
in the CD40 activation pathway resulting from the different methods used to 
immortalize the cell lines, rather than due to interactions with the interferon-signalling 
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pathway. A combination of IL-4/IFN-y/TNF-a plus anti-CD40 Ab (lanes 8) appears to 
down-regulate I-TAC expression compared to IFN-y/TNF-a plus anti-CD40 Ab (lanes 
6) treated cells, again indicating that IL-4 down-regulated IFN-y/TNF-aJCD40 induced 
I-TAC expression. 
3.3.3 Expression of murine I-TAC Con A blasts from knockout mice 
To further analyze murine I-TAC expression and confirm the cell line results, semi-
quantitative RT-PCR, standardized against GAPDH, was carried out on cDNA from 
non-activated and Con A activated splenocytes isolated from a panel of knockout mice. 
Murine I-TAC expression in non-activated splenocyte cDN A samples from the various 
transgenic mice and controls was very low and not significantly different between 
strains of mice (data not shown). In Con A activated splenocyte samples (Fig 3.3) there 
was a significant increase in the level of murine I-TAC expression in splenocytes from 
IFN-aJ~R-1- (lane 3) mice compared to control spleen cells (lanes 1 and 2). These results 
appeared to indicate that IFN-a and/or IFN-~ down regulate murine I-TAC expression 
in wild type mice. Expression of murine I-TAC in splenocytes from IFN-yR·1- (lanes 4 ), 
IFN-aJ~R-yR-/- (lanes 5) and IRF-1-1· (lanes 6) mice were all significantly lower than the 
expression in the splenocytes from control mice (lanes 1 and 2). These results showed 
that the IFN-y signalling pathway is the primary regulator of murine I-TAC mRNA 
expression and that IRF-1 has a significant role in murine I-TAC expression supporting 
the cell line data above. Murine I-TAC expression in activated splenocytes from CD4o-t-
(lane 7) mice was not significantly different to the samples from control mice (lanes 1 
and 2). This corresponds to the in vitro data for the JAWS II cell line (Fig 3.2B) but not 
to the data for the MTHC-D2 cell line (Fig 3.2A). There was no significant difference 
between the level of murine I-TAC detected in TNF-IR-IIR_1_ (lane 8) mice compared to 
control mice (lanes 1 and 2). This suggests that TNF-a does not have an important role 
in regulating murine I-TAC mRNA, in agreement with the in vitro cell line data. 
A MTHC-D2 
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Figure 3.2: Semi-quantitative RT-PCR murine I-TAC and GAPDH mRNA expression 
in the MTHC-D2 (A) and JAWS II (B) cell lines grown in GM-CSF only (lane 1) and 
following exposure to the cytokines; IL-4/TNF-a (lane 2), IFN-y/TNF-a (lane 3), GM-
CSF plus anti-CD40 Ab (lane 4), IL-4/TNF-a plus anti-CD40 Ab (lane 5), IFN-y/TNF-
a plus anti-CD40 Ab (lane 6), IL-4/IFN-y/TNF-a (lane 7), and IL-4/IFN-y/TNF-a plus 
anti-CD40 Ab (lane 8). 
1 2 3 4 5 6 7 8 
Figure 3.3: Murine I-TAC and GAPDH semi-quantitative RT-PCR analysis of Con A 
activated splenocytes from a panel of knockout mice. Two sources of age-matched 
I 
littermate null homozygote (129/Sv x C57BL/6) mice were used as controls (lanes 1 and 
2). The panel of knockout mice were as follows: IFN-a/pR-/- (lane 3), IFN-yR-/- (lane 
4), and IFN-a/pR-yR-/- (lane 5), IRF-1-/- (lane 6), CD4o-/- (lane 7), and TNF-IR-IIR-/-
(lane 8). The cDNA samples from three individual mice in each case were obtained then 
combined equally prior to PCR. amplification for this figure. Individual samples were 
analysed multiple times to ensure reproducibility. 
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3.4 Discussion 
Previous studies suggest that APCs are an important source of I-TAC (Cole et al., 
1998). Expression of I-TAC from IFN-y activated DCs was shown in chapter 2. The 
more detailed analysis here confirmed that murine I-TAC expression from DCs is 
regulated primarily by the IFN-y signalling pathway and appears to be similar to the 
regulation of HuI-T AC, IP-10 and Mig expression. A significant finding was that IL-4, 
a cytokine frequently used to stimulate ex-vivo DCs, does not induce I-TAC expression 
and in fact appeared to decrease IFN-y induced I-TAC expression. Both the Th 1 
cytokines, such as IL-12 and IFN-y, and Th2 cytokines including IL-4, can suppress 
each other. This negative regulation appears to occur at several different levels during 
cytokine signalling. (reviewed in Rook et al., 1994; Ivashkiv, 1995; Yasukawa et al., 
2000). Regulation of ST AT activity may occur by inhibition or activation of the ST A Ts 
themselves, upstream signalling events and also at the DNA promoter level (reviewed in 
Ivashkiv, 1995). For example, IL-4 activates the STAT6 transcription factor, which can 
bind to the same promoter, FcyR 1, as the IFN-y activated STAT 1 factor leading to 
competitive regulation (Lamer et al., 1993). One of the ways IL-4 could antagonize 
IFN-y action and subsequently CMI responses may include the down regulation of I-
TAC via the inhibition of the IFN-y signalling pathway. 
Regulation of murine I-TAC expression by cytokines and downstream signalling factors 
was further examined in Con A activated splenocytes from a panel of knockout mice. 
Expression of murine I-TAC in splenocytes from IFN-yR_1_ and IFN-cx/~R-yR_1_ mice 
were barely detectable compared to I-TAC expression in the splenocytes from control 
mice which confirms the cell line data. Together, these results confirmed that IFN-y is 
the primary regulator of murine · I-TAC. Mice lacking IFN-yR appear to develop a 
normal immune system, however they are far more susceptible to infection by Listeria 
monocytogenes and VV despite apparently normal cytotoxic and T helper cell responses 
(Huang et al., 1993). Although IFN-y initiates a number of anti-pathogen mechanisms, 
it is likely that significantly reduced levels of I-TAC and probably IP-10 and Mig in 
these mice, may reduce migration of immune cells to the site of infection and thereby 
increasing the susceptibility of these mice to infection. In a similar fashion, IFN-a/~R-
yR_;_ mice are also susceptible to lymphocyte choriomeningitis virus (LCMV) and VV 
(van den Broek et al., 1995). The replication rate of VV is much higher in these mice 
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and there was a deficient CTL response against the virus (van den Broek et al., 1995). 
Again, it is likely that in these mice, a lack of I-TAC may decrease the migration of T 
lymphocytes to the infection site, reducing the ability of these mice to mount an 
effective immune response. 
The assays carried out here, also demonstrated that a proportion of I-TAC expression is 
dependent on the action of IRF-1, with the remainder of I-TAC expression possibly 
being regulated by other IRF transcription factors involved in the interferon signalling 
pathway (reviewed in Taniguchi et al., 2001 ). The finding that murine I-TAC is in part 
regulated by IRF-1 may help explain some of the complex phenotype of IRF- 1-1- mice. 
IRF-1-1- mice have defective development of thymic CDS+ cells, severe NK cell 
deficiency and an abnormally high proportion of Th2 CD4+ T cells, which together lead 
to increased susceptibility to pathogens normally controlled by Thl responses (Mamane 
et al., 1999). Thus the decreased expression of murine I-TAC from DCs in IRF-1-1-
rmce, combined with decreased Crg-2 and MIG expression (S Mahalingam, 
unpublished data), may be altering the balance of Thl/Th2 CD4+ T cells and subsequent 
susceptibility to infection. 
Previously it has been shown that IFN-a or IFN-~ can enhance the expression of HuI-
TAC with or without other cell activation signals (Rani et al., 1996). In this study 
however, using the cells from various knockout mice, these two cytokines instead, 
appeared to down regulate the level of murine I-TAC expression. The level of these 
cytokines in the cultures while not analyzed, was probably low (Watanabe and Kawade, 
1988; Noronha et al., 1993). These analyses and others have shown that low levels of 
IFN-a or IFN-~ can increase the expression of IRF-2, which competes with IRF-1 
thereby suppressing IRF-1-regulated genes (Mamane et al. , 1999). Therefore in these 
assays, the lack of IFN-a and/or IFN-~ signalling in the IFN-aJ~R-1- and IFN-aJ~R-yR_1_ 
Con A cultures, and subsequent lower levels of IRF-2 expression, explains why murine 
I-TAC expression was relatively higher than in the wild type and IFN-yR_1_ Con A 
cultures respectively. Thus, comparing this data with previously published human I-
T AC findings, it appears that IFN-a and IFN-~ can act both to increase or decrease I-
T AC expression depending on the relative amount of these two cytokines present 
(Huang et al., 2000). 
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Others have reported that TNF-q and IFN-y synergize to enhance the expression of HuI-
TAC (Gasperini et al., 1999; Sauty et al., 1999; Albanesi et al., 2000). No evidence of 
synergy between IFN-y and TNF-a in either the cell line or Con A culture analyses was 
found in these studies. In these cell line assays TNF-q is included primarily to promote 
cell differentiation during stimulation with other cytokines (Banyer and Hapel, 1999). 
Hence, in the analyses reported by others, TNF-a may have appeared to enhance 
expression of I-TAC induced by IFN-y through increased survival of differentiated 
cells. 
IFN·-y, TNF-a and CD40 have all been shown to activate the NF-KB transcription 
factor, therefore it is of no surprise then, that a synergistic effect is observed between 
IFN-y and either TNF-a or CD40 to induce IP-10 and Mig (Ohmori and Hamilton, 
1995; Baldwin, 1996; van Kooten and Banchereau, 1997; van Kooten and Banchereau, 
2000). However, the synergistic induction of IP-10 by IFN-y and TNF-a occurs via 
activation of NF-KB through independent binding sites (Ohmori and Hamilton, 1995). 
This effect can also be cell type and/or stimulus specific. For example, this cooperative 
effect between TNF-a and IFN-yto induce IP-10 is observed in NIH 3T3 cells, whereas 
in macrophages, no synergy is detected (Ohmori and Hamilton, 1995; Huang et al., 
2000). Therefore, another explanation for the variability in observing synergy between 
these cytokines in the induction of murine I-TAC may be that NF-KB activation in the 
DC cell lines in this study was different to NF-KB activation in the cells used in 
previous reports for IP-10 and Mig. 
The addition of anti-CD40 Ab to MTHC-D2 cells showed that CD40 alone can 
upregulate expression of murine I-TAC and that the CD40 and IFN-y pathways can 
synergize to enhance this expression. This is consistent with a report by Altenburg et al, 
who showed that in cervical carcinoma cells, IFN-y can synergize with CD40L to 
enhance expression of a number of chemokines including IP-10, MCP-1, and to a lesser 
extent RANTES and MCP-3 (Altenburg et al., 1999). Enhanced I-TAC expression 
however, was not detected in the JAWS II cell line following CD40 activation. This 
result could be due to differences in the level of CD40 expression between the two cell 
lines. The JAWS II cell line however, lacks the tumor suppressor p53 and others have 
shown that p53-dependent functions can be regulated by CD40 (Teoh et al., 2000). 
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Hence, the absence of IFN-y/CD40 synergy in the JAWS II cell line could be explained 
by poor responsiveness in some of the downstream CD40 signalling pathways which 
involve p53. An alternative explanation is that the CD40 signalling pathways in the 
MTHC-D2 line was somehow enhanced due to the unregulated expression of truncated 
c-Myb used to immortalize these cells (Gonda et al., 1993). In the Con A activated 
CD40_1_ splenocyte cultures, the lack of CD40 did not appear to reduce murine I-TAC 
expression, which like the JAWS II cell line suggests that CD40/IFN-y do not synergize 
to enhance I-TAC expression. In addition to this the effect of TNF-cx and/or CD40 could 
be obscured by large amounts of IFN-y in the Con A activated splenocyte cultures. 
Therefore, Con A may not be an appropriate stimulus to observe synergy between these 
cytokines. 
In summary, these data indicated I-TAC is primarily induced by IFN-y through the 
transcription factor IRF-1. CD40 may have a synergistic effect on expression, probably 
also via the activity of IRF-1. Together, with the data from chapter 2, I-TAC seems to 
be expressed from maturing DCs. If murine I-TAC is like human I-TAC, then it too 
probably enhances Thl immune responses by attracting activated CD4+ T lymphocytes 
to the site of infection. Examining different disease models would clarify whether or not 
this chemokine has a functional role in immune defense. 
CHAPTER 4. 
I-TAC EXPRESSION DURING DISEASE 
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CHAPTER 4. I-TAC EXPRESSION DURING DISEASE 
4.1 Introduction 
There are many disease models where I-TAC may have a role, especially in diseases 
where the CMI response is activated. To examine this, the expression of I-TAC in 
respiratory syncytial virus (RSV), influenza virus and vaccinia virus (VV) infection 
models as well as the auto immune disease model experimental autoimmune 
encephalomyelitis (EAE) and non-rejected allo- and xenograft transplantation models 
were investigated. 
4.1.1 Chemokine expression initiated by viral infections 
Virus infection leads to the release of a myriad of chemokines that activate the immune 
system. Indeed, many chemokines have been detected during viral infections, for 
example expression of RANTES, MCP-1, MIP-la and IP-10 has been detected during 
an influenza A virus infection of human monocytes (Bussfeld et al., 1998; Matikainen 
et al., 2000). Influenza A primarily infects epithelial cells in the upper respiratory tract, 
as well as infecting macrophages, monocytes and T cells. After infection, a number of 
different cells migrate to the lungs and respiratory tract in response to the multiple 
chemokines released (Bussfeld et al., 1998; Matikainen et al., 2000). 
A large number of chemokines are also expressed by respiratory syncytial virus (RSV) 
infected human lower airway epithelial cell lines (A549 and SAE cells) including, MIP-
la, MIP-1~, RANTES, GRO-a, GRO-~, GRO-y, IP-10 and Hul-TAC (Zhang et al., 
2001). RSV causes a lower respiratory tract disease in young children and is associated 
with obstruction of the airways and enhanced inflammation and infiltration of a number 
of different leukocytes (Chanock et al., 1992). The expression of RANTES induced 
during RSV infection is dependent on the transcription factor NF-KB. Indeed RSV has 
been shown to induce NF-KB, which is also important for IP-10 and Hul-TAC 
expression (Thomas et al., 1998; Roebuck et al., 1999; Zhang et al., 2001). 
The IFN-inducible chemokines Mig and IP-10 have been shown to be upregulated 
during several viral infections, although expression may be dependent on either virus 
strain or host strain. Ectromelia virus (EV), an orthopoxvirus closely related to VV, is a 
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natural mouse pathogen that causes generalized infection resulting in a disease termed 
mousepox. Inbred strains of mice may be classified as resistant or susceptible to 
mousepox. For instance, C57BL/6 mice are resistant to the disease while BALB/c mice 
are highly susceptible. These differences are attributed to the generation of a Thl 
immune response in resistant mice, and a Th2 immune response in susceptible mice 
(Mahalingam et al., 2001). It has been shown that them.RNA and protein expression of 
Mig and Crg-2 are up-regulated in the draining lymph nodes of resistant C57BL/6 mice 
but not in those of susceptible BALB/c mice as early as one day after infection with EV 
(Mahalingam et al., 2000). Local treatment of BALB/c mice with recombinant Crg-2 
shortly after infection, however, results in enhanced NK cell activity in the draining 
lymph node. The data suggest that the lack of NK cell-activating chemokines contribute 
to the suboptimal NK cell-mediated defense. Therefore, the early production of Mig and 
Crg-2 may also contribute to the resistance to EV by affecting the circulating population 
of activated T cells (Mahalingam et al., 2000). 
During VV infections, numerous chemokines are expressed including Mig and Crg-2. 
Expression of Mig and Crg-2 was detected in multiple organs and at relatively high 
levels in C57BL/6 mice after VV infection. Chemokine expression was detected by day 
three and generally peaked at around day six, which coincided with IFN-y expression. 
Expression of IFN-y, Mig and Crg-2 all decreased by day ten post-infection 
(Mahalingam et al., 2000; Mahalingam and Karupiah, 2000a). Given the similarities 
between I-TAC, Mig and Crg-2, it would not be surprising if I-TAC is expressed and 
functions in a similar manner to these other chemokines during such infections. 
4.1.2 Autoimmunity - EAE 
Chemokine expression is not limited to viral or pathogen infections, indeed, expression 
of many chemokines has been detected during autoimmune diseases. During the CNS 
demyelinating disease, EAE, the infiltration of activated Thl autoreactive T cells into 
the CNS occurs. Numerous chemokines are expressed during various stages of EAE and 
include; RANTES, MIP-lcx, MIP-1~, MCP-1 and IP-10 (Hulkower et al., 1993; 
Ransohoff et al., 1993; Glabinski et al., 1995; Godiska et al., 1995; Glabinski et al., 
1997; Youssef et al., 1998; Glabinski and Ransohoff, 1999). The exact role of these 
chemokines however, is still unclear. 
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Arimilli et al has previously used a monoclonal anti-CXCR3 Ab during a murine 
proteolipid protein peptide (PLP139-1s1) induced EAE model. Injection of this Ab on 
days -1, +3, and + 7 post disease induction demonstrated that mice were significantly 
protected from development of EAE (Arimilli et al., 2000). This suggests a plausible 
use for therapeutic agents targeting the CXCR3 receptor for patients suffering from 
multiple sclerosis, and other similar autoimmune diseases (Arimilli et al., 2000). This 
study indicates that Mig, IP-10 and I-TAC possibly enhance the severity of disease via 
CXCR3. 
In addition to this, the high level of I-TAC expression in human astrocytes and its 
ability to attract activated T cells has led some to propose that I-TAC may have a very 
important role during the induction and pathophysiology of neuroinflamrnatory 
disorders including multiple sclerosis (MS) (Cole et al., 1998; Luo et al., 1998). 
Confirmation of a role in animal MS models, such as EAE, has been slow because a 
rodent I-TAC homologue had previously not been identified. Determining how a potent 
chemokine such as I-TAC might fit into the processes of autoimmunity is essential to 
thoroughly understand MS, EAE and perhaps-other inflammatory autoimmune diseases. 
4.1.3 Transplantation 
The migration of leukocytes into a transplanted graft is an essential requirement for 
graft rejection. Surgical trauma and ischemic damage during the early stages of 
transplantation and leukocyte infiltration can lead to further recruitment of excess 
effector leukocytes and hence the enhanced damage to the graft (Nelson and Krensky, 
2001). The graft rejection process also relies heavily on the migration of DCs from the 
graft into secondary lymphoid tissue (Lakkis et al., 2000). The migration of leukocytes 
into the transplanted region as well as the recruitment of DCs to lymphoid tissue 
therefore requires the activity of a multitude of chemokines · being released throughout 
the transplantation process. 
The chemokines Mig and IP-10 are expressed at high levels during acute cardiac 
allograft rejection, and CXCR3 deficient mice show profound resistance in the 
development of transplant rejection. One group of CXCR3 deficient mice were given a 
subtherapeutic course of cyclosporin A, an irnmunosuppressive agent, and subsequently 
showed permanent engraftment (Hancock et al., 2000). In addition to this, mice with 
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normal CXCR3 function that were treated with anti-CXCR3 monoclonal antibody have 
shown delayed onset of allograft rejection (Hancock et al., 2000). Since I-TAC also 
binds to the CXCR3 receptor, it is possible that I-TAC may also have an important 
function in transplant rejection. 
Characterisation of I-TAC expression during different murine disease models may not 
only extend the understanding of the role of I-TAC during an immune response but 
could also help understand the immune processes during such diseases. 
CHAPTER4 
4.2 Materials and Methods 
4.2.1 Mice 
81 
Specific pathogen-free 6-8 week old female C57BL/6, male BALB/c, and CBA/H mice 
were obtained from the Animal Breeding Facility, John Curtin School of Medical 
Research, Canberra, Australia. The origin of the IFN-yR-/- and the age-matched null 
homozygote (C57/BL6 x 129/Sv) mice used for the EAE studies are described in 
section 3 .2.1. 
4.2.2 Virus disease models 
4.2.2.1 RSV infection of mice 
RSV strain A2 (ATCC number CCL-23) was maintained as described previously 
(Ghildyal et al., 1999). BALB/c mice were infected intranasally with 1 x 105 PFU of 
RSV. Lungs were collected on days 0, 3 and 6, RNA isolated and cDNA generated 
before PCR analysis (section 2.2.5, 2.2.12 and 2.2.14). 
4.2.2.2 Influenza A virus infection of mice 
For influenza A (strain A/PR/8/34), C57BL/6 mice were infected intranasally with 200 
HAU of virus as described previously (Karupiah et al., 1998). Lungs were collected on 
days 0, 5, and 10 post infection and RNA isolated and cDNA generated before PCR 
analysis (section 2.2.5, 2.2.12 and 2.2.14). 
4.2.2.3 VV infection of mice 
The tissue culture adapted VV, VV-WR-L929-TK, referred to from hereon as vaccinia 
virus western reserve (VV-WR), was obtained and maintained as described previously 
(Boyle et al., 1985). C57BL/6 mice were infected intranasally with 1 x 104 PFU of VV-
WR. Lungs were collected on days 0, 3, 6, and 9 and RNA isolated and cDNA 
generated before PCR analysis (section 2.2.5, 2.2.12 and 2.2.14). 
4.2.3 EAE model 
The peptide corresponding to arruno acids 35-55 of rat myelin oligodendrocyte 
glycoprotein (MOG - 35Met-Glu-Val-Gly-Trp-Tyr-Arg-Pro-Pro-Phe-Ser-Arg-V al-Val-
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His-Leu-Tyr-Arg-Asn-Gly-Lys55) was synthesized by standard f-moc chemistry and 
the purity determined by reverse phase HPLC (Biomolecular Resource Facility, 
JCSMR, ANU). Rat MOG35_55 (2 mg/ml in saline) was emulsified in an equal volume of 
CF A containing 0.5 mg/ml Mycobacterium butyricum and 4 mg/ml Mycobacterium 
tuberculosis (H37Ra). Each mouse received 100 µl emulsion distributed in the foot pads 
of both hind feet and in the nape of the neck. Total dose of MOG35_55 was 100 
µg/mouse. Immediately before, and 2 days after injection of the emulsion, the mice 
received an i.v. injection of 300 ng of pertussis toxin (List Biological Laboratory, 
Campbell, CA) in 250 µl of PBS. The mice were monitored daily and assigned EAE 
severity scores as described previously (Willenborg et al., 1996). Briefly, phenotypic 
scores were given a rating from zero to five. Zero indicates no visible symptoms; 1, 
partial tail paralysis is observed; 1.5, moderate to full tail paralysis and partial hind limb 
paralysis; 2, tail paralysis and moderate hind limb paralysis; 3, complete paralysis of the 
hind limbs and tail and often associated with incontinence; 3.5, paralysis of the tail and 
hind limbs with partial fore limb paralysis; 4, total paralysis of the tail, hind and fore 
limbs; 5 indicates death. First strand cDNA was also produced rrom mRNA isolated 
from CNS tissue excised using standard techniques from mice with EAE on days 8, 14, 
and 20 post challenge. 
4.2.4 Transplantation model 
Transplantation models were set up as described in Simeonovic et al., (Simeonovic et 
al., 1999). Briefly fetal BALB/c mouse and fetal pig proislets (islet precursors) were 
prepared from BALB/c fetal pancreas ( 17 days gestation) and SLA dd inbred fetal pig 
pancreas (68-76 days of gestation) by collagenase digestion (6mg/mL, Boehringer 
Mannheim, Germany), followed by culture in 10% CO2 in air for 4-7 days. The BALB/c 
mouse proislets were used for the allograft transplantation model where as the pig 
pro islets used for the xenograft transplantation model. Mouse and pig proislets were 
embedded in plasma clots prepared from recipient mice strain plasma ( 1120th fetal pig 
pancreas equivalent of proislets/clot or 2 fetal mouse pancreas equivalents/clot). Six 
plasma clots carrying fetal mouse proislets or two plasma clots loaded with pig proislets 
were transplanted beneath the kidney capsule of recipient CBA/H mice. Mice were 
treated i.p. on days -1, 1, 3, 7 and 10 post transplant with either GKl.5 (anti-CD4) mAb 
(0.48mg Ig/150µL/dose) to generate a non-rejected graft or PBS (150µL/dose) to 
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generate a rejected graft. On days 4, 8 and 14, mice were killed and grafts collected for 
RNA extraction and first strand cDNA synthesis. 
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4.3 Results 
4.3.1 Viral models 
The interferon inducible chemokines IP-10/Crg-2, Mig and human I-TAC have 
previously been shown to be expressed in a number of different viral infections 
including RSV, influenza A and VV (Bussfeld et al., 1998; Mahalingam et al., 2000; 
Mahalingam and Karupiah, 2000a; Matikainen et al., 2000; Zhang et al., 2001). Given 
the potency of I-TAC and the ability for it to recruit cells during a CMI response, 
murine I-TAC expression was investigated in these three viral infections. 
Peak RSV viremia occurs on days 5-6 and virus is cleared by day 10 (S. Mahalingam, 
personal communication.). The study carried out here showed that I-TAC expression 
corresponds to peak viremia with expression detected by RT-PCR on day 3 and 
increased levels on day 6 post infection compared to basal levels on day 0 (Fig 4. lA). 
A high level of I-TAC expression was detected by RT-PCR on day 5 post infection with 
influenza A whereas only basal levels were detected on days 0 and 10 (Fig 4. lB). This 
coincides with most severe disease symptoms as observed by the mice being hunched 
up as well as slight shivering, as well as peak viremia as shown previously (Karupiah et 
al., 1998). 
Expression of I-TAC during a VV-WR infection was not detected by RT-PCR at any 
time point during disease (Fig 4.1 C). Similar results were obtained after mice were 
injected i.p with higher lethal doses (1 x 106 PFU) of VV-WR (data not shown). This 
was surprising considering other published findings with other chemokines such as Mig 
and Crg-2 (Mahalingam et al., 2000; Mahalingam and Karupiah, 2000a). 
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Figure 4.1: Analysis of murine I-TAC expression from mouse lungs during three 
different viral infections. BALB/c mice were injected intranasally with 1 x 105 PFU of 
respiratory syncytial virus (A) and samples analyzed on days 0, 3, and 6 post infection. 
C57BL/6 mice were injected intranasally with 200 HAU of influenza A virus (B) and 
samples analyzed on days 0, 5 and 10 post infection. C57BL/6 mice were injected 
intranasally with 1 x 104 PFU of VV-WR (C) and samples analyzed on days 0, 3, 6 and 
9 post infection with a positive control. 
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4.3.2 Expression of murine 1-T AC in the CNS of mice with EAE 
Previously, it has been reported that IFN-yR-1- mice challenged with rat MOG35_55 
peptide develop severe EAE and die whereas wild type control mice (IFN-)'R+/+) 
develop a milder disease and recover (Willenborg et al., 1996). Given that HuI-T AC 
was isolated from astrocytes in the CNS, attracts activated T cells and is regulated by 
IFN-y, murine I-TAC expression in the CNS of wild type and IFN-yR-/- mice with 
MOG35_55-induced EAE was investigated. Figure 4.2A shows the disease scores of the 
wild type and IFN-yR-/- mice sacrificed on day 8 (before clinical disease), day 14 (peak 
disease in wild type mice) and day 20 (recovery in wild type mice). Semi-quantitative 
RT-PCR analysis detected very low levels of murine I-TAC in the CNS of IFN-yR-/-
mice throughout the time course (lanes 1-9) while these mice developed increasingly 
severe disease (Fig 2B). Analysis of wild type control mice however, showed that I-
TAC levels in the CNS were initially low on day 8 (lanes 1-3), were very high at the 
peak of disease when the mice begin to recover on day 14 (lanes 4-6), but then returned 
to low levels by day 20 (lanes 7-9) (Fig 2C). These results do not provide a direct role 
for murine I-TAC during disease, however they measure I-TAC expression during EAE 
for the first time. 
A s 
4 
(1) 
'-
0 (.) 3 
Cf) 
(1) 
Cf) 
cu 2 (1) 
Cf) 
0 
1 
-. -
- -
--- IFN-yR-1-
..•.. Wt 
-- --
-- --
- --
-0--------------_., 
Day8 Day 14 Day20 
B 1 2 3 4 s 6 7 a 9 
I-TAC 
IFN-yR_,_ mice 
GAPDH 
C 1 2 3 4 s 6 7 a 9 
I-TAC 
Wt mice 
GAPDH 
...__ _ ___.I .__I __ __.I .__I __ __. 
Day8 Day 14 Day20 
Figure 4.2: Analysis of murine I-TAC expression in the CNS of mice with BAE. A) 
Disease scores of wild type (circles) and IFN-yR-/- (squares) mice with MOG35_55 
peptide induced BAE. B) Semi-quantitative RT-PCR analysis of murine I-TAC and 
GAPDH mRNA CNS expression in IFN-yR-/- mice with BAE at day 8 (lanes 1 to 3), 
day 14 (lanes 4 to 6) and day 20 (lanes 7 to 9). C) Semi-quantitative RT-PCR analysis of 
murine I-TAC and GAPDH mRNA CNS expression in wild type mice with BAE at day 
8 (lanes 1 to 3 ), day 14 (lanes 4 to 6) and day 20 (lanes 7 to 9). 
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4.3.3 Transplantation model 
Two different transplantation models were examined for I-TAC expression and 
therefore whether or not I-TAC has a possible role during the process of transplantation 
rejection. A murine allograft transplantation model was assessed, which uses a 
transplanted graft derived from a mouse of the same strain as the recipient. In addition 
to this, a xenograft model was also utilized where the transplant sample was derived 
from a fetal pig pancreas and grafted into a mouse recipient. In both cases non-rejected 
grafts were established by injecting anti-CD4 mAbs which inhibits CD4 T cell activity 
within the transplantation site. 
Low levels of murine I-T.L.\.C mRNA expression are observed on days 4 and 8 in both 
rejected and non-rejected allograft samples but \are absent on day 14 (Fig 4.3A). This 
shows that I-TAC is expressed from within the grafts most likely leading to the 
recruitment of T cells to the site of transplantation. As I-TAC is expressed in both 
rejected and non-rejected samples, expression is most likely a result of the 
transplantation process itself, causing general damage, inflammation and DC activation 
in the graft rather than as a result of allograft rejection or autoimmunity caused by T 
cells. 
The results observed with the xenograft samples are less clear, with relatively high 
levels of I-TAC mRNA expression being observed in the rejected PBS treated mice, on 
day 4, none on day 8 and a moderate level on day 14. These changes in I-TAC 
expression may indicate a relapsing-remitting rejection process however the sample 
numbers are too low to be certain. A greater pool of sample numbers may establish a 
clearer trend. I-TAC expression was observed at high levels on days 8 and 14 from the 
non-rejected xenograft (anti-CD4 mAb treated) mice (Fig 4.3B). Recruitment of 
immune cells into the graft site is therefore likely to occur a week or so post operation, 
however the sample numbers are again to low to be confident of a significant trend. The 
results however, suggest that there must be cells, including DCs infiltrating the graft 
which subsequently express murine I-TAC, presuming that the RT-PCR is unable to 
amplify pig I-TAC, the sequence of which is unknown to date. 
Rejected Non-rejected 
~~
Day 4 8 14 4 8 14 
I-TAC 
Figure 4.3A: Semi-quantitative RT-PCR of rejected and non-rejected allograft samples 
collected on days 4, 8 and 14. 
Rejected Non-rejected 
~~
Day 4 8 14 4 8 14 
GAPDH 
Figure 4.3B: Semi-quantitative RT-PCR of rejected and non-rejected xenograft 
samples collected on days 4, 8 and 14. 
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4.4 Discussion 
4.4.1 I-TAC expression during viral infections 
The induction of murine I-TAC from DCs, after stimulation with IFN-y, suggests that I-
T AC may have a role in CMI responses. Expression during different disease models 
was examined to observe if I-TAC expression was consistent with the known immune 
mechanisms functioning in each model. Many different viral infections including RSV, 
influenza A and VV can cause the induction of IP-10/Crg-2 and Mig (Bussfeld et al., 
1998; Mahalingam et al., 2000; Mahalingam and Karupiah, 2000a; Matikainen et al., 
2000). Not surprisingly, human I-TAC expression has been detected during an RSV 
infection (Zhang et al., 2001). The studies carried out here demonstrated that murine I-
TAC was expressed during both RSV and influenza A viral disease models. Expression 
coincided around peak infection suggesting that murine I-TAC has a role during viral 
infection. I-TAC most probably functions by recruiting NK and Thl cells to the site of 
infection and enhancing viral clearance and as a result may have an important role 
during CMI responses. The primary control of an influenza infection does not appear to 
require IFN-y, although a lack of IFN-y results in a significant reduction in cellular 
recruitment to the site of infection (Graham et al., 1993; Baumgarth and Kelso, 1996; 
Karupiah et al., 1998). This suggests that the main function for IFN-y during an 
influenza infection is to regulate leukocyte trafficking, probably via I-TAC and the 
other IFN-inducible chemokines (Baumgarth and Kelso, 1996). Given the relative 
potency of I-TAC compared with the other IFN-inducible chemokines, artificially 
enhancing I-TAC expression in the lungs during either an influenza or RSV infection 
may reduce disease and be beneficial as part of a therapeutic regime. Inhibition of 
natural I-TAC expression by whatever reason, e.g. a genetic disorder, may make the 
disease worse, although there would presumably be some compensatory mechanism 
initiated by other chemokines. 
I-TAC expression however, was not detected by RT-PCR in the VV-WR infection. This 
was somewhat surprising considering previous findings, which detected both Mig and 
Crg-2 in the liver, spleen, uterus and ovaries during similar experiments (Mahalingam et 
al., 2000; Mahalingam and Karupiah, 2000a). In these previous studies expression 
levels of Mig, Crg-2 and IFN-y however, were quite variable between these tissues, 
moreover, expression in lungs was not assessed. It may be that during an intranasal 
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infection of VV, DCs in the lung do not express I-TAC but instead mature and express 
this chemokine in the draining lymph nodes, which were not assessed. Also, recent 
findings in the vaccine immunology group, at the John Curtin School of Medical 
Research, have demonstrated that VV can kill immature DCs (from a DC line) very 
early during an in vitro infection (unpublished data). Hence if both of these effects 
operate in vivo, then there would be a reduced number of these cells capable of 
expressing I-TAC. 
It is possible therefore, that the lack of I-TAC expression may be due to VV having a 
mechanism that inhibits I-TAC expression. Poxviruses including VV have developed 
several mechanisms to help evade the immune system (Lalani et al., 2000). In fact, the 
genomes of most poxviruses appear to encode soluble cytokine and chemokine binding 
proteins (Puehler et al., 1998). For example, the Lister strain of VV secretes a 35 kDa 
protein that inhibits eotaxin function. This chemokine binding protein also binds and 
inhibits activity of other CC chemokines including RANTES, MIP-la, MCP-1, and I-
309 (Alcami et al., 1998). Poxviruses can also encode chemokine receptor homologues 
that also inhibit chernokine activity, for example, swinepox virus encodes a CXCRl 
homologue, K.2R reducing the effects of IL-8 (Cao et al., 1995). Binding proteins or 
their receptors however, would probably not inhibit mRNA expression suggesting that 
inhibition of I-TAC in the assays here occurred upstream of initial expression. 
VV encodes a soluble IFN-yR homologue, the B8R gene, which neutralizes the 
biological activity of IFN-y in a number of species including man, cow, rabbit, rat and 
chicken, however it does not inhibit IFN-y in the mouse (Goebel et al., 1990; Alcami 
and Smith, 1995; Mossman et al., 1995; Puehler et al., 1998). Therefore, expression of 
I-TAC and the other IFN-inducible chernokines, Mig and Crg-2, may be inhibited 
directly by the B8R protein in these other animals but this could not be the case in mice. 
However, it has recently been demonstrated that VV-WR can inhibit IFN-y signal 
transduction (Najarro et al., 2001). The mechanism utilized by VV-WR is independent 
of the B8R gene blocking IFN-y activity and instead uses a viral phosphatase, VHl, 
encoded by VV-WR. The activity of VHl inhibits phosphorylation and subsequent 
nuclear translocation of the STATl transcription factor. Consequently, this blocks 
expression of mRNAs normally induced by IFN-y (Najarro et al., 2001). This study also 
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demonstrated that the inhibition of STATl by VHl does not alter the activity of 
upstream signalling molecules such as J AKl and J AK.2. As ST AT 1 is a crucial 
component of the major IFN-y pathway, it is likely that inhibition of STATl by VHl 
inhibits I-TAC expression during VV-WR infection in mice. The expression of Mig and 
Crg-2 during a VV infection may be due to an alternative signalling pathway, not 
requiring STATl. 
Inhibition of NF-KB, a transcription factor involved in the IFN-y, CD40 and TNF-a 
signalling pathways, by pox viruses has also been demonstrated (Bowie et al., 2000; Gil 
et al., 2001; Oie and Pickup, 2001). The strain of virus appears to be important for NF-
KB inhibition, for example Cowpox, molluscum contagiosum, racoonpox, VV 
Copenhagen strain and VV-WR can inhibit NF-KB activity. In contrast the modified VV 
Ankara strain, an attenuated virus, lacks the ability to inhibit NF-KB (Bowie et al., 
2000; Gil et al., 2001; Oie and Pickup, 2001). The lack of NF-KB activity induced by 
poxviruses occurs by components expressed by the viruses (i.e. SalF9R and SalF15R 
genes expressed by VV-WR), which interfere with the degradation process of IKBa, a 
negative regulator of NF-KB (Oie and Pickup, 2001). As a result of VV-WR inhibiting 
NF-KB it is possible that murine I-TAC may not subsequently be expressed during 
infection. NF-KB activation can also induce Mig and IP-10 expression (Ohmori and 
Hamilton, 1995; Ohmori et al., 1997). It would be expected then, that NF-KB inhibition 
by VV-WR may reduce or inhibit expression of these two chemokines compared to 
other infections such as RSV or influenza A. 
Inhibition of I-TAC and other chemokine expression by poxviruses such as VV and 
variola (smallpox) may explain why these viruses are such successful pathogens. 
Artificially expressing I-TAC at the site of a VV infection, and possibly other poxvirus 
infections, may inhibit this immune evasion mechanism and aid viral clearance and 
recovery. 
4.4.2 1-T AC expression during EAE 
It has been speculated that human I-TAC, expressed from astrocytes and other APCs in 
the CNS, can exacerbate neuroinflammation and autoimmunity because it can recruit 
activated T cells and appears to be an early mediator of immune responses (Cole et al., 
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1998; Luo et al., 1998). The expression of murine I-TAC during EAE was examined to 
see if it had a role in this disease model. Analysis of wild type mice with MOG peptide-
induced EAE demonstrated that murine I-TAC expression was highest at the peak of 
disease severity when the animals first begin to recover. This was somewhat later than 
expected and suggests that I-TAC does not have a role in the early disease processes. 
This is consistent with a previous study that showed that the main function of the 
currently known BAE-associated chemokines is to regulate later CNS inflammatory 
reactions as opposed to aiding the initial entry of autoreactive T cells into the CNS 
(Glabinski et al., 1999). 
Recently, Willenborg et al, reported that IFN-y R-1- mice with MOG peptide-induced 
EAE develop severe disease and die whereas wild type mice develop mild disease and 
recover (Willenborg et al., 1996). The report by Willenborg et al, demonstrated that 
IFN-')', while primarily a proinflammatory cytokine, is also important for disease 
recovery. This ?tudy found that I-TAC expression was very low at all stages of EAE 
disease when induced in IFN--yR-/- mice. These results do not provide a direct link 
between the function of murine I-TAC and the EAE disease phenotype. It is however, 
interesting to speculate, given the lack of murine I-TAC in the IFN-yR_1_ mice that I-
T AC might have a role during disease recovery in wild type mice by recruiting 
suppressor T cells. It is more likely however, given that antibodies to a functional 
domain of CXCR3 protect mice from EAE, that murine I-TAC acts to enhance 
neuroinflammatory processes (Arimilli et al., 2000). As there are other chemokines that 
bind to CXCR3, a thorough assessment of the contribution of murine I-TAC in the 
progression of neuroinflammation however, remains to be investigated. 
4.4.3 I-TAC expression during two graft transplant models 
The migration of leukocytes into the regions of transplanted grafts as well as the 
recruitment of DCs to lymphoid tissue requires the activity of numerous chemokines. 
Characterising the chemokines involved could aid in the development of therapeutic 
agents to block leukocyte infiltration and ultimately inhibit the rejection process. I-TAC 
mRNA expression is observed throughout the early to mid stages of allograft 
transplantation (in both rejected and non-rejected samples). This expression pattern is 
unlike the viral models or the EAE transplantation model indicating that I-TAC may be 
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expressed as a result of general damage following transplantation surgery rather than as 
a direct result of specific allograft rejection or autoimmunity. Previous studies have 
examined the expression of IFN-')' during transplantation models (Morris et al., 1995; 
Simeonovic et al. , 1999). Expression of IFN-')' appears around day five during rejected 
allografts although there is very little expression during non-rejected allografts 
(Simeonovic et al., 1999). 
The study analyzing tissues from rejected xenograft transplantation showed varying 
results throughout the time course, which may indicate differing levels of inflammation 
and cellular recruitment in different mice. The necessity of murine DCs to migrate into 
the graft before beginning to express chemokines may explain why murine I-TAC was 
not expressed until day 8 in the non-rejected samples. The nature of the transplantation 
models used here however, meant that only one mouse sample was taken at each time 
point. This means that variation between individual mice could not be addressed and 
determining whether I-TAC expression or indeed any other chemokine was important 
was difficult. Although these results do not appear to show a clear trend of I-TAC 
expression in the different transplantation models they perhaps show that cells 
expressing I-TAC migrate into the graft provided there is no RT-PCR cross-reactivity to 
pig I-TAC which is unlikely. These cells may be DCs or other APCs, which then 
express I-TAC in order to recruit T cells. Utilizing anti-CD4 mAbs to block rejection 
did not clarify the situation with respect to I-TAC expression. Anti-CD4 mAbs inhibit 
CD4 cell activity resulting in the inhibition of the rejection process however, this would 
not alter I-TAC expression from APCs from within the transplanted graft. Inhibiting 
early events such as host APCs from infiltrating transplantation grafts may help reduce 
the rejection process. Blocking chemokine receptors, including CXCRl , CCRl and 
CCR2, which are expressed on APCs during early migration events, may be one way of 
achieving this. Recently it has been demonstrated that the administration of anti-CD40L 
Ab to non-human primates can prevent rejection of renal allografts (Kirk et al. , 1999). 
The mechanism for rejection inhibition is still unclear, however T cell infiltration still 
occurs (Kirk et al., 1999). The lack of CD40 activity may halt CD4+ T cell activation 
required before rejection can be initiated. 
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Many studies have demonstrated that CXCR3 and CD4+ T cell activity are important 
during the rejection process and indeed, inhibition of T cell activation or mononuclear 
migration has been shown to inhibit or at least delay the onset of the rejection process 
(Russell et al., 1996; Chandraker et al., 1998; Melter et al., 1999; Hancock et al. , 2000). 
As such, blocking the activity of individual chemokines like I-TAC, as well as Mig and 
IP-10 may be a useful therapeutic tool to inhibit or delay the rejection process. It is 
probably more practical however, to block the CXCR3 receptor which binds all three 
chemokines as has previously been demonstrated (Hancock et al. , 2000). 
These studies have confirmed that I-TAC is expressed during immune responses 
towards disease situations. The outcome of I-TAC activity most likely depends on the 
disease in question. I-TAC expression during viral infections probably supports viral 
clearance by attracting NK and Th 1 cells to the site of infection, whereas during EAE, I-
T AC may exacerbate disease by recruiting autoreactive T cells into the CNS. To further 
analyze the in vivo function of I-TAC during disease challenges several methods could 
be applied. Two commonly approved methods to deregulate and/or overexpress a gene 
of interest are by utilizing either DNA plasmid vaccines or recombinant viral vectors . 
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I-TAC 
5.1 Introduction 
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Expression of I-TAC from DCs in response to IFN-y (chapters 2 and 3), and during 
different Thl biased disease models (chapter 4) suggested that I-TAC may have an 
important role during induction and/or recall of cell-mediated immune responses. 
Exploiting chemokines for therapeutic agents or using them to augment vaccines has 
been postulated and tried in several different model systems (Youssef et al., 1998; 
Biragyn et al., 1999; Narvaiza et al., 2000; Stoof et al., 2001). Utilizing I-TAC to 
attempt to modulate the immune response during disease not only assesses its potential 
for therapeutic and/or vaccine agents but also aids the further understanding of its 
functions in vivo. 
5.1.1 Recombinant VV encoding I-TAC 
An approach commonly used in conjunction with transgenic and gene knock out mice to 
study the in vivo effects of cytokines and chemokines is to engineer recombinant viruses 
that express the cytokines or chemokines of interest. These constructs are then utilized 
to study the effects of these factors on host immune responses during virus infection. 
During replication in vivo, the recombinant virus produces the encoded factor, which is 
then secreted from infected cells. The location and extent of virus replication determines 
the levels and sites of cytokine or chemokine production. This approach enables the 
effects of these molecules on the development of both the innate and adaptive immune 
responses mounted against the virus infection to be studied in vivo. 
Many of the encoded factors, including the cytokines IL-2 and IL-12, and the 
chemokines Mig and Crg-2, have demonstrated potent antiviral activity in vivo (Flexner 
et al., 1987; Ramshaw et al., 1987; Yilma et al., 1987; Ramshaw et al., 1997; Hogan et 
al., 1998; Mahalingam et al., 1999). Each of these factors induced particular antiviral 
host defense mechanisms, whilst for other encoded factors such as, IFN-y, TNF-cx and 
CD40 ligand, a direct antiviral effect was demonstrated (Kohonen-Corish et al., 1990; 
Sambhi et al., 1991; Ruby et al., 1995). IL-12, which also showed potent antiviral 
activity when expressed by rVV, is a strong stimulator of IFN-y production. As early as 
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one day after infection, VV encoding IL-12 was recovered at titres approximately 100-
fold lower than a control rVV in normal mice. However, IL-12 itself may also exert 
antiviral activity, as demonstrated by the observation that mice deficient in this factor 
failed to mount significant antiviral CTL responses or to clear the virus efficiently, 
despite unimpaired IFN-y expression (van Den Broek et al., 2000). Thus, in addition to 
its regulatory activity in Thl cell development, IL-12 may also play an important role as 
an antiviral mediator, both through the activity of IFN-y and independently of this factor 
(Banyer et al., 2000; Banyer et al., 2002 submitted, see appendix le). 
Expression of the T cell surface molecule CD40 ligand in rVV also produced, 
somewhat unexpectedly, a highly attenuated virus phenotype in viv~ (Ruby et al., 
1995). The attenuation of rVV-CD40 ligand in wild type mice was, however, 
completely reversed in CD40-deficient mice. Interestingly, CD40 expression is not 
restricted to B cells, macrophages and DC, but is also found on tumour cells and may be 
induced on fibroblasts incubated with IFN-y and TNF-a. Thus, it has been speculated 
that CD40 ligand/f cell-mediated activation of CD40 on virus-infected cells may act to 
limit the production of progeny virus, possibly through apoptosis of infected cells (Ruby 
et al., 1995). 
Using this recombinant VV expression system, Mig and Crg-2 have been shown to 
exhibit antiviral activity in vivo (Mahalingam et al., 1999). In infected mice, rVV-
encoded Mig or Crg-2 (rVV-Mig or rVV-Crg-2) enhanced the cytolytic activity of 
natural killer (NK) cells, mononuclear cell infiltration in livers and IFN secretion by 
two- to threefold and resulted in significant viral clearance and survival in nude mice. In 
contrast, mice infected with a control virus (rVV-X) that did not express a chemokine 
succumbed to generalized infection (Mahalingam et al., 1999). 
Construction of a recombinant VV encoding I-TAC would enable studies similar to the 
Mig and Crg-2 experiments to be carried out. The results obtained would enable further 
understanding of the function of murine I-TAC in vivo. 
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5.2 Materials and Methods 
5.2.1 Mice 
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Five to eight week old female C57BL/6 (wild-type) mice, and athymic, Swiss nude 
outbred mice were bred under specific pathogen free (SPF) conditions and obtained 
from the ABE, JCSMR. 
5.2.2 Cell lines 
A human osteosarcoma cell line, 143B, (Rhim et al. , 1975) were maintained in F15 
minimum essential medium (MEM) supplemented with 5% heat inactivated foetal calf 
serum (FCS; Flow laboratories, North Ride, Australia), 1 mM L-glutamine (Gibco), 10 
mM HEPES (Sigma) , and antibiotics (PSN;): 30 µg/mL penicillin G, 50 µg/mL 
streptomycin sulphate and 50 µg/mL neomycin sulphate (all from Sigma). 143B cells 
were incubated at 37°C, in 5% CO2 in air. 
5.2.3 Histology 
Organs were removed and immediately fixed in 10% neutral buffered formalin solution, 
processed and embedded in paraffin wax. Tissue sections (5µM thick) were mounted on 
glass slides and stained with hematoxylin and eosin (H and E) in the Histology facility, 
JCSMR. 
5.2.4 Plasmid cloning 
Cloning of target cDNA into the plasmid, pTK7.5A (Khanna et al., 1991) was carried 
out using methods described in section 2.2.7 and using the BamHl/Sall restriction 
enzyme sites. Plasmid DNA was grown and prepared as described in section 2.2.9. 
5.2.5 Recombinant VV construction 
A recombinant VV construct was made by inserting the target I-TAC cDNA into the 
multiple cloning site of the shuttle plasmid pTK7.5A (sections 2.2.7 and 5.2.4). This 
plasmid contains the thymidine kinase (tk) gene following the PF vaccinia promoter as 
well as the P7 .5 early/late promoter upstream of the multiple cloning site. The cloned 
plasmid was used to generate a recombinant VV by marker rescue recombination with 
the tissue culture adapted VV, VV-WR-L929-TK with the thymidine kinase gene region 
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previously disrupted by recombination with another plasmid, pBCB07 (Boyle et al., 
1985; Coupar et al., 1988). 
The parent VV WR-L929 tk- virus was trypsin treated for 30 min at 37°C (100 µL virus 
to 100 µL 1 mg/m.L trypsin) and the reaction stopped by adding 800 µL 5% FCS F15 
MEM media. L929 cells were infected with 0.01-0.05 multiplicity of infection (MOI) of 
virus for 1 hr and covered with 5% FCS F15 MEM media. Plasmid DNA was 
precipitated by making up dilutions of 10, 20 and 40 µg DNA in 20 µL MQW, and 2 µL 
calf thymus DNA (10 µg/m.L) and 1 rnL Hepes buffered saline (pH 7.0). 65 µL of 2M 
CaCh was added dropwise, then allowed to stand for 45 min. Media was removed from 
infected cells and plasmid DNA precipitate added evenly and left at room temp for 30 
min. Fresh 5% FCS F15 MEM media was then added and left at 37°C, 5% CO2 for 6 
hrs. Media was then replaced with 1 x MT AGG (3 µM Methotrextate; 15 µM 
Thymidine; 50 µM Adenosine; 50 µM Guanosine; 100 µM Glycine, made up to 1 mL 
MQW) in 5% FCS F15 MEM media and incubated at 37°C 5% CO2 for two days. 
Amplification of virus stocks was then carried out. Cells were collected by scraping and 
centrifuged (5 min, 3000 rpm) and resuspended in PBS. 100 µL of the virus was trypsin 
( 100 µL of 1 mg/mL) treated for 30 min at 37°C and the reaction stopped by adding 800 
µL 5% FCS F15 MEM media, then added to a small flask of 50% confluent 143B cells. 
Media containing MT AGG selection was added 1 hr later and grown for two days. 
5.2.6 Plaque purification 
An aliquot ( 100 µl) of the amplified virus stock was trypsinized with 1 00µL trypsin ( 1 
mg/mL) in PBS and was incubated at 37°C for 30 min. A range of dilutions of the virus 
stock were used to infect 143B cells grown in 6 well cluster plates for 1 hr before media 
containing FCS was added. The titration was carried out using 10-1 to 10-6 dilutions 
under selection conditions (2 mL selection media/well containing MTAGG). After two 
days of incubation at 37°C, 5% CO2 in air, the medium was removed by aspiration, 
individual plaques picked in 2-3 µl PBS and used to infect fresh 143B cells grown in 24 
well plates (Flow Laboratories). The virus was incubated for 1 hr at 37°C before 1 
m.L/well of selection medium was added and the plate incubated for a further 2 days at 
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37°C. The media was removed from each well of cells and 50 µL PBS added. Each 
plate was stored at -20°C until screened for the presence of the cloned I-TAC gene. 
5.2. 7 Detection of recombinant VV by dot blot hybridization 
To screen for the presence of the inserted gene, 5µL of the virus samples were dotted 
onto Hybon-N+ nylon membranes (Amersham) and allowed to dry. The membranes 
were placed once on 0.5M N aOH soaked 3 MM Whatman paper for 5 min, followed by 
three washes on 1 M Tris (pH 7 .5) soaked 3 MM Whatman paper, each for 5 min, then 
twice on 0.5 M Tris (pH 7.5), 1.5 M NaCl soaked 3 MM Whatman paper for 5 min. The 
membranes were fixed by UV exposure then incubated at 68 °C in prehybridization 
solution (5x SSPE, 0.2% SDS, 0.2% skim milk powder, 0.2mg/mL salmon sperm DNA) 
for 4 hrs. The membrane was then hybridized for 24hr at 68°C. The hybridization mix 
was similar to the prehybridization mix except it contained a radio-labelled cDNA 
probe. I-TAC cDNA was labelled for hybridization with 5µL a32P-dCTP (Bresatec) 
using the Ready-To-Go labelling system (Pharmacia), according to the manufacturer's 
protocol. Labelled cDNA was purified by passage through a Nick Column (Pharmacia). 
Membranes were then washed twice in 2x SCC, 0.1 % SDS for 15 min, one wash in 0.5x 
SCC, 0.1 % SDS for 15 min and one in 0.lx SCC, 0.1 % SDS for 15 min to eliminate 
non-specific hybridization. The membranes were then blotted dry, sealed in a plastic 
bag and autoradiography was carried out at -70°C using XAR5 X-ray film (Kodak). 
5.2.8 Detection of rVV and absence of wild-type VV by PCR 
The presence of the inserted gene was detected by dot blot hybridization and the 
absence of wild-type VV in the plaque purifications was confirmed by PCR. Viral DNA 
was extracted as previously described (Heine and Boyle, 1993). A small volume (~5-10 
µl) of 143B cells from 24 well plates (described in section 5.2.2) was mixed with 0.5 
mg/ml Proteinase K in 100 µl lysis buffer (10 mM Tris-HCL, 50 mM 2-
mercaptoethanol, 100 mM NaCl, 10 rnM EDTA, 1 % N-Lauroylsarcosine, 26% sucrose, 
pH 7 .6) and incubated for 1 hr at 56°C. DNA was then extracted and precipitated using 
the phenol/chloroform and ethanol precipitation (section 2.2.7). The DNA was 
resuspended in 20 µl H20 and a PCR was carried out on 2 µL of the template DNA for 
both the I-TAC gene (described in section 2.2.5) and the wild-type VV. The primers 
used for the wild-type VV were; F region sense 5'- GGTTAATATGACGCTCG -3 ' and 
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antisense 5' - GCGTCACAGAATCT ACC -3'. The PCR thermal cycle was as described 
in section 2.2.5 with an annealing temperature of 42°C for 30 cycles. 
5.2.9 Amplification of virus stocks and storage 
Once a suitable recombinant virus clone was identified, both the rVV I-TAC and VV-
WR viruses were amplified by growing the viruses in 75 cm2 tissue culture flasks on 
143B cells. These cells were then used to seed 143B cells growing in 2L roller bottles 
(Corning Inc., USA) in media without selection. The infected cells were harvested 2 
days later by scraping the cells into the media (with the use of a cell scraper), and the 
media centrifuged at 3,000 rpm for 5 min. The pellets were resuspended in 1 0mL 
gelatin saline with 2 mM HEPES and aliquoted into sterile 1.5mL ampoules and stored 
at 70°C. 
5.2.10 Titration of virus 
To titrate viral samples and stock solutions, 1 00µL of sample was trypsinized by 
incubating with l00µL trypsin (lmg/ml) at 37°C for 30 min. The trypsin was then 
neutralized by adding 800µ1 of F-15 MEM, 5% FCS. Serial 10-fold dilutions were then 
made in F-15 MEM (no FCS added) and used to infect 143B cells grown in 6-well 
tissue culture plates (described in section 5.2.2) for 1 hr, after which the cells were 
overlaid with media (F15 MEM, 5% FCS). Two days after incubation at 37°C the media 
was removed and the cells were fixed and stained with 2mL of 0.1 % crystal violet and 
20% ethanol in MQW for 5 min. The plaques were counted and the plaque forming 
units per mL (PFU/mL) of viral supernatant were calculated. 
5.2.11 Chemotaxis detection of I-TAC expression by rVV 
Functional chemokine protein expression by the recombinant VV was determined by 
chemotaxis assay. Supernatant from 143B cells infected with either VV-WR or rVV I-
TAC was collected 24 hrs post infection and concentrated approximately 4 fold 
( described in section 2.2.11) and used in a chemotaxis assay using Con A activated 
splenocytes as described in sections 2.2.12 and 2.2.13. This assay was repeated multiple 
times to confirm the data. 
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s.i.12 Determination of virus titres in ovaries 
Ovaries were removed aseptically from groups of 5 C57BL/6 mice infected with either 
VV-WR or rVV I-TAC (1 x 106 PFU i.p), on day 6 post-infection, and immediately 
frozen in dry ice and stored at -70°C. The ovaries were homogenized in lmL of PBS. 
100 µl of homogenate was incubated for 30 min with 100 µl trypsin ( 1 mg/ml) at 3 7°C. 
Ten-fold serial dilutions were made in F15 MEM media and 100 µl of each dilution was 
added to 143B cell monolayers grown in six-well cluster plates (Flow laboratories). 
After incubation for 48 hrs at 37°C, 5% CO2, the monolayers were stained with 0.1 % 
crystal violet in 20% ethanol for 5 min and the plaques enumerated. 
5.2.13 Mortality studies 
Groups of six C57BL/6 and athymic Swiss nude mice of the age of five weeks old were 
infected i.v with varying doses (1 x 104 - 1 x 107 PFU) of either VV-WR or rVV I-TAC 
and their progress monitored daily. Mice with severe symptoms including, shaking, 
severe weight loss, mangy fur, reduced activity and lack of responsiveness to external 
stimuli were euthenised and one day added to their mortality recording. 
5.2.14 Foot pad analysis 
Both hind footpads of naYve mice and pre immunized mice ( 1 x 105 PFU, 5 weeks before 
· challenge) were injected with 1 x 107 PFU (in 20µL) of either VV-WR or rVV I-TAC. 
Footpad thickness was measured daily using calipers. Basal footpad thickness 
(measured prechallenge) is standardized as zero inflammation. Footpads were also 
removed from euthanised mice 24 hrs post infection and fixed in 10% neutral buffered 
formalin solution and embeded in paraffin wax (section 5.2.3). Footpad sections were 
cut perpendicular to the sole of the footpad and stained with H and E for histology 
analysis (section 5.2.3). 
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5.3 Results 
5.3.1 Construction of a recombinant VV encoding I-TAC (rVV I-TAC) 
Studies examining VV encoding the chemokines Crg-2 and Mig demonstrated an 
attenuation of this virus due to enhanced recruitment of NK cells and T lymphocytes 
(Mahalingam et al., 1999; Mahalingam and Karupiah, 2000a). To assess if I-TAC has a 
similar effect, a shuttle vector plasmid, pTK7.5AI-TAC (Fig 5.1) was constructed and 
used to generate a TK+ recombinant VV encoding murine I-TAC using marker rescue 
recombination. The VV-WR-L929-TK+ virus (referred to from here on as VV-WR) was 
used as a control throughout all following experiments as rVV I-TAC is a TK+ virus due 
to the construction and selection process. Functional protein expression of this 
chemokine by rVV I-TAC was demonstrated by carrying out a chemotaxis assay, using 
VV-WR as a control (Fig 5.2). Chemotactic activity by rVV I-TAC was similar to that 
as described in chapter two while VV-WR samples were consistent with the media only 
control. The similarity between this assay and the baculovirus based expression system 
( chapter 2) is not surprising given that both assays use the concentrated protein 
preparation in the same F15 media contained in the chemotaxis chambers. 
5.3.2 Viral titres in C57BL/6 mice 
To test the immune response against VV-WR and rVV I-TAC, a number of different 
analyses were carried out. Initially ovaries were isolated from mice infected with either 
virus on day 6 and viral titres enumerated. Ovaries were chosen as this organ is a 
sensitive indicator of viral growth and subsequent immune responses against the virus 
(Karupiah et al., 1990). The average titre for mice infected with either VV-WR or rVV 
I-TAC was (1.7 + 0.18) x 106 and (1.5 + 0.25) x 103 respectively. These results were 
significantly different (p < 0.05, student's t-test). The lower viral titre indicated that 
expression of I-TAC significantly inhibited the growth of the virus in vivo. 
5.3.3 Mortality studies in VV infected mice 
To assess whether lower titres in ovaries influenced the overall immune response 
against VV infection, mortality studies were carried out. Mortality studies of VV-WR 
and rVV I-TAC of five week old C57BL/6 and athymic Swiss nude mice were assessed. 
Groups of six female mice were injected i.v. with varying doses of either VV-WR or 
rVV I-TAC and observed for 30 days. The doses ranged from 1 x 104 to 1 x 107 PFU. 
Figure 5 .3 shows the mortality rate of C57BL/6 mice at different infection doses. 
pTK-7.SA I-TAC 
7.66 kb 
I-TAC 
Figure 5.1: Construction of insertion plasmid pTK7.5-I-TAC. A BamHI and Sal I 
fragn1ent containing I-TAC was excised from bluescript. The gene fragment was then 
subcloned into pTK7.5A at the BamHI and Sal I sites located behind a P7.5 promoter 
(Coupar et al. , 1998). AmpR, ampicilin resistance gene; PF, vaccinia promoter; HSV 
TK, thymidine kinase gene of herpes simplex virus; P7.5, vaccinia early/late promoter. 
50 
45 
40 
35 
+-' 30 C 
::J 
0 (.) 25 
Q.) 20 
(_) 15 
10 
5 
0 
0 
Chemotaxis assay using rVV produced 1-T AC 
10 50 
• VV-WR 
• rVV I-TAC 
100 
Amount of concentrated supernatant (µI) 
Figure 5.2: Chemotaxis assay using rVV produced I-TAC. Supernatant from VV-WR 
or rVV I-TAC infected 143B cells was collected and concentrated ""'4 fold and used for 
a chemotaxis assay as described in chapter 2. Con A blasted splenocytes (24 hrs 
stimulation) from naive C57BL/6 mice were used for the assay. Standard deviation is 
shown and there is a significant difference between rVV I-TAC and both VV-WR at the 
50 µL supernatant amount and media only samples (student's t-test p<0.0002). 
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Figure 5.3: Mortality studies. Groups of 6 C57BL/6 mice were challenged i.v. with 
either VV-WR or rVV I-TAC at varying doses with their time of death being recorded. 
Doses used were 1 x 107 PFU (A), 1 x 106 PFU (B), 1 x 105 PFU (not shown) and 1 x 
104 PFU (not shown). All mice in the last two challenge doses survived. Solid lines 
(- ) represent mice infected with VV-WR, whereas dashed lines (······) represent mice 
infected with rVV I-TAC. 
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Most C57BL/6 mice were able to resolve infection at doses of 107 PFU challenged with 
rVV I-TAC and all mice survived at lower doses whereas all mice succumbed to VV-
WR infection at 107 PFU and 66% died after infection of 106 PFU VV-WR. Similar to 
rVV I-TAC infected C57BL/6 mice, VV-WR infected mice were able to resolve 
infection when challenged with 105 and 104 PFU. 
Athymic Swiss nude mice have a defective immune system with immunity dependent 
primarily on NK cells activity. Figure 5.4 shows the mortality rate for Swiss nude mice 
infected with different doses of VV-WR or rVV I-TAC. Some Swiss nude mice were 
able to fully resolve infection of rVV I-TAC after infection with 104 and 105 PFU, but 
not with 106 or 107 PFU, while all mice succumbed to infection and died at all doses of 
VV-WR. This suggests that I-TAC can also attract NK cells that can reduce vaccinia 
virerma. 
The mean time to death (MTD, in days) for both strains of mice, at varying doses of 
VV-WR and rVV I-TAC, are shown in table 5.1. The number of mice that died versus 
total numbers used is shown in brackets. The MTD was dose dependent in both strains 
of mice with the MTD being delayed in rVV I-TAC mice compared to VV-WR infected 
mice. The MTD was also found to be mouse strain dependent as the Swiss nude mice 
succumbed to infection and died earlier and with lower doses of virus than C57BL/6 
. 
nuce. 
5.3.4 Histological studies in virus infected mice 
Lungs, liver and ovaries were isolated and processed from groups of 6-8 week old 
C57BL/6 and athymic Swiss nude mice infected with either VV-WR or rVV I-TAC ( 1 x 
106 PFU i.p) on days 0, 3, 6, and 9 (for C57BL/6 only) and histological slides were 
prepared, fixed and stained with hematoxylin and eosin. Figure 5.5 shows a 
representative sample of lungs on days 0, 3, 6 and 9 mice infected with either VV-WR 
or rVV I-TAC. There was a significant increased in the inflammation and mononuclear 
cellular infiltration observed in C57BL/6 mice infected with rVV I-TAC than those with 
VV-WR in all tissues analyzed. Day 6 showed the highest level of cellular infiltration 
compared to days 0, 3 and 9. 
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Figure 5.4: Mortality studies. Groups of 6 athymic Swiss nude mice were challenged 
i.v. with either VV-WR or rVV I-TAC at varying doses with their time of death being 
recorded. Doses used were 1 x 10 7 PFU (not shown), 1 x 106 PFU (A), 1 x 105 PFU (B) 
and 1 x 104 PFU ( C). There was no significant difference in the survival rates of mice 
challenged with 1 x 10 7 PFU, with all dying by day 8. Solid lines ( - ) represent mice 
infected with VV-WR, whereas dashed lines (··· .... ) represent mice infected with rVV 
I-TAC. 
CHAPTERS 110 
Table 5.1: Mean time to death (days) for both athymic Swiss nude mice and C57BL/6 
mice at varying doses of VV-WR and rVV I-TAC. The number of mice that died versus 
total numbers used is shown in brackets. 
Swiss nude mice C57BL/6 mice 
Viral dosage VV-WR rVV I-TAC VV-WR rVV I-TAC 
(PFU) 
1 X 107 6.5 (6/6) 7.3 (6/6) 6.3 (6/6) 8.3 (3/6) 
1 X 106 8.8 (6/6) 11.5 (6/6) 10.5 (4/6) - (0/6) 
1 X 105 12.5 (6/6) 14.8 (4/6) - (0/6) - (0/6) 
1 X 104 15.0 (4/6) 16.0 (1/6) - (0/6) - (0/6) 
Figure 5.5: Histology of C57BL/6 mouse lungs. Uninfected (A), VV-WR infected 
mice on days 3 (B), 6 (D), 9 (F) and rVV I-TAC infected mice on days 3 (C), 6 (E) and 
9 (G). 
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Figure 5.6 shows a representative sample of lungs on days 0, 3 and 6 from na:ive Swiss 
nude mice infected with either VV-WR or rVV I-TAC. Like the C57BL/6 mice, 
increased inflammation and mononuclear cellular infiltration is observed in mice 
infected with rVV I-TAC than those infected with VV-WR in all tissues analyzed. Day 
six shows the highest level of infiltration. Swiss nude mice infected with VV-WR 
succumbed to infection before samples could be collected at day 9. In both strains of 
mice similar results to lung tissue was observed in both ovaries and liver. 
5.3.5 Footpad infiltration in VV infected C57BL/6 mice 
To examine the ability of murine I-TAC to recruit cells, two methods of measuring 
inflammation was examined. Footpads of na:ive mice were injected with 1 x 107 PFU of 
either VV-WR or rVV I-TAC to measure the relative rate of swelling as the first 
measure of inflammation. Mice injected with VV-WR had significantly larger footpads 
than VV I-TAC challenged mice, although the rate of recovery was similar (Fig 5.7A). 
This result indicated that expression of I-TAC, elicited by VV, might reduce 
inflammation. Mice preimmunized (with 1 x 105 PFU of VV-WR) were also subjected 
to the same footpad analysis as a second measure of inflammation (Fig 5.7B). VV 
preimmune mice injected with VV-WR had significantly larger footpads than rVV I-
TAC challenged mice. In addition, the rate of swelling reduction was faster in rVV I-
T AC mice than VV-WR infected mice (Fig 5.7B). Overall, the initial increase in 
footpad size was greater and the rate of swelling reduction slower, in na:ive mice 
compared to VV preimmune mice. 
The data suggested that I-TAC has a role in reducing inflammation. Histology of 
footpads 24 hrs post viral challenge gave an indication of cellular recruitment to the site 
of infection. There was a significant increase in cellular infiltrate in the na"ive mice 
infected with rVV I-TAC compared to those infected with VV-WR (Fig 5.8). This 
suggests that I-TAC expression may recruit NK and T cells that respond to infection 
more efficiently, thereby reducing overall inflammation. In the VV preimmune mice 
however, slightly more cellular infiltration is observed in mice infected with VV-WR 
than those injected with rVV I-TAC (Fig 5.8). I-TAC may be recruiting memory T cells 
to the site of infection again resulting in a faster clearance of virus. 
Figure 5.6: Histology of lungs from athymic Swiss nude mice. Uninfected (A), Day 3 
post infection with VV-WR (B) or rVV I-TAC (C), and day 6 post infection with VV-
WR (D) or rVV I-TAC (E). Swiss nude mice infected with VV-WR succumbed to 
infection before samples could be collected at day 9 post infection. 
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Figure 5.7: Footpad inflammation. Groups of 4 na1ve C57BL/6 mice (A) or VV 
preimmune (with lx105 PFU of VV-WR) C57BL/6 mice (B) were challenged with VV-
WR or rVV I-TAC (lx107 PFU) injected into each hind footpad. Footpad thickness was 
measured daily. Basal footpad thickness is standardized to zero swelling for each 
mouse. Standard errors of the mean are shown, all results except for day 1 for na1ve 
mice (A) are significantly different (p < 0.005; student's t-test). 
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Figure 5.8: Histology of footpads from C57BL/6 mice 24 hrs post challenge. 
Representative samples of uninfected (A), naive mice infected with VV-WR (B) or 
rVV I-TAC (C), or VV preimmune mice infected with VV-WR (D) or VV I-TAC (E) 
are shown. 
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5.4 Discussion 
Murine I-TAC is expressed during various viral infections such as RSV and Influenza A 
( chapter 4) and therefore this molecule may play an important role in viral clearance. 
Previous studies have shown that the IFNs and IFN-inducible chemokines Mig and Crg-
2 are important for the control of viral infection (Dalton et al., 1993; Huang et al., 1993; 
Muller et al. , 1994; Mahalingam et al., 1999). Surprisingly, murine I-TAC was not 
detected during a VV infection ( chapter 4 ), which may be due to the virus having a 
mechanism that inhibits the expression of chemokines that are detrimental to the 
survival of the virus. 
A recombinant VV encoding I-TAC was able to express the chemokine as a functional 
protein and recruit Con A activated splenocytes. Viral titres in C57BL/6 mice were 
lower in rVV I-TAC challenged mice than those in mice challenged with control virus. 
The lower level of virus demonstrates that I-TAC either enhances viral clearance or 
restricts viral replication in vivo, or a combination of both. During mortality studies the 
control virus (VV-WR) proved lethal at high doses in C57BL/6 mice and at moderate to 
low doses in athymic Swiss nude mice whereas there was marked attenuation in those 
mice challenged with rVV I-TAC. I-TAC expressed from rVV did not provide complete 
protection at high doses, however the mean time to death for each respective VV dose 
was delayed in all groups of mice tested. I-TAC therefore provided some mechanism to 
slow virus replication at low doses and provide some protection at higher doses but not 
sufficient to clear the virus. 
Enhanced mononuclear cell infiltration was observed in histological slides of liver, 
lungs and ovaries in both C57BL/6 mice and athymic Swiss nude mice infected with 
rVV I-TAC at several time points during infection. In addition to this, in Swiss nude 
mice, rVV attenuation compared to the control virus is not as marked as in C57BL/6 
mice. The cellular infiltration in both strains of mice correlates with the time course of 
infection with peak infiltration occurring around the peak of infection. By comparing 
these results with previous studies examining rVV Mig and rVV Crg-2, it is likely that 
the cells recruited by I-TAC were T cells and NK cells in the C57BL/6 mice and 
predominantly NK cells in the athymic Swiss nude mice (Mahalingam et al., 1999; 
Mahalingam and Karupiah, 2000a). 
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Measuring footpad thickness in na:ive mice after viral challenge showed lower peak 
swelling in mice challenge with rVV I-TAC than challenged with the control virus. 
While at first glance this appears surprising, this corresponds well with the notion that I-
TAC enhances the recruitment of specific cells, primarily NK and Thl cells to control 
the viral infection reducing viremia and the overall number of immune cells infiltrating 
the footpad. While this was not directly examined the experiments carried out using VV 
preimmunized mice suggest the observation is consistent with this interpretation. 
The effect of preimmun1z1ng rmce with low doses of VV-WR before challenge 
significantly reduced footpad swelling compared to na:ive mice probably by recruitment 
of specific T and B cells. Expression of I-TAC via rVV I-TAC in such mice resulted in 
a further reduction of swelling in mice post viral challenge. In addition to this, the rate 
at which this swelling decreased was faster in rVV I-TAC challenged mice than mice 
challenged with wild type virus. The recruitment of primed memory T cells would 
explain why, in VV preimmune mice, infiltration and inflammation is less in rVV I-
TAC infected mice compared to VV-WR infected mice. This subsequently would lead 
to rVV I-TAC challenged mice resolving infection more efficiently with less overall 
infiltrate and inflammation and presumably reduced viremia. These results however, are 
for one virus model and it would be interesting to see if similar results can be obtained 
in different pathogen infections, especially in disease models where dependence on cell-
mediated clearance mechanisms are not as pronounced. 
CHAPTER 6. 
FINAL DISCUSSION 
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CHAPTER 6. FINAL DISCUSSION 
This thesis explores the characteristics of the murine chemokine, I-TAC. These were 
examined by a number of methods, including sequence analysis, in vitro and in vivo 
expression studies, as well as functional studies during different disease models. The 
ability of murine I-TAC to modify immune responses was also analyzed. Together these 
experiments provide a broad characterisation of the role that I-TAC has in the immune 
system. 
A complete cDNA clone of the murine chemokine, I-TAC was isolated from an IFN-y 
stimulated dendritic cell line using a cDNA subtraction method. The cDNA clone was 
sequenced and confirmed subsequently by published data and is now also referred to as 
murine CXCLl 1 according with new international nomenclature- (Meyer et al., 2000; 
Widney et al. , 2000). Murine I-TAC is a non-ELR CXC chemokine that is 67% 
homologous to HuI-TAC and ~35% homologous to Crg-2 and MuMig respectively. The 
open reading frame is 100 amino acids long with a predicted 21 amino acid leader 
sequence, which coincides with the leader sequence of HuI-T AC. If cleaved at this point 
murine I-TAC would be a 79 aa residue mature protein with a molecular mass of 9112 
Da (Meyer et al., 2000; Widney et al., 2000). In addition, murine I-TAC maps to 
chromosome 5 at position 5E3, which is close to the positions of MuMig and Crg-2 
(Meyer et al., 2000; Widney et al., 2000). Moreover murine I-TAC contains four exons 
with intron/exon boundaries at similar positions to human I-TAC (Meyer et al. , 2000). 
Together, these data confirm a strong mouse/human homology and as a result the two 
proteins would probably have the same, or very similar, functions in vivo. 
As indicated earlier, munne I-TAC binds to the chemokine receptor, CXCR3 and 
induces a dose dependent calcium signal (Meyer et al., 2001). As a result murine I-
TAC, like human I-TAC, is likely to attract activated CXCR3 expressing NK and T 
lymphocytes, predominantly of the Thl phenotype. Calcium mobilization assays have 
demonstrated that calcium signals were obtained using 10 nM murine I-TAC whereas 
higher concentrations (300 nM) of MuMig and Crg-2 were required to obtain the same 
signal (Meyer et al. , 2001). Like its human counterpart it has been demonstrated that 
murine I-TAC is a more potent chemokine than either MuMig or Crg-2 (Meyer et al. , 
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2001). The relative potency of munne I-TAC in the published data above was 
demonstrated by chemotaxis assays using CXCR3 transfected B cells where optimum 
migration rates required 3 nM of murine I-TAC as compared to 30 nM of Crg-2 and 100 
nM MuMig (Meyer et al., 2001). 
Although the stability of I-TAC in vivo is unknown, the similarities of potency, rate of 
migration, as well as receptor binding between the murine and human chemokine 
homologues allows functional chemokine gradient models to be speculated. There is a 
potency hierarchy between the three chemokines with I-TAC being the most potent 
followed by IP-10/Crg-2, then Mig (Cole et al., 1998; Cox et al., 2001; Meyer et al., 
2001). It is possible that a chemokine gradient is set up with Mig being released 
locally, with IP-10/Crg-2 having a wider dispersal area. As much lower concentrations 
of I-TAC are required for effective migration this potent chemokine could be widely 
dispersed throughout the body and away from the site of infection. NK and T cells 
would firstly be exposed to I-TAC and subsequently follow the increasing chemokine 
concentration to IP-1 0/Crg-2 then to Mig to fight infection. 
There are however several pieces of data suggesting that the above model is not the 
case, firstly human I-TAC is able to displace IP-10 or HuMig bound to the CXCR3 
receptor which also occurs in a concentration dependent manner whereas HuMig nor IP-
10 can not completely displace HuI-TAC (Cole et al., 1998). Secondly, it has been 
shown that during a Toxoplasma gondii or VV infection Crg-2 expression was co-
localized with a respective infection site whereas MuMig was expressed more 
systemically (Amichay et al., 1996). Thirdly, peak murine I-TAC expression occurred 
later than peak Crg-2 expression in both IFN-y and LPS stimulated RAW264.7 
macrophage cells and in lungs from mice given LPS (Widney et al., 2000). This 
differential expression has also been observed in the MTHC-D2 cells (Banyer et al., 
2002 submitted, appendix le). Interestingly, CD40 activation enhanced levels of I-TAC 
expression in these cells (chapter 3) whereas Crg-2 expression was reduced (Banyer et 
al., 2002 submitted, appendix le). Together, these features suggest a different 
chemokine gradient model where the timing and dispersal areas of the chemokines 
would be important. Mig may be dispersed early and widely followed by IP-10/Crg-2. 
The expression of I-TAC may occur later and locally and displace the other chemokines 
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from CXCR3. If this were the case, I-TAC would be the last chemokine to bind to the 
CXCR3 receptor. This chemokine receptor would then be desensitized, a rapid process 
rendering the cell umesponsive to stimulation through that receptor (Chuang et al., 
1996). The receptor is then internalized for degradation or recycling which subsequently 
re-establishes chemokine responsiveness (Solari et al., 1997; Aragay et al., 1998; 
Signoret et al., 1998). In a recent study it was demonstrated that CXCR3, expressed on 
T cells, was rapidly internalized when exposed to IFN-)' activated human saphenous 
vein endothelial cells (HSVEC) (Sauty et al., 2001). Importantly it was shown that I-
T AC was the primary chemokine responsible for internalization even though it was 
secreted at lower levels than both IP-10 and Mig (Sauty et al., 2001 ). The stability of 
the IFN-inducible chemokines is a determining factor for which model is operating, for 
example while I-TAC may be the most potent chemokine, it may also be the most 
unstable, supporting the second gradient model. 
Different binding regions to the CXCR3 receptor and with varied affinities, suggests 
that the three IFN-inducible chemokines not only establish a gradient for cells to 
migrate follow, but may have distinct functions in vivo (Cox et al., 2001). Indeed, 
expression levels of these three chemokines differ between cells (Amichay et al., 1996; 
Mach et al., 1999). During the development of atherosclerotic lesions, four major cells 
are involved including endothelial cells, smooth muscle cells, macrophages and 
lymphocytes (Ross, 1999). Examining chemokine expression from these cells within 
atherosclerotic plaques, a differential chemokine expression pattern was found. 
Endothelial cells, smooth muscle cells and macrophages all expressed IP-10, whereas 
only endothelial cells and macrophages express HuI-TAC (Mach et al., 1999). Different 
expression levels of the chemokines would enable a chemokine gradient for the 
migration of T lymphocytes and NK cells to be initiated as described above. Differential 
expression between cell types within a lesion however, suggests different functions 
within the immune response, though this remains to be elucidated. 
Examining the signalling pathway responsible for I-TAC induction can give an insight 
into the type of immune response that involves I-TAC and hence an insight into the 
chemokine's function. The DC line and knockout mouse data indicated I-TAC is 
primarily induced by IFN-)' via the transcription factor IRF-1 (chapter 3). Published 
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findings also support that IFN-y is the major cytokine required for I-TAC expression 
(Meyer et al., 2000; Widney et al., 2000; Meyer et al. , 2001). As a result, other 
signalling transcription factors crucial for IFN-y signalling are also implicated in murine 
I-TAC expression including the Janus kinases, ST . .\.Tl and NF-KB (reviewed in Stark et 
al., 1998; Schindler, 1999; Taniguchi et al., 2001). While IFN-y initiates a number of 
different anti-pathogen mechanisms, it is possible that when there is low or absent IFN-
y signalling, such as in IFN-yR KO mice, the reduced amount of I-TAC and probably 
IP-10 and Mig results in increased susceptibility to infection. This would result in 
immune cells having reduced migration efficiency to the site of infection. Mice lacking 
IFN-yR are far more susceptible to infection by Listeria monocytogenes and VV despite 
apparently normal cytotoxic and T helper cell responses is one example of this (Huang 
et al., 1993). This explanation becomes more complex when autoimmunity is examined. 
For example, the EAE data in chapter four demonstrated that the IFN-yR knockout 
mice, which had no detectable I-TAC expression were far more susceptible to disease 
thereby raising questions regarding the kinetics of autoreactive T cell recruitment into 
the CNS. 
The experiments presented here (chapter 2) also clearly demonstrated that IL-4 
suppressed murine I-TAC expression. This is not surprising considering that the Th 1 
cytokines, such as IL-12 and IFN-y, can down regulate Th2 cytokines including IL-4, 
and vice versa (reviewed in Rook et al., 1994; Ivashkiv, 1995; Yasukawa et al., 2000). 
IL-4 can inhibit ST ATl via STAT6 activation, which subsequently would inhibit I-TAC 
expression (Larner et al., 1993). Therefore one of the ways IL-4 could inhibit IFN-y 
immune responses may include the down regulation of I-TAC via the inhibition of the 
IFN-y signalling pathway. 
Others have also demonstrated that IFN-cx/~ can weakly induce both human and murine 
I-TAC whereas the knockout mouse studies in chapter 3 did not confirm this (Rani et 
al., 1996; Widney et al. , 2000; Meyer et al., 2001). Low levels of IFN-cx/~ can down 
regulate IRF-1 via IRF-2 activation and probably subsequent I-TAC expression as seen 
in Con A activated splenocytes (Watanabe and Kawade, 1988; Noronha et al. , 1993; 
Mamane et al., 1999). However, stimulation with higher concentrations of these 
cytokines may in fact induce low levels of I-TAC. Hence it appears that IFN-cx and 
CHAPTER 6 123 
IFN-~ may act to either increase or decrease I-TAC expression depending on the 
relative amount of these two cytokines, and subsequent level of IRF-1 activation or 
inhibition. 
Synergy between TNF-a. and IFN-y to enhance the expression of murine I-TAC has 
been observed (Widney et al., 2000). The degree at which this occurs however appears 
to be dependent on initial levels of IFN-y induced I-TAC, for example, strong 
synergistic effects are observed in Swiss 3T3 cells where initial IFN-y induction of 
murine I-TAC is low (Widney et al., 2000). However, in the cell line or Con A culture 
studies carried out here (chapter 2), the levels of murine I-TAC were initially relatively 
high, no evidence of synergy between IFN-y and TNF-a was observed. 
The addition of anti-CD40 Ab to MTHC-D2 cells showed that CD40 alone can 
upregulate expression of murine I-TAC and that the CD40 and IFN-y pathways can 
synergize to enhance this expression. These results are consistent with activation of the 
NF-KB transcription factor through independent binding sites by IFN-y, TNF-a and 
CD40 individually as well as in a synergistic manner (Ohmori and Hamilton, 1995; 
Baldwin, 1996; van Kooten and Banchereau, 1997; van Kooten and Banchereau, 2000). 
It is likely that this effect is cell type and/or stimulus specific as synergy between IFN-y 
and TNF-a was not observed in the induction of I-TAC in the DC lines ( chapter 2) 
whereas in other cells synergy has been observed (Ohmori and Hamilton, 1995; Huang 
et al., 2000; Widney et al., 2000). In addition to this, enhanced I-TAC expression was 
not detected in the JAWS II cell line following CD40 activation, which may however, 
be due to the immortalization process of JAWS II DC line. 
The studies carried out here suggest that munne I-TAC is expressed from munne 
progenitor DCs exposed to IFN-y in vivo. Bone marrow derived DCs as well as other 
cell lines such as RA W264.7 macrophages, Swiss 3T3 fibroblasts and J744A.1 cells 
have all subsequently been shown to express murine I-TAC after IFN-y stimulation. The 
expression levels however, differ considerably depending on the cell type which may be 
reflective of their function in vivo (Meyer et al., 2000; Widney et al., 2000; Meyer et 
al., 2001). For example, RAW264.7 macrophages can induce high levels of murine I-
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TAC whereas relatively low levels are observed 1n IFN-y stimulated Swiss 3T3 
fibroblasts (Widney et al., 2000). 
As I-TAC, Mig and IP-10/Crg-2 are expressed from DCs and other APCs and recruit 
CXCR3+ NK and T lymphocytes it is likely that I-TAC and the other IFN-inducible 
chemokines are important in the interactions between the innate and adaptive immune 
systems. Indeed, many chemokines including the IFN-inducible chemokines have been 
detected during viral infections aiding the CMI response to clear infection. Expression 
of murine I-TAC around peak infection indicates that I-TAC has a role in enhancing 
viral clearance such as during RSV and influenza infections, probably by recruiting 
CXCR3+ expressing NK and Thl cells. 
One interesting finding from this work was that I-TAC expression was not detectable 
during a VV infection whereas others have shown that Mig and Crg-2 were present 
(Mahalingam et al., 2000; Mahalingam and Karupiah, 2000a). As these three 
chemokines have different expression patterns in vivo, it is likely that they have 
different regulatory factors controlling signalling pathways. In fact it has previously 
been shown that Crg-2 can be upregulated by both the IFN-y and IFN-a/~ signalling 
pathways whereas Mig is stimulated by IFN-y only (Amichay et al., 1996). VV induced 
inhibition of I-TAC but not Crg-2 or Mig expression may occur at some point during 
the IFN-y signalling pathway, possibly through altering activation states or expression 
levels of the ST AT 1 or NF-KB transcription factors (Bowie et al., 2000; Gil et al., 2001; 
Najarro et al., 2001; Oie and Pickup, 2001). VV and other poxviruses such as 
ectromelia and variola (smallpox) are very successful viruses due to their ability to 
avoid the immune system (reviewed in Smith et al., 1997; Mahalingam and Karupiah, 
2000b; Moss and Shisler, 2001). Through constant evolution, they have developed 
several mechanisms to inhibit expression of antiviral cytokines, chemokines and their 
receptors (reviewed in Smith et al., 1997; Mahalingam and Karupiah, 2000b; Moss and 
Shisler, 2001). Inhibition of I-TAC, the most potent known IFN-inducible chemokine 
would therefore be a logical target for pox viruses. Indeed over-expression of I-TAC 
through the use of a recombinant VV significantly attenuates viral growth and efficacy 
demonstrating how valuable I-TAC is in viral clearance. Poxviruses belonging to the 
same genera tend to have similar immune evasion genes. Although VV is relatively 
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harmless to humans, and is in fact commonly used as a vaccine against smallpox, it is 
also closely related to smallpox as well as other orthopoxviruses including cowpox, 
ectromelia and monkeypox. As a result, each of the orthopoxviruses share many 
conserved immune evasion genes (reviewed in Smith et al., 1997; Moss and Shisler, 
2001). It is likely then that smallpox virus may also have the ability to inhibit I-TAC 
expression, aiding to its success as a human disease. 
The ability of I-TAC to recruit NK and Thl cells does not automatically mean that I-
TAC is beneficial in all diseases. Others have speculated that I-TAC can exacerbate 
neuroinflammation and autoimmunity since it can recruit activated T cells (Cole et al., 
1998; Luo et al., 1998). Given that antibodies to a functional domain of CXCR3 protect 
mice from EAE, murine I-TAC may act to enhance neuroinflammatory processes 
(Arimilli et al., 2000). The expression of murine I-TAC during peak EAE disease may 
mean that I-TAC has an integral role in autoreactive T cell recruitment. Many studies 
have also demonstrated that T cell recruitment is important during the rejection process 
of transplants and indeed, inhibition of T cell migration has been shown to inhibit or at 
least delay the onset of the rejection process (Russell et al., 1996; Chandraker et al., 
1998; Melter et al., 1999; Hancock et al., 2000). Although a trend of murine I-TAC 
expression was not clear during the transplantation grafts carried out in this study, it is 
likely that this was due to the models utilized. Murine I-TAC as well as Crg-2 and 
MuMig have been shown to be upregulated during a cardiac allograft rejection model 
(Meyer et al. , 2001). All of these studies have confirmed that I-TAC is expressed during 
immune responses in various disease situations. The outcome of I-TAC activity whether 
it is beneficial, such as in viral infections, or detrimental, such as in autoimmune 
diseases, most likely depends on the disease in question. I-TAC expression during viral 
infections probably supports viral clearance by attracting NK and Thl cells to the site of 
infection, whereas during EAE, I-TAC may exacerbate disease by recruiting 
autoreactive T cells into the CNS. 
The data acquired in this study has enabled the formulation of a two-part model, 
showing how I-TAC may interact with the rest of the immune system especially during 
a disease where the CMI response is required, such as during an influenza viral 
infection. At the site of infection, chemokines that are expressed by infected cells under 
inflammatory conditions, including IL-8, MIP-la, RANTES, MCP-1 and MCP-4, 
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recruit immature DCs and other innate immune cells such as NK cells and macrophages 
(Cyster, 1999; Sallusto et al., 2000; Marquez and Martinez, 2001). While such 
migrating DCs are beginning to mature as well as being exposed to antigen they are also 
exposed to cytokines such as IFN-y, TNF-a, IL-1 and bacterial or viral products such as 
LPS or dsRNA which initiate the expression of chemokines including I-TAC, Mig and 
IP-1 0/Crg-2. The expression of the IFN-inducible chemokines occurs relatively quickly 
(within 6 hours) after DCs have been stimulated with IFN-y, as has been shown in 
chapter 2 and by others (Banyer et al., 2002 submitted, appendix le; Meyer et al., 
2001). Circulating memory T cells would migrate directly to the site of infection and an 
adaptive immune response would then be initiated against the antigen (Fig 6.1 ). For this 
to be possible, memory T cells must express the CXCR3 receptor, and indeed this has 
been shown by others previously (Qin et al., 1998; Sallusto et al., 1998). Such a 
response would occur when the host has previously been exposed to the antigen, as 
occurs in vaccinated hosts, for example the preirnrnunized mice in the footpad 
experiment carried out in chapter 5. 
The second part of the model outlines the process that may occur if the animal has not 
previously been exposed to antigen (Fig 6.2). DCs would migrate to the site of infection 
as described above, however, once DCs become fully mature a complete alteration in 
chemokine receptor expression also occurs. The receptors CXCR4, CCR4 and CCR 7 
are all up regulated while the initial receptors expressed at the infection site are all down 
regulated. This enables the DC to then migrate to the lymph node to activate the 
adaptive immune response, all the while secreting I-TAC, Mig and IP-10/Crg-2 (Cyster, 
1999; Sallusto et al., 2000; Marquez and Martinez, 2001 ). Along with chemokine 
receptor expression switching, a significant change in chemokine expression from DCs 
also alters during later stages of ·maturation. The chemokines expressed also differ 
depending on the stimuli that the DC received while maturing as well as the effector 
cells that are required for activation, i.e. a Thl or Th2 phenotype (Sallusto et al., l 999; 
Sallusto and Lanzavecchia, 2000). For the activation of a Thl, cell mediated immune 
response expression of 1-T AC, Mig and IP-1 0/Crg-2 are also upregulated during this 
time of DC maturation (Sallusto et al., 1999; Sallusto and Lanzavecchia, 2000; Meyer 
et al., 2001). The expression of I-TAC may also be enhanced further by CD40-CD40L 
interactions during the antigen presentation process. 
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Figure 6.1: Schematic diagram showing how murine I-TAC might interact in the 
immune system during a viral infection (part I). Red arrows show migration pathways, 
black arrows show cytokine or chemokine expression. 
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Figure 6.2: Part 2 of how murine I-TAC might interact in the immune system during a 
viral infection. Red arrows show migration pathways, black arrows show cytokine or 
chemokine expression. 
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The studies carried out here suggest that I-TAC is still expressed from DCs in the latter 
stages of the immune response (48 hours) when the DC would be in the lymph node, 
provided there is still sufficient IFN-y stimulation. I-TAC, Mig and IP-10/Crg-2 would 
mainly function to recruit T lymphocytes to the DC for antigen presentation. They may 
however, have other important functions, for example, they could down regulate 
chemokine receptor expression and other factors no longer required by the mature DC 
such as those receptors previously used by the immature DC for migration to the site of 
infection (Sallusto and Lanzavecchia, 1999; Sallusto and Lanzavecchia, 2000). Once the 
T cell has become mature and antigen specific, it is necessary for it to migrate out of the 
lymph node via the efferent lymphatic vessel and back to the site of infection. At this 
stage it is conceivable that I-TAC, expressed in the lymph node is responsible for the 
desensitization and internalization of the CXCR3 receptor (Sauty et al., 2001). At this 
stage the activated T cell may then respond to other chemokines and migrate back into 
the circulation whereupon it can track back to the site of infection, a process mediated 
by either newly expressed CXCR3 or by other chemokine gradients. At the end of an 
immune response, I-TAC expression would need to be down regulated. This would 
probably occur in conjunction with a decrease in IFN-y expression, possibly due to 
inhibition by IL-4. 
The experiments carried out here have provided a broad characterization of murine I-
T AC ranging from sequence and molecular characteristics to its expression and role in 
disease and cell mediated immune responses. The model proposed above raises several 
questions and therefore provides a foundation and direction for future investigation. 
Murine I-TAC has been shown to bind to the CXCR3 receptor, however, full 
characterisation of the cell types recruited remains to be examined. Correlation of 
murine I-TAC with human I-TAC and the other IFN-inducible chemokines will most 
likely demonstrate that this chemokine recruits T cells and NK cells. The range of cells 
recruited in mice however, needs to be investigated. In addition to this, further 
elucidating the signalling pathways of the IFN-inducible chemokines in detail will aid 
the understanding of the different chemokine expression patterns necessary for, and in 
response to, various immune stimuli. This in tum may enable specific chemokine 
targeting for vaccines and therapeutics, in such diseases as multiple sclerosis. Further 
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understanding of the role that I-TAC has in immune responses may be addressed by 
creating an I-TAC knockout mouse. Compensation by the other IFN-inducible 
chemokines however, may occur so that the immunological effect of I-TAC might be 
masked. The exact mechanism whereby VV inhibits I-TAC expression is not clear 
however, once the signalling pathway for I-TAC induction has been thoroughly 
elucidated, the factor(s) that VV inhibits may be more easily identified. 
Autoimmune disease progression has been inhibited by blocking the CXCR3 receptor, 
presumably blocking the function of multiple chemokines (Arimilli et al., 2000). Being 
the most potent IFN-inducible chemokine, it is possible that developing vaccines to 
block I-TAC alone may produce a more direct and specific therapy. In preliminary 
studies however, passive EAE in the rat was not inhibited by treatment of recipients 
with anti-rat IT AC (David Willenborg, personal communication). Co-expressing I-TAC 
in conjunction with a vaccine or therapeutic agents may aid the establishment of cell 
mediated immunity. One possibility could be to generate a cancer antigen presenting 
DC, capable of also secreting I-TAC to enhance T cell recruitment and subsequent 
priming and activation against a specific tumour. 
The generation of polyclonal antibodies to I-TAC, using the baculovirus protein 
expression system for example, could allow for further characterisation of this 
chemokine. Antibodies could be used for several assays including blocking I-TAC 
receptor binding studies, I-TAC secretion and tracking analyses. Blocking I-TAC in 
vivo in diseases, other than EAE, for example during viral diseases may further aid the 
understanding of immune responses that are normally induced. Having antibodies to the 
three IFN-inducible chemokines may also allow for the elucidation of their individual 
functions to be more thoroughly characterised. 
In conclusion, the work presented in this thesis explores the characteristics of the 
murine chemokine, I-TAC. The results of these studies not only highlight the properties 
exhibited by murine I-TAC but gives a valuable insight into the attributes that human I-
TAC and the other IFN-inducible chemokines, Mig and IP-10 have, especially with 
respect to their role in the immune system. With this knowledge and the rate of research 
into chemokines generally, the use of chemokines in therapeutic agents may become 
feasible in the not too distant future. 
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Cytokines in innate and adaptive immunity 
Abstract: Cytokines and chemokines are hormone-like messengers which 
act to regulate the development and expression of the broad array of immune 
responses that are mounted against a variety of pathogens. As such, they 
are critical determinants of the types of cells which will regulate and partici-
pate in innate and adaptive immune responses, they may act both in highly 
localised environments but also in a systemic manner, and they may, them-
selves, directly mediate antimicrobial effector activities. In this article, we 
will outline current concepts of the activities of cytokines and chemokines 
in the immune response and discuss the various cell types, including den-
dritic cells and other antigen-presenting cells, T cells and B cells, which both 
produce and respond to these potent regulatory molecules. 
Host defense mechanisms are numerous and range from relatively 
primitive and constitutively expressed, non-specific defenses to 
sophisticated adaptive mechanisms that are specifically induced in 
response to foreign antigen (invading pathogens). Although the role 
of innate immunity was originally considered to be a process for 
defense of the host early in infection, it is now clear that there is 
an important reciprocal relationship between innate and adaptive 
immune responses. Cytokines and other mediators play an essential 
role in this process and, indeed, may ultimately determine the type 
of effector response that is generated towards a pathogen. These 
factors are first produced at sites of infection following interactions 
of pathogens and danger signals from damaged tissues. This pro-
cess requires recognition of invariant molecular structures common 
to a variety of pathogens by innate immune cells; these are called 
pathogen-associated molecular patterns. Well known examples of 
microbial stimulators of innate immune responses include lipopoly-
saccharides and teichoic acids shared by a variety of bacteria and 
unmethylated CpG motifs found in microbial but not mammalian 
DNA. Host organisms have evolved cellular receptors with broad 
specificities that can recognise these molecules and detect infectious 
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microbes. The immediate result of this recognition is the production 
of chemokines and cytokines that not only activate the innate cell 
population but also drive the adaptive immune response down dif-
ferent pathways of differentiation. Cytokines may be grouped into 
two broad categories; those that act to stimulate Thl type immune 
responses, which mainly protect against intracellular viral, bac-
terial, fungal and protozoan pathogens, (including IL-12 and IFN-y) 
and those that stimulate Th2 responses involved in protection 
against extra cellular infections such as helminths (including IL-4, 
IL-5, IL-6, IL-10 and IL-13). The cytokine microenvironment also 
influences innate cell populations, including macrophages and natu-
ral killer (NK) cells, and particularly stimulating the differentiation 
of dendritic cells (DC) with distinct immunoregulatory properties 
which may promote Thl- or Th2-type adaptive immune responses. 
The profile of chemokines expressed by -innate immune cells may 
also influence the phenotype of the immune response by directing 
the homing of different T cell subsets to sites of infection. This has 
the effect of amplifying the immune response, a process which is 
also mediated by the effector cytokines produced by local T cells 
which act in a feedback loop on the innate immune cells. To ensure 
that inflammatory cell-mediated immune responses do not cause too 
much damage to the host, the immune system has inbuilt protective 
mechanisms. Those with which we are most familiar include the 
director 
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Pathogen o 0 ~ 0 ~ o-:.. -
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Fig. 1. Immunological determination of self and non-self. Invading 
microorganisms expressing pathogen-associated molecular patterns (PAIV!Ps) 
are recognised by innate immune cells (including macrophages, dendriti c 
cells and NK cells) via pattern recognition receptors (PRR). This process 
signals to innate cells the presence of foreign organisms and activates the 
secretion of a myriad of effector cytokines which play a variety of roles in 
directing the immune response. 
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reciprocal cross-regulatory effects of Thl and Th2-type effector 
cytokines, such as IFN-y and IL-4. However, Th2-type cytokines 
may also have strong down regulatory effects on the Thl-promoting 
properties of DC. Thus, innate and adaptive immune responses are 
intimately linked and controlled by sets of molecules and receptors 
that act to generate the most effective form of immunity suitable 
for protection against each given pathogen. In addition, improved 
understanding of how these molecules may influence the immune 
response has facilitated their use as immunological adjuvants in a 
variety of vaccination strategies. In this article, we will outline cur-
rent concepts of cytokine regulation of the development and ex-
pression of antimicrobial immune responses. 
Initiation of innate immune responses 
An efficient immune system must achieve, during development, the 
ability to distinguish self from non-self. The enormous variability, 
molecular heterogeneity and rapid mutational rates of invading 
pathogens adds to the difficulty of this task. There are, however, 
characteristic structural features that are shared by many patho-
gens and which may be recognised by the innate immune system. 
These are termed pathogen-associated molecular patterns (PAMPs). 
PA1\1Ps include lipopolysaccharides and teichoic acids 1,vhich are 
shared by all gram-positive and gram-negative bacterial DNA, 
double stranded RNA which is characteristic of RNA viruses, and 
yeast cell walls which contain mannan (1, 2). The conserved nature 
of PAMPs is illustrated by the bactericidal effect of penicillin, which 
targets PAMPs and inhibits peptidoglycan synthesis in bacteria (2). 
Since PAMPS are not produced in vertebrates, host cells have de-
veloped non-clonal, broad specificity receptors that can recognise 
a wide range of pathogens. These are termed pattern recognition 
receptors (PRR) which are encoded in the germline and expressed -
on cells that will encounter a pathogen early in infection, e.g. epi-
thelial cells and effector cells of the innate immune system. 
As shown in Fig. 1, engagement of PRR with PAlVIPs create 
signals which can be divided into several pathways: (i) those that 
induce opsonization of bacteria for phagocytosis and/or the acti-
vation of the lectin pathways of complement, (ii) those that promote 
uptake of pathogens by phagocytes and DC, and (iii) those that 
induce effector functions which initiate the expression of inflamma-
tory cytokines and initiate adaptive immunity (2). 
PAMP/PRR interactions are important for stimulating cellular 
secretion of effector cytokines (Fig. 1). The types of effector cyto-
kines which are produced by cells of the innate immune system, 
and particularly DC, are influenced by the types of antigen which 
bind particular PRR on innate cells. For example the mannose recep-
tor, which is expressed on macrophages and DC, induces expression 
of several cytokines, including IL-1, IL-6, GM-CSF, TNF-a, IL-12 and 
IL-18. Bacterial cell wall engagement of another PRR, the FcyR, 
down regulates secretion of IL-12 from DC, thereby favouring the 
development of a Th2-type adaptive immune response (3). However, 
virus-binding PRR induce expression of Type 1 IFNs (a and ~), 
factors which potently increase expression of class I MHC molecules 
on DC and also increase the efficiency of presentation of viral pep-
tides to cytotoxic T cells (4). 
Effector cytokines are, in turn, important for regulating express-
ion of PRR, e.g. IFN--y and other factors that down regulate tran-
scription of the mannose receptor and endotoxic activity in acti-
vated macrophages and the up regulation of this activity by IL-4. 
Interestingly, IFN--y can enhance mannose receptor-mediated phago-
cytosis and killing of the yeast, Candida albicans, indicating that 
endocytic activity mediated through ligation of .this receptor is inde-
pendent from mannose receptor phagocytic activity (5). Whilst it is 
believed that PAMPs are the major determinant factor in innate 
immune recognition, there are probably additional mechanisms in-
volved, including the 'recognition of altered self' and the 'absence 
of self'. In the case of viral DNA pathogens, where all of the compo-
nents of the virus are synthesized and assembled internally in the 
host cells, it may be assumed that there are no recognisable PAMPs. 
How the immune system recognises such pathogens is unclear and 
requires further study. 
Unmethylated CpG motifs from prokaryotic pathogens have been 
targeted as likely candidates for binding to PRR (6). Recent evidence 
indicates that the CpG receptor is intracellular, however the mechan-
ism of action and downstream signalling pathways remain to be 
elucidated (6, 7). Activation of NFKB and the mitogen-activated pro-
tein kinase (MAPK) pathway have been associated with CpG pro-
cessing (8--10). A variety of cell types may be activated by CpG 
DNA directly, including macrophages, DC, NK cells and B cells and 
are stimulated to release a variety of cytokines, predominantly Thl 
cell-inducing factors, such as IL-12 and IL-18 (11). Increased under-
standing of the mechanism of CpG DNA recognition by the immune 
system now provides researchers with an opportunity to incorpor-
ate these motifs into vaccine preparations in order to further en-
hance their efficacy. 
Importantly, antigen binding of PRR, CpG activity, phagocytosis 
and stimulation by effector cytokines all promote the maturation of 
DC and their migration from peripheral t~ssues via afferent lym-
phatics or blood to lymphoid organs. In their more mature state, 
DC upregulate expression of the co-stimulatory molecules CD80 and 
CD86 and also clonal antigen-presenting class I and II MHC anti-
gens. At this point, co-stimulatory molecules may communicate to 
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adaptive immune cells the presence of recognition sequences from 
infectious agents, whilst the clonal MHC receptors communicate the 
nature of the pathogen which is to be targeted. More recently, com-
munication of a third signal, directing the nature of the adaptive 
immune response, has been assigned to DC, however the nature of 
this signal is unknown (12). 
Induction of Th cell differentiation by 
innate immune cell cytokine production 
It is now clear that different sub-populations of Th cells develop 
from the same precursor T cell, an immature CD4-bearing T 
lymphocyte which secretes IL-2 upon stimulation by antigen which 
is often termed a Th0 cell (13). Several factors are now known to 
be important in determining whether this cell will ultimately take 
on Thl - or Th2-type characteristics. The cytokine milieu at the 
point of initiation of the immune response is a key determinant of 
the commitment of precursor cells to a particular developmental 
pathway (14). For example, viral and bacterial pathogens, in part 
through their possession of PAMPS binding to PRR and, through 
recognition of CpG DNA motifs, usually stimulate innate immune 
cells to produce factors which promote the development of Thl 
cells. Thus, DC and macrophages commonly secrete large amounts 
of IL-12, and subsequently NK cells produce IFN--y, the effects of 
which are to drive Thl cell differentiation from the Th0 precursor 
cell. This results in the development of a Thl-type immune re-
sponse, the effects of which, in combination with the innate re-
sponse itself, are to assist in the eradication of microbial pathogens. 
Conversely, the early production of IL-4 by a variety of innate cell 
types directs Th2 cell development, although the relative import-
ance of each of these sources remains to be clarified (13, 15). 
The predominant role of IL-12 as a determinant of Thl cell devel-
opment is now well-established (16, 17). IL-12 signals primarily 
through the transcription factors, signal transducer and activator of 
transcription-3 (Stat3) and Stat4 (18, 19), although the recent dis-
covery of T-bet provides clear evidence for further important lin-
eage-specific transcription factors in Thl cell development (20). T-
bet, which belongs to the T-box family of transcription factors, is 
rapidly and selectively induced in developing Thl cells (but not Th2 
cells), upregulating, in turn, the expression of IFN--y. This factor is 
inducible by IL-12, a process enhanced by IL-18 and diverts naive 
T cells into the Thl differentiation pathway. T-bet may even convert 
committed Th2 cells into Thl-type cells, at least partly via re-
pression of IL-4 and IL-5 gene expression (20). 
Functional receptors for IL-12 are expressed on recently acti-
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vated, committed naive T cells and Thl cells, but are lost during 
Th2 cell differentiation. The unresponsiveness of Th2 cells to IL-12 
may thus be explained by down regulation of the IL-12 receptor ~2 
chain (IL-12R~2) by IL-4. Conversely, IFN-r acts to upregulate IL-
12R~2 expression by Thl cells and counteracts the activity of IL-4 
in this respect (21, 22). Two further cytokines, IL-lex and IL-18, may 
play important roles as co-factors in the induction of Thl cell devel-
opment and IFN-r production (23). IL-18 (previously known as IFN-
r-inducing factor, IGIF) is structurally related to IL-1; indeed its 
receptor is termed IL-1 receptor-related protein GL-lRrp) (24). IL-18, 
like IL-12, is expressed from activated macrophages, DC, keratino-
cytes, astrocytes, osteoblasts, microglia and Kupffer cells, and in-
duces IFN-r expression by splenocytes, B cells and Thl cells (25-
27). However, unlike IL-12, IL-18 does not directly activate Stat4 in 
Thl cells, and does not appear to act independently, rather it sy-
nergises with IL-12 in the production of IFN-r and, therefore, in the 
development of Thl cell-mediated immune responses (25, 26). 
Just as IL-12 is the key factor in Thl cell lineage commitment, IL-
4 appears to play a similar role in initiating Th2 cell development. In-
deed, the influence of IL-4 on na1ve Th cells appears to be dominant 
over that of IL-12, such that threshold levels of IL-4 at the point of 
induction of an immune response will lead to Th2 cell development 
and upregulated IL-4 production (13, 28). IL-4 signals through the 
transcription factor Stat6 (29) to upregulate expression of IL-4, IL-5 
and IL-13, although Stat activation is a transient event and is unlikely, 
of itself, to determine Th cell phenotype development as this is a pro-
cess which takes several days (14, 30). Additional lineage-specific 
transcription factors also appear to be required; c-Maf increases IL-
4 expression (31), whilst GATA-3 induces expression of several Th2 
factors in both developing and committed T cells and may inhibit 
IFN-r secretion (32, 33). The source of IL-4 early in the immune re-
sponse which is important for Th2 cell differentiation remains contro-
versial. Non-T cells, including mast cells, basophils and eosinophils 
are prime candidates (13), as are CD4+ and CD4-CD8- T cells of the 
NKl + subset (15) and LACK (Leishmania homologue of receptors for 
activated kinase C)-specific CD4+ T cells expressing V~4 and V~8 
TCR (34). Recently, it has also been suggested that certain pathogens 
may trigger IL-4 secretion from DC themselves (35). In particular, a 
key role for NKl + cells in Th2 cell development was suggested by 
their capacity to produce large amounts of IL-4 immediately following 
activation (15). However, mice deficient in CDl, the selecting antigen 
for NKl + cells, were able to mount Th2-type responses in the absence 
of this cell subset (36). Whilst IL-4 is clearly a critical mediator of Th2 
differentiation, the mechanisms underlying its activity are yet to be 
fully understood. 
Clearly, cells of the innate immune system, in addition to their 
roles in mediating early, non-specific immune responses, play a var-
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iety of key functions in initiating the development of different lin-
eages of Th cells and in the ultimate expression of immunity. Whils t 
macrophages, NK cells, mast cells, basophils and eosinophils are all 
important players in these respects, it is now evident that the activ-
ity of DC is vital for the co-ordinated development of the adaptive 
immune response. 
Dendritic cells and regulation of the 
immune response 
Discrete sets of DC are strategically positioned to perform the im-
portant functions of antigen sampling and triggering of T and B 
lymphocyte development. The origi~s and inter-relationships of dif-
ferent DC subtypes is unresolved, however the highly plastic nature 
of these cells indicates that differences in tissue location and anti-
genic and cytokine stimuli are major determinants of DC phenotype. 
They are in fact, a product of their microenvironment and recent 
studies have clearly demonstrated the determinant effects of Thl 
and Th2-type cytokine expression on DC and their subsequent ca-
pacity to stimulate either Thl or Th2-type adaptive immune re-
sponses (37) (Figs. 2 and 3). 
There are conflicting theories on the origins of different DC lin-
eages, however a consensus has now been established that distinct 
DC populations exist in different tissues and perform different irn-
munoregulatory activities. These include DC in the periphery, which 
efficiently take up and process antigens and then migrate to lymph-
oid tissues where they interact with T and B cells. In these lymph-
oid tissues, further DC subtypes interact with T cells, probably me-
diating the maintenance of tolerance to self antigens. Peripheral DC 
are known as myeloid-related DC, whilst resident lymphoid tissue 
DC are thought to be lymphoid in origin (12, 38, 39). 
The types of DC which develop and the nature of the adaptive 
immune response which is ultimately expressed correlate strongly 
with the levels of bioactive IL-12 produced by these cells. A number 
of studies have established a link between DC subtype, IL-12 secre-
tion and the polarization of Thl and Th2-type adaptive immunity 
(Fig. 2). In the mouse, CD8cx +, CDl le+ lymphoid-related DC secrete 
IL-12 and promote Th 1-type responses, whereas CD8a - , CD l lc + 
myeloid DC, which do not secrete IL-12, promote Th2-type re-
sponses (40). Interestingly, the opposite association is apparent in 
humans, where lymphoid-related DC do not secrete IL-12 and pro-
mote Th2-type responses, whilst myeloid DC secrete high levels of 
IL-12 and promote Thl-type responses (41). To complicate matters 
further, additional DC types have been described, including the 
CD8cx- CD4- murine DC, which secrete low levels of IL-12 (38), and 
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Fig. 2. The influence of dendritic cells on 
the development of cell-mediated immun-
ity. Immediately following infection by intra-
cellular pathogens, a combination of danger s ig-
nals from surrounding tissues, effector cytokines 
and the pathogen itself, all trigger immature den-
dritic cells to undergo maturation. This process 
leads to antigen processing, increased surface ex-
pression of MHC molecules and co-stimulatory 
molecules, secretion of chemoattractants (which 
act to recruit other leukocytes), and secretion of 
bioactive IL-12. The dendritic cell then migrates 
to lymphoid tissues and secretes further chemo-
attractants which recruit activated, memory Thl 
and naive T cells. These T cells are activated, 
in the presence of co-stimulatory molecules, by 
the antigen, which is presented to the T cell recep-
tor as peptides associated with MHC molecules. 
Activated T cells secrete IFN-y and an assort-
ment of chemokines, and also express chemokine 
receptors, which facilitate their sequential mi-
gration to sites of infection. Here, they exert anti-
gen-specific effector activity against infected 
cells and also act on immature dendritic cells to 
further promote cell-mediated immunity. 
Fig. 3. The influence of dendritic cells on 
the development of humoral immunity, Fol-
lowing infection by extracellular pathogens, a 
combination of danger signals, effector cyto-
kines, and phagocytosis of the pathogen trig-
gers maturation events in immature dendritic 
cells. This maturational process leads to enhanced 
antigen processing, increased surface expression 
of l\1HC molecules and co-stimulatory molecules, 
and secretion of chemoattractants which act to 
recruit other leukocytes. Dendritic cells also up 
regulate secretion of effector cytokines, including 
IL-1, IL-4, IL-6, IL-10 and IL-13. The maturing 
dendritic cells then migrate to lymphoid tissues 
where they present antigen to na'ive T cells and 
pass non-processed antigen to B cells through ex-
osomal transfer. The T cells proliferate follow-
ing both interaction with MHC and co-stimu-
latory molecules on the dendritic cells and stimu-
lation by effector cytokines, and becorne 
activated Th2 cells. The B cells are stimulated 
to differentiate and produce antibodies. Th2-type 
effector cytokines, including IL-4, IL-5, IL-6 and 
IL-10, are secreted by the activated Th2 cells and 
B cells and act, in turn, to promote this pathway 
of adaptive immunity by stimulating further 
populations of T and B cells and immature den-
dritic cells. 
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the human plasmacytoid CD11c- CD4hi DC, which secrete large 
amounts of IFN-a (42). 
The levels of IL-12 that are released by DC are, in turn, tightly 
regulated by the cytokine milieu and other activation signals (38). 
A combination of IFN-y, GM-CSF and IL-4, plus other activation 
stimuli, appear to be the most potent inducers of IL-12 secretion 
from CD8a+ DC. The nature of the pathogens which interact with 
DC are also key determinants of IL-12 secretion levels (12). Many 
intracellular pathogens induce IL-12 (17, 43, 44), whereas extracellu-
lar pathogens, such as helminths (45) and Schistosoma manosoni 
eggs (46), inhibit IL-12 production. The importance of the determi-
nant role played by DC for the ultimate expression of adaptive im-
mune responses is perhaps best illustrated by the variety of patho-
gens which have evolved immune escape mechanisms. For example, 
intracellular parasites such as HIV (47), Leishmania major (48), and 
measles virus (49), may all fail to induce IL-12 production and effec-
tive cell mediated Thl immunity. 
Many studies have focused on mechanisms of Thl cell induction 
via IL-12 produced by DC. However, significant questions remain as 
to the nature of Th2 cell induction by DC and the source and influ-
ence of IL-4 on the DC-T cell interaction. It is clear that basophils 
and mast cells present at sites of infection can secrete IL-4 (Fig. 3), 
however there appears to be a requirement for antibody-mediated 
cross-linking of their receptors, indicating that an adaptive immune 
response must have already been generated (13). Of particular inter-
est is the recent finding that certain pathogens may actually trigger 
IL-4 secretion from DC themselves. Thus, Candida in the form of 
hyphae, but not as yeast cells, down regulate IL-12 secretion by DC, 
but increase their secretion of IL-4 and, to a lesser extent, IL-10 (35). 
Consequently, protective Thl-type immune responses are generated 
against yeast cells, whilst hyphae elicit non-protective Th2-type re-
sponses. This example highlights the importance of the nature of 
the pathogen, together with early events during the process of infec-
tion, in directing the type of immune response which is generated. 
Interactions of DC, Th2 cells and B cells are particularly import-
ant in situations where DC have been directed to secrete minimal 
levels of IL-12. Distinct DC subtypes have been shown to differenti-
ally regulate B cell responses. Langerhans cells (epidermal) and 
CD14-derived interstitial (dermal) DC enhance proliferation of CD40-
activated B cells and induce differentiation of memory B cells. How-
ever, only interstitial DC induce naive B cells to differentiate into 
IgM-secreting cells (50). Interestingly, these DC also capture and 
retain unprocessed antigen, which is then transferred to na'ive B 
cells resulting in the initiation of specific antibody responses (50). 
It has also been suggested that murine myeloid DC regulate anti-
body class switching, a function also associated with Th2 cell devel-
opment and activity (40, 51, 52). 
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Th2-type cytokines, including IL-4, IL-6, IL-10, IL-13, have been 
shown to play important roles in enhancing B cell and DC interac-
tions. IL-13 appears to be an essential factor promoting interdigitat-
ing DC (IDC)-induced antibody secretion and also mediates Th2 cell 
development (53). This factor also enhances surface expression of 
CD23/Fec:RII and class II MHC antigens on resting B cells and 
stimulates B cell proliferation (54). IL-10 acts to modulate prolifer-
ation of CD40-activated B cells, naive B cells, memory B cells and 
germinal centre B cells, in addition to its role in enhancing antibody 
production. IL-10 is also a major antibody subclass switch factor 
and, together with TGF-~, forms a potent combinatio·n which pro-
motes IgA isotype switching (50, 55, 56). 
It is still unclear whether discrete DC lineages have a pre-deter-
mined immunoregulatory function or whether single, na'ive progeni-
tor DC circulate at a basal level in healthy individuals, taking up 
residence in the periphery or lymphoid tissues and reacting to stim-
uli from the surrounding microenvironment. These would act then 
either to retain the DC in lymphoid tissues or enable them to survey 
surrounding peripheral sites. It is clear, however, that continuing 
stimulation of adaptive immune cells by DC results in production 
of effector cytokines by activated T and B cells and that these fac-
tors promote the expression of appropriate immune responses 
against invading pathogens. A challenge whichremains is to deter-
mine which combinations of antigen- and cytokine-stimulated pro-
genitor cells give rise to the assortment of DC subtypes which act 
ultimately to drive different adaptive immune responses. The result-
ant information will be valuable not only for improved understand-
ing of immune regulation by DC, but also for the development of 
more effective vaccines against a variety of pathogens. 
Cytokine regulation of cell migration in the 
innate and adaptive immune response 
Cytokines play a key role in controlling immune cell migration, 
acting initially to retain DC at the site of infection for 2-3 hours, 
then to promote their migration to lymphoid organs where they 
attract T cells. Finally, cytokines stimulate migration of Thl and 
Th2 cells to sites of infection. Cytokines achieve this by stimulating 
the expression of a range of adhesion molecule selectins and inte-
grins, chemokines, and chemokine receptors on the DC and adaptive 
T lymphocytes. 
It has been shown, among proliferating murine DC. that chemok-
ine receptor expression of CCRl is upregulated immediately (ie. by 
30-60 min) after inflammatory stimulation by LPS or TNF-a (Figs. 
2 and 3). In this way, DC are attracted to sites of infection through 
a gradient of inflammatory chemokines including macrophage in-
flammatory protein (MIP 1-a) (57). The expression of CCRl is subse-
quently down regulated by 2 hours, but then progressively in-
creased, peaking at 4 to 6 hours after stimulation (58). The short 
period during which CCRl is down regulated enables these cells to 
remain at the site of infection. Here, the DC sample antigen and 
amplify the inflammatory response by secreting chemokines such 
as MIP-lo: and MIP-2, which attract leukocytes to the site of infec-
tion (57). The antigen- and cytokine-stimulated DC then migrate to 
lymphoid organs once the levels of CCRl expression rise again. 
A number of studies have suggested roles for effector cytokine 
stimulation of DC in promoting secretion of various T cell-attracting 
chemokines. These factors differentially attract activated, memory, 
or naive CD4+ and CDS+ T cell subsets, and mediate their effects 
in the lymphoid tissues where their expression by DC peaks at the 
time of maturation (approximately 24 hrs after stimulation). CC-
chemokines (MIPl-a, MIPl-0 and RANTES) and CXC-chemokines 
(Crg-2, or IP-10, and mig) preferentially attract Thl cells (Fig. 2) 
(59). MCP-1 and SDF-la attract both Thl and Th2 cells (59), al-
though SDF-1 preferentially attracts the latter together with naYve 
T cells (Fig. 3) (60). Interestingly, the CC-chemokine, DC-CKl, which 
is activated by IL-4 but not IFN-y stimulation of DC, attracts naYve 
T cells (61). RANTES and MCP-1 have been found to act predomi-
nantly on activated/memory stages of T cells (62, 63). Importantly, 
MCP-1 directly stimulates IL-4 production by T cells (64, 65), there-
by enhancing Th2 cell development (66, 67). Over expression of 
MCP-1 is also associated with defects in cell-mediated immunity 
(68), whilst MCP-1-deficient mice are unable to mount Th2 re-
sponses (69). Together, these results suggest a determinant role for 
Thl and Th2-type cytokines in the development of adaptive im-
mune responses. Thus, IFN-y appears to stimulate DC to secrete 
chemokines which preferentially attract activated/memory Thl 
cells, whereas IL-4 stimulates these cells to produce factors preferen-
tially attracting naYve T cells. 
Chemoattractants also have a regulatory role in effector cytokine 
expression, acting here to support chemotaxis of particular adaptive 
Th subsets. For example, MCP-1,-2,-3,-4 and C5a, but not SDF-1, 
MIP-la, RANTES or eotaxin, may each inhibit IL-12 production by 
DC in response to stimulation with IFN-y, Staphylococcus aureus 
and Cowan strain 1 (SAC) (70). 
IL-12, transforming growth factor beta (TGF-0), IFN-y, and IL-4 
also play important roles in directing specific Th cell subsets to 
sites of infection by modulating expression of specific chemokine 
receptors, such as CXCR3 and CCR5 on Thl cells (Fig. 2) and CCR3, 
CCR4 and CCR8 on Th2 cells (Fig. 3) (71-74). Possession of these 
receptors enables the cells to respond to different chemotactic sig-
nals. Thus, IP-10, CXCR3 ligand and cutaneous lymphocyte-associ-
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ated antigen (CLA) each act to recruit Thl cells (75, 76). Conversely, 
MDC and I-309 (CCR8 ligand) preferentially attract Th2 cells (77). 
Interestingly, IL-12 promotes Thl-type immune responses by inhib-
iting the secretion of the Th2 cell-attracting chemokines, I-309 and 
MDC, by Thl cells (78). 
Cross-regulation of adaptive and innate 
immunity by cytokines 
In addition to their determinant roles in the induction of immune 
responses, cytokines and chemokines, in this case produced largely 
by T cells, clearly play a pivotal role in immune regulation. A wide 
range of mechanisms are involved, including alteration of the ex-
pression of MHC molecules (79, 80), adhesion molecules (81) and 
costimulatory molecules (82), and direct activation or deactivation 
of immune cells (83, 84). These changes may lead to the activation 
of cellular immune responses involving NK cells and CTL, and anti-
body-mediated clearance of pathogens (Fig. 4) (85). 
The realisation that different subsets of CD4+ T cells were dis-
tinguishable by their ability to produce discrete patterns of cyto-
kines (86) provided a rational explanation for the early observations 
of Parish and colleagues showing that qualitatively different im-
mune responses may be elicited in response to antigen challenge 
(87). As discussed above, many different factors influence the nature 
of an immune response, however cytokines secreted by T helper 
cells are critical regulatory molecules. As has been well docu-
mented, the Thl cell subset secrete cytokines usually associated 
with inflammation, such as IFN-y and TNF-a, and induce cell-me-
diated immune responses. The Th2 subset produce factors such as 
IL-4, IL-5 and IL-13 that provide signals for the differentiation and 
proliferation of B cells and thus stimulate humoral immune re-
sponses. This Thl/Th2 paradigm may now be regarded as too sim-
plistic and has thrown up many inconsistencies and contradictions. 
Indeed, polarised Thl and Th2 responses may, in reality, represent 
the extremes of chronic inflammation or chronic disease states (14). 
Helper T cells and clones which appear to secrete mixtures of both 
Thl and Th2 cytokines have recently been identified and termed 
"ThO" cells (88, 89). These may be precursors for Thl and Th2 cells 
or, alternatively, represent a separate lineage, possibly acting in the 
elimination of pathogens against which concomitant and appropri-
ately regulated humoral and cell-mediated immune responses are 
required. Despite these developments, decisive advances in our 
understanding of immune regulation resulted from the development 
of the Thl/Th2 paradigm and many of its tenets remain valid. 
One such issue is the important roles played by Thl- and Th2-
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type cytokines and, indeed, other subsets, in reciprocally cross-regu-
lating each other's development and maintaining their phenotype 
and function (Fig. 4). Indeed, whilst these cells appear to be major 
determinants of cell-mediated and humorai immune responses 
against invading pathogens as outlined above, their dysregulation 
can have disash-ous consequences. Thus, Thl cells may cause auto-
immune disease if improperly regulated (90, 91), whilst allergic con-
ditions result from the over-production of factors such as IL-4 and 
IL-5 by Th2 cells (92, 93). Thus, IFN-y secreted by Thl cells may 
inhibit the development of Th2 cells (94) and immune responses 
mediated by antibodies of the IgGl, IgE and IgA subclasses. Con-
versely, IL-4 and IL-10 produced by Th2 cells may block the devel-
opment and activation of Thl cells and macrophage activity (13, 
88). It has been proposed that a major function of Th2 cells may be 
to down regulate Thl cell-mediated immune responses and limit 
their damaging effects (29). 
Further regulatory subsets, distinct from Th2 cells, have also 
been proposed or identified in order to explain novel experimental 
phenornenc1. Sorni: of thest:\ often termed ThJ CP.Jl s (95), rl.rP rlblP tn 
inhibit inflammatory diseases mediated by Thl cells (95-97) and 
Th2 cells (95, 97), and this is thought to be related to their express-
ion of TGF-~. This immunosuppressive or anti-inflammatory factor 
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Fig. 4. Cytokine regulation of anti-
microbial immune responses and immuno-
pathologies. The types of cytokines which are 
produced during the early stages of an immune 
response are major determinants of the types of 
immune cells that are generated as a result. Cyto-
kines may be divided into two categories: those 
driving T cell development towards either a Thl/ 
Tel phenotype (associated with cell-mediated im-
munity), or those which promote a Th2/Tc2 
phenotype (leading to the production of anti-
bodies by B lymphocytes). At the earliest stages 
of the immune response, these factors are pro-
duced by a variety of cells, including macro-
phages (IL-12), NK cells (IFN-y) and mast cells/ 
basophils (IL-4). As the response develops, T 
cells become the major producers of these factors. 
In addition, Thl-associated cytokines recipro-
cally down regulate the development and activity 
of Th2-associated responses and vice versa. Most 
virus infections stimulate strong antiviral Thl/ 
Tel responses, which act to resolve the infection. 
TGF-~, produced by a putative "Th3" subset, 
may down regulate the development of both Thl 
and Th2 subsets and inhibit inflammatory patho-
logies (e.g. autoimmunity and allergies). Solid ar-
rows indicate cell lineage development, streaked 
arrows indicate reg1.1latory/effector activity. 
was previously shown to inhibit the development of both Thl and 
Th2 cell subsets (98, 99). 
Cytokine-mediated feedback regulation of 
innate immune cells 
Cytokines expressed during an adaptive immune response may, in -
addition to regulating the expression of Th cell phenotypes, also 
act on innate cells as a feedback mechanism for the purposes of 
maintenance or amplification of immunity. Thus, IFN-y may act in 
synergy with CD40 activation of DC, increasing IL-12 production 
and promoting cell-mediated immunity and further IFN-r secretion. 
IFN-r, in turn, activates macrophages to express bacteriocidal activ-
ity and phagocytosis, to undergo an oxidative burst and to produce 
nitric oxide and secrete IL-12 and TNF-a, both of which support 
further Thl cell development (100). 
Th P. rn lP. nf TT .-4 in rl irPCJly priming fnr rl iffP.rP.nti;::itinn nf n;::ii v P 
CD4+ T cells into Th2 is well documented. Both IL-4 and IL-13 
may also influence Th2 development by acting directly on DC to 
downregulate IL-12 secretion (100). We have recently reported that 
IL-4 may also support development of Th2 responses by acting on 
DC progenitors to maintain high levels of expression of FcyR and 
macrophage mannose receptors during maturation (101). These ele-
ments are important for binding extracellular pathogens and are 
known to down regulate IL-12 production (102). In contrast, IFN-y 
stimulation of DC progenitors results in reduced levels of FcyR and 
macrophage mannose receptor expression and promotes high levels 
of expression of Thl cell-attracting chemokines such as RANTES 
(reviewed in 101). Finally, IL-10 produced by DC, Th2 cells and B 
cells may also act on innate immune cells to support Th2-type adap-
tive immune responses through its activities both as an endogenous 
and an exogenous regulator of IFN-a production (103). 
Virus-encoded homologues of cytokines 
and their receptors 
The critical importance of cytokines and chemokines in innate and 
adaptive immune defenses is illustrated by the expression of a var-
iety of inhibitors and homologues by many different pathogens, 
particularly viruses (104). Several poxviruses, including cowpox, 
variola (smallpox), ectromelia (a rodent pox virus), and myxoma 
(rabbit pox) viruses, encode for proteins which have cytokine or 
cytokine receptor homology. These molecules have apparently 
evolved to aid the virus in evading host immunity (105). An out-
standing example of such a strategy is provided by cowpox virus, 
which encodes three TNF receptor homologues, termed, CrmB, 
CrmC, and CrmD which may all bind TNF-a, but with different 
affinities. Unlike CrmC, the TNFR homologues CrmB and CrmD 
also bind TNF-~. CrmB is expressed early during infection whereas 
CrmC and CrmD are expressed at later times during infection (106). 
The exact function of these TNFR homologues is unclear although 
it has been demonstrated that the deletion of the CrmB protein (also 
termed T2) from myxoma virus markedly decreases virus pathgen-
icity in rabbits (107). This protein also inhibits virus-induced 
apoptosis in rabbit T lymphocytes (108). Herpesviruses are another 
group which have evolved an extensive array of strategies for im-
mune evasion, some of which have developed to counteract antiviral 
cytokine activity. For example, Epstein-Barr virus (EBV) encodes a 
17kDa product, termed BCRFl, which has 78 % homology with hu-
man IL-10 and which is expressed during the lytic phase of EBV 
infection. Both recombinant IL-10 and BCRFl inhibit macrophage 
and monocyte activation, as well as IFN-y expression by NK cells 
and T cells, resulting in inhibition of the up regulation of IVIl-IC 
molcules by antigen-presenting cells, nitric oxide production and 
other antiviral pathways (109) . Another herpesvirus, human cyto-
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megalovirus (HCMV) inhibits both IFN-a and IFN-y-induced ex-
pression of class I and II IVIl-IC molecules by decreasing JAKl and 
p48 expression, thus down regulating the ]AK/STAT signalling 
pathway (110). 
In addition, several viruses have developed strategies to modu-
late chemokine activity (105). These include (i) the production of 
molecules which mimic chemokines themselves, (ii) the expression 
of chemokine receptor homologues, which presumably compete for 
chemokine binding, and (i ii) the production of chemokine-binding 
proteins to inhibit host chemokine activity. 
In vivo studies of the immunoregulatory 
and antimicrobial activity of cytokines 
Numerous approaches have been used to study the role of cytokines 
both in regulating immune responses and in protecting the host 
against infection. The use of transgenic and gene knock out mice 
has proved extremely useful in this regard. One approach we have 
used has been to engineer recombinant viruses to express genes 
encoding cytokines and chemokines and to use these constructs to 
study the effects of these factors on host immune responses. Some 
of our key results are summarised in Table 1. 
During replication in vivo, the recombinant viruses produce the 
encoded factor which is secreted from infected cells. The location 
and extent of virus replication thus determines the levels and sites 
of cytokine or chemokine production. This approach has enabled us 
to study the effects of these molecules on the development of both 
innate and adaptive immune respons_es and also their role in mediat-
ing immunity to infection. Many of the encoded factors, including 
the cytokines IL-2 and IL-12, and the chemokines Mig and Crg-2, 
showed potent antiviral activity in vivo. Each of these factors in-
duced particular antiviral host defense mechanisms, whilst for other 
encoded factors (e.g. IFN-y, TNF-a and CD40 ligand), a direct anti-
viral effect was demonstrated (111). The use of mice rendered genet-
ically deficient for IFN-y or IFN-y receptor expression allowed us to 
show that both IL-2 and IL-12 mediated their antiviral activity large-
ly through the induction of host IFN-y production (112, 113). The 
antiviral activity of IL-2 lay in the ability of this factor to activate 
and attract NK cells to sites of infection and to stimulate their pro-
duction of IFN-y, which, in turn, limited the growth of the recombin-
ant virus. IL-12, which also showed potent antiviral activity when 
expressed by rVV, is a strong stimulator of IFN-y production. As 
early as 1 day after infection, VV encoding IL-12 was recovered at 
titers approximately 100-fold lower than a control rVV in normal 
mice. However, IL-12 itself may also exert antiviral activity, as dem-
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Known functions of cytokines and their effects in vivo when expressed by recombinant vaccinia viruses 
Cytokine 
Type 1 factors 
IL-2 
TNF-a 
IFN-y 
IL-12 
Type 2 factors 
IL-4 
IL-5 
IL-6 
Other factors 
IL-1a 
IL-7 
CD40L 
Mig 
Crg-2 
Table 1 
Major known function 
T cell growth factor, activates 8 cells, monocytes and NK 
cells 
Antiviral activity in vitro, activates cytotoxic T cells 
Up-regulates MHC molecules on antigen presenting cells, 
anti- viral activity 
Helps initiate type 1 responses, promotes IFN-y production 
Regulates antibody responses, especially lgE. Down-
regulates type 1 responses 
Regulates antibody production 
Involved in the maturation of B cells to ASCs 
Activates T cells . 
Early activator of T and B cells 
Triggers B cells to make antibody 
Recruits leukocytes to sites of inflammation 
onstrated by the observation that mice deficient in this factor failed 
to mount significant antiviral CTL responses or to clear the virus 
efficiently, despite unimpaired IFN-y expression (114). Thus, in ad-
dition to its regulatory activity in Thl cell development, IL-12 may 
also play an important role as an antiviral mediator, both through 
the activity of IFN-y and independently of this factor. 
TNF-a, which is produced predominantly by macrophages, also 
displays potent antiviral activity when expressed by recombinant 
VV. Studies using mice deficient in TNF receptor 1 (P55) and/or 
TNF receptor 2 (P75) showed that both receptors were involved in 
antiviral activity (115). Indeed, as outlined above, several pox vi-
ruses have naturally acquired genes encoding for proteins which 
have homology with these TNF receptors and which are thought to 
be important in viral pathogenesis (107). 
Expression of the T cell surface molecule CD40 ligand in r VV 
also produced, somewhat unexpectedly, a highly attenuated virus 
phenotype in vivo (116). The attenuation of VV-CD40 ligand in wild 
type mice was, however, completely reversed in CD40-deficient mice. 
Interestingly, CD40 expression is not restricted to B cells, macro-
phages and DC, but is also found on tumor cells and may be in-
duced on fibroblasts incubated with IFN-y and TNF-a. Thus, we 
have speculated that CD40 ligand/T cell-mediated activation of 
CD40 on virus-infected cells may act to limit the production of pro-
geny virus, possibly through apoptosis of infected cells. 
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Effect on immunity when expressed by rW 
Attenuates growth of virus, stimulates natural killer cells to 
produce IFN-y 
Limits growth of vW, allowing T cell-deficient mice to resolve 
infection. 
As above. 
Limits growth of rVV. stimulates IFN-y secretion, down 
regulates type 2 responses 
Increases pathogenicity of rW, down-regulates CTL 
responses 
Stimulates antigen specific mucosa! lgA responses 
Stimulates antigen-specific systemic lgG and mucosa! lgA 
responses 
Enhances memory antibody responses 
Stimulates T cell and non-specific antiviral immunity 
Antiviral activity 
Antiviral activity leading to resolution of infection 
References 
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In addition to its roles in promoting Th2 cell development and 
down regulating Thl cell differentiation, IL-4 may influence the dif-
ferentiation of other lymphocyte populations. For example, in vitro 
stimulation of naive CD8+ T cells in the presence of IL-2, IL-12 or 
IFN-y generates classical cytotoxic T cells which express IFN-y,(also 
termed Tel cells), whereas CD8+ cells stimulated in the presence of 
IL-4 develop a Tc2 phenotype resulting in their expression of IL-4, IL-
5, IL-6 and IL-10, often with markedly reduced cytotoxic activity (117, 
118). In our studies, expression of IL-4 by recombinant poxviruses 
markedly increases their pathogenicity via down regulation of the 
antiviral CTL response and IFN-y production (119). Limiting dilution 
analysis revealed a 12-fold reduction in CTL precursor frequency in 
VV-IL-4 infected mice. Others have shown that treatment of activated 
Tel cells with IL-4 also results in defective IFN-y, TNF-a and IL-2 ex-
pression. Although IL-4 treated Tel cells retained short-term in vitro 
cytotoxic activity, they failed to proliferate in response to antigen 
stimulation, compromising their long-term functional capability to 
control infection (118). It has recently been shown that NK cells cul-
tured in the presence of either IL-12 or IL-4 may differentiate into 
"NIG" or "NK2" cells respectively, with distinct patterns of cytokine 
secretion similar to Thl and Th2 cells, although this does not appear 
to effect their in vitro cytotoxic activity (120). Thus, expression of IL-
4 early in infection, can dramatically down regulate, or even prevent, 
induction of protective immune responses to infectious pathogens. 
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These examples illustrate that the profiles of cytokines which 
are induced early in infection are of critical importance for the im-
munological control of infection. Cytokines and chemokines not only 
regulate the types of cells which are activated, but many of these 
factors also have direct antiviral effector function or the capacity to 
stimulate immune cells to secrete further antiviral molecules. Cyto-
kines may also act as reciprocal messengers to co-ordinate innate 
and adaptive immune responses against infectious agents. The ini-
tial encounter with a pathogen elicits an innate response that will, 
to a large extent, determine the nature of the subsequent adaptive 
response. The nature of the invading pathogen, the route of infec-
tion and the genetic background of the host all play a role in influ-
encing the types of responses which are induced. Conversely, cyto-
kines produced by cells of the adaptive immune system may also, 
via feedback mechanisms, influence the types of effector activity 
expressed by innate immune cells. This highly developed regulation 
of innate and adaptive immune responses has evolved to ensure 
that the most efficient immunological effector mechanisms are un-
leashed on any particular infectious agent among the wide variety 
of pathogens which are likely to be encountered. 
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Murine interferon-inducible T cell alpha chemokine (I-TAC) is a potent non-ELR Cys-X-Cys (CXC) 
chemokine that predominantly attracts activated T lymphocytes and binds to the receptor CXCR3. 
Using semiquantitative reverse transcription-polymerase chain reaction (RT- PCR) we analysed mur-
ine I-TAC expression in two different progenitor dendritic cell (DC) lines, MTHC-D2 and JAWS II which 
were exposed to various cytokines, and Con A -activated splenocytes from a panel of knockout mice. 
Analysis of the progenitor DC lines and Con A cultures demonstrated that murine I-TAC is primarily 
regulated by interferon (IFN)-y via interferon regulatory factor (IRF)-1. It has been proposed that I-TAC 
may have a role in autoimmune diseases such as multiple sclerosis (MS). Because I-TAC appears to 
be secreted from antigen-presenting cells (APCs) and attracts activated T cells, we examined the level 
of murine I-TAC mRNA in the central nervous system (CNS) of wild-type and IFN-y-receptor 
knockout (IFN-yR_1_) mice with myelin oligodendrocyte glycoprotein (MOG)35 _ 55 peptide-induced 
experimental autoimmune encephalomyelitis (EAE). Peak I-TAC expression was detected in wild-type 
mice on day 14 when the mice begin to recover, whereas very low levels of I-TAC were detected in 
the CNS of IFN-y R-/- mice which develop severe EAE and die. The expression characteristics of murine 
I-TAC suggest an important mediator of immune cell communication that could augment vaccines 
and autoimmune therapies. 
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INTRODUCTION 
Chemokines are small proteins that mediate the recruitment 
and activation of leucocytes and other cells during immune 
responses . How various chemokines influence dendritic 
cell (DC)/T-cell migration during early immune events has 
recently received increased attention, as the importance 
of chemokines during these events has become apparent. A 
number of key chemokines have already been shown to be 
© 2002 Blackwell Science Ltd 
involved in regulating the migration and maturation of DCs 
as they travel to the draining lymph nodes and as they 
influence early T-cell events in the lymph [l]. 
Relatively recently the human non-ELR CXC chernokine 
('E-L-R' refers to the amino acid motif required for recruit-
ing neutrophils), interferon-inducible T cell alpha chemo-
kine (I-TAC) , also known as H174 [2], ~-RI [3] , SCYBl 1 
[4], IP-9 and CXCLl 1 [5], was identified and found to be 
a potent chemoattractant for_ activated T lymphocytes , 
172 N. H. R . Hwnift on et al. 
NK cells [6, 7] and monocyte-like cells [8]. Human I-TAC is 
homologous to IP- IO and monokine induced by IFN-y 
(MIG), and like these chemokines , binds to the chemokine 
receptor CXCR3 but with a significantly higher affinity 
suggesting a key role in T cell-mediated immunity [6 , 9]. 
Expression of human I-TAC has been detected in cultured 
primary monocytes, cultured foetal astrocytes , microglial 
cell line [6], astrocytoma cells [3], atheroma-associated 
cells [1 O] , bronchial epithelial cells [11], polymorphonuclear 
neutrophils [7] and keratinocytes [12]. Moderate expression 
has also been detected in human central nervous system 
(CNS) [8], pancreas, lung, thymus and spleen tissues [6]. 
In vitro studies have demonstrated that the expression 
of human I-TAC appears to be upregulated following 
the exposure to mainly interferon (IFN)-cx, IFN-0 or 
IFN-y plus other cell regulators such as interleukin (IL)-1, 
lipopolysaccharide (LPS) or tumour necrosis factor 
(TNF)-cx [3, 6]. 
The increased I-TAC expression in human astrocytes and 
its ability to attract activated T cells has led some researchers 
to propose that I-TAC may have a role during the induction 
and pathophysiology of neuroinflammatory disorders such 
as multiple sclerosis (MS) [6, 8]. An animal model for MS, 
experimental autoimmune encephalomyelitis (EAE), is a 
CNS-demyelinating disease induced in susceptible mice, 
rats, guinea pigs, or nonhuman primates following immun-
ization with myelin-derived antigens, peptides, or following 
the transfer of autoreactive CD4+ T-cell lines or clones [ 13] . 
During the initiation of EAE, activated-Th! autoreactive 
T cells appear to infiltrate the CNS by an antigen- and 
apparently chemokine-independent process which leads to 
the increased expression of a range of proinflammatory 
cytokines within the CNS [14, 15]. These proinflammatory 
cytokines, among other effects, upregulate the expression 
of a suite of chemokines which have been implicated in 
various stages of EAE disease [15- 21] . Confirmation of a key 
role for I-TAC during EAE has been slow because of the delay 
in the identification of a rodent I-TAC homologue. M urine 
I-TAC, however, has been recently identified , but its role 
during EAE has not been examined [22, 23]. 
In this study, we report that murine I-TAC is expressed 
from two progenitor DC lines , JAWS II and MTHC-D2. 
Murine I-TAC expression in Con A-activated splenocytes 
from a panel of knockout mice allowed us to further deline-
ate the cytokine regulation of murine I-TAC expression. 
Murine I-TAC was primarily regulated by IFN-y but not 
IL-4 or TNF-cx. Finally , given the central role of antigen-
presenting cells (APCs) in the CNS of animals with EAE and 
the fact that I-TAC is expressed from DCs and is IFN-y 
regulated , we anal ysed murine I-TAC expression in the CNS 
of both wild-type and IFN-yR knockout mice during EAE. 
Taken together, these results suggest that I-TAC may have 
an important regulatory role during the T cell-medi ated 
immunity. 
MATERIALS AND METHODS 
Mice . Specific pathogen-free 6-8-week-old female mice were 
obtained from the Animal Breeding F acility, John Curtin School 
of Medical Research , Canberra, Australia. IFN-cx/ pR-/-, IFN-y R-/-
and IFN-cx/ PR-yR-/- double knockout mice homozygous for the 
disrupted gene(s) and backcrossed onto the 129/Sv background , 
were obtained from Dr Michel Aguet, University of Zurich [24- 26). 
Interferon regulatory factor (IRF)-1 -/- mice backcrossed onto the 
129/Sv background were obtained from Prof Charles Weissman , 
University of Zurich [27) . CD4o-/- mice were obtained from Prof 
Hitoshi Kikutani , Osaka University [28) . TNF-IR-IIR-/- double 
knockout mice were obtained from Dr Jacques Peschon, Immunex 
Research and Development Corporation [29] . Two sources of 
age-matched null homozygote (C57/BL6 x 129/Sv) mice were u sed 
as controls for these assays (Max-Planck Institute for Immunbiologie, 
Freiburg, Germany and University of Zurich, Switzerland) as 
described elsewhere [30, 31). 
DC cell lines and Con A blasts. The progenitor DC cell line, 
JAWS ,II (A TCC, CRL-11904), isolated from p5T1- mice, was 
maintained in alpha minimum essential medium with ribonucleo-
sides and deoxyribonucleosides containing L-glutamine (Gibco/ 
BRL Paisley, UK) and supplemented with 20 % foet a l bovine 
serum (FBS) (Gibco/BRL), 1 mM sodium pyruvate and 5 ng/ ml 
murine GM-CSF (Sigma, St. Louis, MO, USA) . 
The DC progenitor cell line, MTHC-D2, whose features are 
summarized by Banyer and Hape! [32), was subcloned from 
MTHC lines described previously [33]. This cell line was maintained 
in Iscove's modifed eagle medium (IMEM; Gibco/ BRL) supple-
mented with 10% FBS (Gibco/BRL) , 2 mM glutamine (Si gma) , 
and 50 U /ml GM-CSF. 
JAWS II and MTHC-D2 cell lines were stimulated for 24 or 48 h 
with TNF-cx (500 U /ml) and GM-CSF (5 ~L /ml) , and either IFN-y 
(2 U/ml) or IL-4 (50 U /ml). Aliquots of these cell samples were then 
activated for a further 24 h by CD40 cross-linking using CD40 Ab 
(25 µg /ml) protein A column-purified from supernatant of cultured 
FGK45.5 cells [34). 
Con A blasts from mice were generated from RBC-lysed spleno-
cytes (2-5 x 106 cells/ml) by culturing for 2days in Fl5 MEM 
containing 10% FCS (Gibco/BRL) and Con A (2 µg /ml, Pharmacia 
Biotech, St. Quentin, Yvelines , France). 
Reverse transcription- polymerase chain reaction ( RT- PCR). Murine 
I-TAC expression was analysed by hot-start semiquantita tive RT-
PCR. Briefly, mRNA was isolated from either cell lines (5 x 106 cells) 
or Con A blasts (1 x 106 cells) using the QuickPrep Micro mRNA 
Purification Kit (Pharmacia Biotech) and first strand cDNA prepared 
using a Ready-To-Go T-Primed First Strand Kit (Pharmacia Bio tech). 
First strand cDNA was also produced from mRNA isolated from CNS 
tissue excised using standard techniques from mice with EAE. The first 
strand cDNAs (1 ~Li) from DC cell lines, Con A blas ts and CNS tissue 
were PCR-amplified in various experiments (reaction vo lume 20 ~Li) 
using Taq polymerase (1 .5 U/reaction , Gibco/BRL), the supplied 
lO x buffer, MgCb (2 mM), dNTPs (0.2 mM) (Pha1macia Bi otech), 
and o li gonucleot ide primers (2 ~LM). The thermal pro fi le used was as 
fo llows: denaturing at 94 °C for 10 s, annealing at 66 °C fo r 20s, and 
extension at 72 °C for 30 s for 30-32 cycles. Oligonucleotide primers 
used to amplify a 252-bp I-TAC fragment were mITAC sense, 
5' -GAACAGGAAGGTCACAGCCA T AGC-3' and mITAC antisense, 
5' -ATGAGGCGAGCCTGCTTGGATCTG-3' . RT- PCR products 
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were viewed by gel electrophoresis (3% Nuseive GTG agarose, 
BioWhittaker, Rockland, ME, USA). All results were standardized 
against murine GAPDH by amplifying a 551-bp fragment using the 
primers mGAPDH sense, 51-ACCACAGTCCATGCCATCAC-3' 
and mGAPDH antisense, 5'-TCCACCACCCTGTTGCTGTA-3'. The 
thermal profile used to amplify the GAPDH fragment was as follows: 
denaturing at 94 °C for 10 s, annealing at 58 °C for 20 s, and extension 
at 72 °C for 30 s for 28 cycles. Prior to the actual assays, the thermal 
conditions and number of cycles used were optimized for both primer 
pairs so that the PCR products obtained did not proceed past the expo-
nential phase of the PCR reaction nor exceed analysis limits . All semi-
quantitative RT- PCR experiments were carried out more than once. 
EAE model. The peptide corresponding to amino acids 35-55 
of rat MOG (35Met-Glu-Val-Gly-Trp-Tyr-Arg-Pro-Pro-Phe-Ser-
Arg-Val-Val-His-Leu-Tyr-Arg-Asn-Gly-Lys55) was synthesized by 
standard f-moc chemistry and the purity determined by reverse 
phase HPLC (Biomolecular Resource Facility, JCSMR, ANU). 
Rat MOG35_55 (2 mg/ml in saline) was emulsified in an equal volume 
of CFA containing 0.5 mg/ml Mycobacterium butyricum and 4 mg/ml 
Mycobacterium tuberculosis (H37Ra). Each mouse received 100 ~LI 
emulsion distributed in the footpads of both hind feet and in the 
nape of the neck. The total dose of MOG35_55 was 100 µg /mouse. 
Immediately before and 2 days after injection of the emulsion, 
the mice received an i.v. injection of 300 ng of pertussis toxin 
(List Biological Laboratory, Campbell, CA, USA) in 250 ~ti of 
phosphate-buffered saline (PBS). The mice were monitored daily 
and assigned EAE severity scores as described previously [13]. 
RESULTS 
Cytokine-induced expression of murine I-TAC in DC lines 
To investigate which cytokines regulate murine I-TAC 
expression, we carried out semiquantitative RT-PCR ana-
lysis (Fig. 1) on mRNA isolated from the JAWS II (Fig. IA) 
and MTHC-D2 (Fig. 1 B) cell lines exposed to TNF-cx. plus 
IFN-y or TNF-cx. plus IL-4 cytokines. These two cell lines are 
progenitor cells of DC isolated from different tissues and 
which have been transformed by two different approaches. 
Semiquantitative R T-PCR analysis of both the JAWS II 
(Fig. IA) and the MTHC-D2 (Fig. lB) cell lines showed 
that the expression of murine I-TAC was upregulated by 
IFN-y/TNF-cx. (lanes 3) compared with the IL-4/TNF-cx. 
(lanes 2) or untreated cells (lanes 1) both of which had no 
detectable murine I-TAC band . These data also indicate 
indirectly that IL-4 and TNF-cx. alone do not upregulate 
I-TAC expression and that the key cytokine for expression 
appears to be IFN-y. Northern blot analysis (not shown) of 
the MTHC-D2 cells confirmed the RT- PCR data and also 
confirmed the reported size of the full-length murine I-TAC 
mRNA at approximately 1.3 kb [22). 
CD40 Ab-induced expression of murine 1-T AC in DC lines 
Synergy between IFN-y and CD40L has been shown to 
enhance the expression of a number of chemokines from 
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cervical carcinoma cells [35). In conjunction with the cyto-
kines above, we examined the effect of anti-CD40 Ab 
on murine I-TAC expression (Fig. 1) . Semiquantitative 
RT-PCR analysis, standardized against GAPDH, showed that 
in the absence of IFN-y, anti-CD40 Ab upregulated the 
expression of murine I-TAC in MTHC-D2 cells (Fig. I B: 
lanes 1 and 2 versus lanes 4 and 5, respectively), but not in 
the JAWS II cell line (Fig. IA: lanes 1 and 2 versus lanes 4 
and 5, respectively). An increased expression pattern was 
detected in cells exposed to both CD40Ab and IFN-y with 
the MTHC-D2 cell line demonstrating synergy (Fig. 1 B: lane 
3 versus lane 6) whereas synergy in the JAWS II was not 
detected (Fig. IA: lane 3 versus lane 6). The different I-TAC 
expression pattern between the cell lines appears to be pri-
marily owing to differences in the CD40 activation pathway 
rather than in the interferon-signalling pathway. 
Expression of murine 1-T AC Con A blasts from knockout mice 
' To further analyse murine I-TAC expression and confirm the 
cell line results, semiquantitative RT-PCR, standardized 
against GAPDH, was carried out on cDNA from inactivated 
and Con A-activated splenocytes isolated from a panel of 
knockout mice. Murine I-TAC expression in inactivated 
splenocyte cDNA samples from the various transgenic mice 
and controls was very low and not significantly different 
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Fig, 1. Semiquantitative reverse transcription-polymerase chain 
reaction (RT-PCR) murine interferon-inducible T cell alpha 
chemokine (I-TAC) and GAPDH mRNA expression in the JAWS 
II (A) and MTHC-D2 (B) cell lines without cytokine sti mnl a tinn 
(lane 1) and following exposure to the cytokines; interleukin (IL)-4/ 
tumour necrosis factor (TNF)-0'. (lane 2), interferon (IFN)-y/TNF-o: 
(lane 3) , without cytokine stimulation plus anti-CD40 Ab (lane 4), 
IL-4/TNF-cx plus anti -CD40 Ab (lane 5), and IFN-y/TNF-cx plus 
anti-CD40 Ab (lane 6). 
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Fig. 2. Murine interferon-inducible T cell alpha chemokine (I-TAC) 
and GAPDH semiquantitative reverse transcription-polymerase 
chain reaction (RT-PCR) analysis of Con A-activated splenocytes 
from a panel of knockout mice. Two sources of age-matched 
littermate null homozygote (129/Sv x C57BL/6) mice were used as 
controls (lanes 1 and 2). The panel of knockout mice were as follows: 
interferon (IFN)-cxmR-/- (lane 3), IFN-yR-/- (lane 4), and IFN-cx/ 
~R-yR-/- (lane 5), interferon regulatory factor (IRF)-1 -/- (lane 6), 
CD4o-/- (lane 7) , and tumour necrosis factor (TNF)-IR-IIR-/- (lane 
8). The cDNA samples from three individual mice in each case were 
obtained and then combined equally prior to PCR amplification. 
( data not shown). In the Con A-activated splenocyte samples 
(Fig. 2), there was a significant increase in the level of murine 
I-TAC expression in splenocytes from IFN-cx/ ~R-/- (lane 3) 
mice compared with control (lanes 1 and 2). These results 
appear to indicate that IFN-cx and/or IFN-~ were down-
regulating murine I-TAC expression in these assays. Expres-
sion of murine I-TAC in splenocytes from IFN-yR- /- (lane 
4), IFN-cx/ ~R-yR- /- (lane 5) and IRF-1 - /- (lane 6) mice were 
all significantly lower than the expression in the splenocytes 
from control mice (lanes 1 and 2). These results showed that 
the IFN-y signalling pathway is the primary regulator of 
murine I-TAC mRNA expression and that IRF-1 has a 
significant role in murine I-TAC expression. Murine I-TAC 
expression in activated splenocytes from CD4o-/- (lane 7) 
mice was not significantly different to the samples from 
control mice (lanes 1 and 2), corresponding to the in vitro 
data for the JAWS II cell line (Fig. IA) but not to the data 
for the MTHC-D2 cell line (Fig. 1 B). There was no signifi-
cant difference between the level of murine I-TAC detected 
in TNF-IR-IIR-/- (Fig. 3, lane 8) mice compared with con-
trol mice (lanes 1 and 2), which suggests that TNF-cx does 
not have an important role in regulating murine I-TAC 
mRNA, as also shown indirectly by the in vitro cell line data. 
Expression of murine I-TAC in the CNS of mice ivith EAE 
Previously, it has been reported that IFN-yR-/- mice chal-
lenged with rat MOG.3 5_55 peptide develop severe EAE and 
die whereas wild-type control mice (IFN-y R +i+) develop a 
milder disease and recover [13] . Given that I-TAC attracts 
activated T cells, is regulated by IFN-y and is expressed 
from astrocytes in the CNS , we investigated murine I-TAC 
expression in the CNS of wild-type and IFN-yR-/- mice with 
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Fig. 3. Analysis of murine interferon-inducible T cell alpha 
chemokine (I-TAC) expression in the central nervous system (CNS) 
of mice with experimental autoimmune encephalomyelitis (EAE) . 
(A) Disease scores of wild-type (circles) and interferon (IFN)-yR- /-
(squares) mice with myelin oligodendrocyte glycoprotein (MOG)35_ 
55 peptide-induced EAE. (B) Semiquantitative reverse transcription-
polymerase chain reaction (RT-PCR) analysis of murine I-TAC 
and GAPDH mRNA CNS expression in IFN-yR-/- mice with EAE 
at day 8 (lanes 1-3), day 14 (lanes 4-6) and day 20 (lanes 7- 9). (C) 
Semiquantitative RT- PCR analysis of murine I-TAC and GAPDH 
mRNA CNS expression in wild-type mice with EAE at day 8 (lanes 
1-3), day 14 (lanes 4-6) and day 20 (lanes 7-9). 
MOG35_55-induced EAE. Figure 3A shows the disease scores 
of the wild-type and IFN-yR-/- mice sacrificed on day 8 
(before clinical disease), day 14 (peak disease in wild-type 
mice) and day 20 (recovery in wild-type mice). Semiquanti-
tative RT- PCR analysis detected very low levels of murine 
I-TAC in the CNS of IFN-yR-/- mice throughout the time 
course (lanes 1-9) while these mice developed increasingly 
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severe disease (Fig. 3B). Analysis of wild-type control mice, 
however, showed that I-TAC levels in the CNS were initially 
low on day 8 (lanes 1-3), were very high at the peak of 
disease when the mice begin to recover on day 14 (lanes 4-6) , 
but then returned to low levels by day 20 (lanes 7- 9) (Fig. 3C). 
These results do not provide a direct role for murine I-TAC 
during disease; however, they measure I-TAC expression 
during EAE for the first time. 
DISCUSSION 
The function and potency of human I-TAC suggests that it 
may be a key regulatory chemokine in the immune system. 
Previous studies suggest that antigen-presenting cells are an 
important source of this chemokine [6]. An analysis of 
murine I-TAC expression from DCs, which are key mediators 
of the immune response, however, has not been reported. To 
study the regulation of murine I-TAC in DC, we analysed its 
expression in two different DC progenitor cell lines, JAWS II 
and MTHC-D2, exposed to the cytokines IFN-y, IL-4 and 
TNF-cx. These analyses showed that murine I-TAC expres-
sion from DCs is regulated primarily by the IFN-y signalling 
pathway and appears to be similar to the regulation of 
human I-TAC expression. Others have recently reported 
that IL-4 and/ or TNF-cx can also upregulate murine I-TAC 
in different cell types to those used here [22, 36]. Hence, it 
appears that the regulation of murine I-TAC can vary 
depending on the cell type and cytokine environment 
involved. 
To further examine the regulation of murine I-TAC by 
cytokines and downstream signalling factors, we analysed 
the expression in Con A-activated splenocytes from a panel 
of knockout mice. These results confirmed the cell line data 
that murine I-TAC expression is regulated primarily by 
the IFN pathway. These assays also demonstrated that a 
proportion of I-TAC expression is dependent on the action 
of IRF-1 , with the remainder probably being regulated by 
other IRF transcription factors involved in the interferon-
signalling pathway [37] . The finding that murine I-TAC is in 
part regulated by IRF-1 may help explain some of the complex 
phenotypes of IRF-1 - /- mice. IRF-1- /- mice have defective 
development of thymic CD8 + cells, severe NK cell deficiency 
and an abnormally high proportion of Th2 CD4+ T cells , 
which together lead to increased susceptibility to pathogens 
normally controlled by Thl responses [37]. Thus the lowered 
expression of murine I-TAC from DCs in IRF-1-/- mice, 
combined with lowered Crg-2 and MIG expression (S Maha-
lingam , unpublished data) , may cause the alteration in the 
balance of Th I /Th2 CD4 + T cells . 
Previously it has been shown that IFN-cx or IFN-~ 
enhance the expression of human I-TAC with or without 
other cell activation signals [3]. But, in our study, using the 
cells from various knockout mice , these two cytokines 
appeared to instead downregulate the level of murine 
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I-TAC expression. However, during these analyses , the 
level of these cytokines in the cultures while not analysed , 
was probably low [38 , 39]. Others have shown that low levels 
of IFN-cx or IFN-~ can increase the expression of IRF-2, 
which competes with IRF-1 thereby suppressing IRF-1-
regulated genes [37]. Therefore in our assa ys, the lack of 
IFN-cx/ ~ signalling in the IFN-cx/~R-/- and IFN-cx/ ~R-yR- /-
Con A cultures, and subsequent lack of IRF-2 expression , 
explains why murine I-TAC expression was higher in the 
wild type and IFN-yR-/- Con A cultures, respectively . Thus , 
comparing our data with previously published findings , it 
appears that IFN-cx and IFN-~ can act both to increase 
or to decrease I-TAC expression depending on the relative 
amount of these two cytokines present [40]. 
Others have reported that TNF-cx and IFN-y synergize to 
enhance the expression of both murine and human I-TAC 
[7, 11, 22, 36]. We did not find any evidence of synergy 
between IFN-y and TNF-cx in either our cell line or Con A 
culture analyses. In our cell line assays, TNF-cx was included 
primarily to promote cell differentiation during stimulation 
with other cytokines . Hence , in the analyses reported by 
others, TNF-cx may have appeared to enhance the expression 
of I-TAC induced by IFN-y through increased survival of 
differentiated cells. Others have also reported in a series of 
studies that for IP- I 0, a related chemokine, synergy between 
TNF-cx/IFN-y can be cell type and/or stimulus-specific [40] . 
Therefore, another explanation for our inability to detect 
synergy between these cytokines may be that our cell lines 
were different to those used in the previous reports and that 
Con A may not be an appropriate stimulus to observe the 
synergy in splenocyte cultures. 
The addition of anti-CD40 Ab to MTHC-D2 cells showed 
that CD40 alone can upregulate the expression of murine 
I-TAC and that the CD40 and IFN-y pathways can synergize 
to enhance this expression. This is consistent with a report by 
Altenburg et al. who showed that in cervical carcinoma cells, 
IFN-y can synergize with CD40L to enhance the expression 
of a number of chemokines including IP-10 , MCP-1, and to a 
lesser extent RANTES and MCP-3 [35]. Enhanced I-TAC 
expression, however, was not detected in the JAWS II cell 
line following CD40 activation. This result could be owing to 
differences in the level of CD40 expression between the two 
cell lines. The JAWS II cell line though lacks the tumour 
suppressor p53, and others have shown that p53-dependent 
functions can be regulated by CD40 [41]. Hence , the absence 
of IFN-y/CD40 synergy in the JAWS II cell line could be 
explained by poor responsiveness in some of the downstream 
CD40 signalling pathways which involve p53 . An a lterna ti ve 
explanation is that the CD40 si gnalling pathway in the 
MTHC-D2 line was somehow enhanced owing to the unre-
gulated expression of truncated c-Myb used to immorta li ze 
these cells [33] . In the Con A-activated CD4o- J- splenocyte 
cultures , the lack of CD40 did not appear to reduce the 
murine I-TAC expression , which like the JAWS II cell line 
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suggests that CD40/IFN-y do not synergize to enhance 
I-TAC expression. The absence of CD40 signalling, however, 
may have been compensated for by either direct costimula-
tion of APCs by Con A, or more likely, by the large amounts 
of IFN-y induced following Con A stimulation. 
The APC/DC and T-cell interaction is frequently import-
ant in the regulation and exacerbation of autoimmune 
diseases. Given that I-TAC potentially enhances this inter-
ac tion through the recruitment of activated T cells, we 
examined its role in an autoimmune disease model. Others 
have proposed that human I-TAC expressed in the CNS of 
MS patients may exacerbate the neuroinflammation asso-
ciated with this disease [6 , 8]. Our analysis of wild-type mice 
with MOG peptide-induced EAE demonstrated that murine 
I-TAC expression was the highest at the peak of disease 
severity, when the animals first began to recover. High 
expression at the peak of disease is consistent with a 
previous study that showed that known EAE-associated 
chemokines regulate the later CNS inflammatory processes 
as opposed to aiding the initial entry of autoreactive T cells 
into the CNS [15]. 
Recently , Willenborg et al. reported tha t IFN-yR-/- mice 
with MOG peptide-induced EAE develop severe disease 
and die, whereas wild-type mice develop mild disease and 
recover [13]. The report by Willenborg et al. demonstrated 
that IFN-y, while primarily a proinflammatory cytokine, is 
also apparently important during disease recovery. In this 
same EAE di sease model , we found that IFN-yR-/- mice 
expressed very low levels of rnurine I-TAC. Our results do 
not provide a direct link between the function of murine 
I-TAC and the EAE disease phenotype. It is, however, 
interesting to speculate, given the lack of murine I-TAC in 
the IFN-yR- /- mice, that I-TAC might have a role during 
disease recovery in wild-type mice by recruiting suppressor 
T cells. It is more likely , however, given that antibodies to a 
functional domain of CXCR3 protect mice from EAE, that 
murine I-TAC acts to enhance neuroinflammatory processes 
[42] . As there are other chemokines that bind to CXCR3, a 
thorough assessment of the contribution of murine I-TAC in 
the progression of neuroinflammation, however , remai ns to 
be performed. 
In summary, murine I-TAC is a potent CXC chemokine 
and its expression is induced predominantly in response to 
IFN-y. Our studies raise interesting questions as to the 
biological relevance of I-TAC since it is a chemokine that 
is expressed from pro genitor DC lines and thought to 
recruit already activated CXCR3 expressing T cells. Murine 
I-TAC may therefore have an important role in DC/T cell 
interactions in early immune respo nses. This study should 
accelerate the thorough characterization of murine I-TAC 
and may have important implications for the devel opment 
of vaccines and therapies for a range of different pathogens 
and diseases. 
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Abstract 
IFN-y and IL-4 are necessary for the development of cell-mediated immu~ity (CMI) 
and humoral immunity (HI) respectively. How these cytokines differentially effect the 
development of DC immunoregulatory properties has not been resolved~ To address this we 
have stimulated a DC progenitor-like cell line, MTHC-D2 with these cytokines. The 
expression of immunoregulatory molecules, phagocytic and T cell stimulatory function, and 
cellular morphology were differentially regulated. In addition, genetic profiling found IFN-y 
induced expression of genes associated with mature DCs and important for CMI responses, 
whereas IL-4 induced genes associated with cellular adhesion and uptake of extracellular 
pathogens. Interestingly, the addition of both cytokines induced development of a unique set 
of immunoregulatory properties that were consistent with mature DCs but retained phagocytic 
properties characteristic of immature DCs. These studies demonstrate that IFN-y and IL-4 can 
induce distinct immunoregulatory profiles that may underlie the ability of DCs to direct 
different adaptive immune responses. 
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Introduction 
At the point of contact with a pathogen till the end of an adaptive immune response 
cytokines play an important role in directing and regulating immunity. Pathogens themselves 
can induce innate immune cells to secrete particular cytokines that go on to direct immune 
response development. Viruses for example, can induce IFN-y production from NK cells that 
in turn stimulate DCs to induce IFN-y-producing T cell responses imporiant for CMI [ l]. 
Whereas, yeast induces IL-4 production from DCs that supports HI [2]. How these cytokines 
differentially affect the immunoregulatory properties of DCs, that in turn allows them to direct 
these immune responses, is not well understood. One mechanism proposed is the regulation 
of DC IL-12 p70 production, where high levels induce CMI, and low levels support HI [3] [ 4] 
[5]. Given the association of IFN-y with CMI, it would be expected that this cytokine could 
stimulate DCs to produce IL-12 p70. However, it has been shown that IFN-y induces DCs to 
express the p40 homodimer fonn of IL-12 that instead antagonises p70' s ability to induce 
CMI by competing for binding to the IL-12 receptor [ 6]. In the presence of IL-4, however, 
IFN-y is able to induce high levels of p70 production from DCs [6] [7]. Therefore, a DC 
situated in a microenvironment containing both CMI and HI associated cytokines is more able 
to support IL-12 p70 production. It is more likely the DC exposed to IFN-y utilises other, as 
yet unidentified mechanisms to induce CMI as recent studies have shown that DCs can induce 
this type of in1111unity in the absence IL-12 p70 [8]. Detailed analysis of the types of 
immunoregulatory molecules induced within DCs in response to cytokine combinations of 
IFN-y and IL-4 may provide insight into how CMI and HI cytokine microenvironments 
influence the DCs ability to support different types of adaptive immunity. 
To examine cytokine induced changes to the immunoregulatory properties of DCs it is 
beneficial to utilise DC progenitor or immature cells because the maturation pathway is 
uncommitted, and they are thought to reside in and/or enter infected tissues early during an 
immune response [9]. Cell lines that mimic progenitor DCs are well suited to such studies as 
they provide large nu111bers of homogeneous cells for molecular exarnination that requires a 
high degree of consistency. To confirm the cell line findings results from these analyses can 
then be cross-compared with DCs isolated ex vivo that have been exposed to inflammatory 
and HI responses. A cell line that mimics progenitor DCs is the cloned myb-transformed 
hematopoetic cell line, MTHC-D2, derived from C3HeJ mouse fetal liver cells [10] [1] [11]. 
MTHC-D2 has myeloid precursor cell properties and like myeloid DCs, is GM-CSF 
dependent. This line expresses F4/80, Mac-1, FcyRII, Gr-1, and Pgp-1 markers, does not 
express T and B lyn1phocyte antigens, is esterase negative and functionally is weakly 
pinocytotic and non-phagocytic [ 1 OJ. MTHC-D2 cells have been previously shown to 
differentiate into cells with DC-like properiies, including the expression of DC associated 
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markers, in response to effector cytokine stimulation [ 1 OJ [ 1]. 
In this study we report the cellular and functional changes of MTHC-D2 following 
stimulation with IFN-"( and IL-4 separately or together. TNF-cx was also used to stimulate the 
cells in combination with IFN-"( and IL-4 as this cytokine is produced at early stages of an 
immune response, and has been shown to induce morphological differentiation of MTHC 
cells and mediate myeloid cell maturation [12] [13] [11]. The morphology, cell surface marker 
phenotype, gene expression profile, phagocytic activity and ability to stimulate T cell 
proliferation were all examined. 
Materials and Methods 
Maturation and activation of the MTHC-D2 cell line 
MTHC-D2 cells were cloned previously from the MTHC myb-transformed 
progenitor cell line derived from C3H.HeJ murine fetal liver cells [14] [11]. The cells were 
maintained in Iscove's modified eagle medium (IMEM; GIBCO BRL) supplemented with 
10% FCS, 2 n1M glutamine (SIGMA), 60 U/mL of gentamicin (SIGMA), and 50 U/mL GM-
CSF. MTHC-D2 cell maturation was induced by exposure for 6 h (cDNA subtraction 
analysis) or 48 h (all other analyses) to Tl~F-a (500 U/uiL) and Grv1-CSF (5 U/uiL), and 
either IFN-y (2 U/mL) or IL-4 (50 U/rnL), or both IFN-y plus IL-4. Sequential addition of 
IFN-"( and IL-4 was achieved by adding the one of these cytokines 24 h after the other 
cytokine. This resulted in transdifferentiation of MTHC-D2 cells that was observed 
morphologically within 6 h when IL-4 was added to IFN-"( exposed cells or when IFN-"( was 
added to IL-4 exposed cells. CD40 Ab purified from FGK45.5 [15] was used at 25 µg/mL to 
activate maturing MTHC-D2 cell types by CD40 cross linking for the final 16 h of 
differentiation. 
Transmission electron microscopy (TEM) 
Cytokine-stimulated and un-stimulated MTHC-D2 cells (5Xl06 to 107) were washed 
once with PBS then fixed with 2% glutaraldehyde (LADD Research Industries, Inc, Vermont, 
USA) in 0.1 M sodium cacodylate (BDH) buffer pH 7 .4 for 2 h, followed by two 30 min 
washes in fresh PBS. Secondary fixation was carried out using 1 % osmium tetroxide (BDH) 
in 0 .1 IV[ sodiu1n cacodylate uuffer 1-JH 7.4 fof 1.5 h followed Ly t,1✓0 30 rniu PBS washes . 
Samples were washed a further three times in distilled water, stained en bloc in 2 % uranyl 
acetate (BDH) for 2 h and rinsed another three times in distilled water. Samples were 
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dehydrated in graded alcohol series, embedded in Spurrs' Resin (Agar Scientific, Essex, UK) 
and sectioned to 80 nm using a Reichhe11 Ultracut E (Austria). Sections were then stained 
with Reynold's lead citrate (BDH) for 15 min and examined using a Phillips EM 301 (The 
Netherlands) electron microscope at 60 kV (JCSMR EM facility). 
FACS analysis of immunofluorescently labeled MTHC-D2 cells 
Commercially available antibodies were used to stain cytokine-stimulated and un-
stimulated MTHC-D2 cells ( l-5x 105) according to the manufacturer's instructions and 
analysed using a Becton-Dickinson bench-top Flow Cytometer (FACScan) using the standard 
filter configuration (JCSMR FACS sorting facility). Samples were prepared in triplicate and 
experiments were repeated. Data were analysed using Becton-Dickinson Cell Quest™ 
software and an experiment representative of those performed is presented. The average of 
triplicate medium relative fluorescent intensities of unstained controls and stained samples and 
their standard deviation are presented. Commercial antibodies used included CD 11 c 
(Pharrningen), CD69 (Pharmingen), CD90 (CALTAG), CDI lb (CALTAG), CD45R (B220) 
(CAL TAG), CD8a (Pharrningen), CD4 (Pharmingen), CD44 (Pharmingen), CD40 (Southern 
Biotechnology Associates, Inc), CD80 (Pharmingen), CD86 (Pharrningen), CD8 ~ 
(Pharn1ingen), and DEC-205 (Serotec). 
Phagocytosis Assays 
Cytokine-stimulated and un-stimulated MTHC-D2 cells were co-cultured with 
haemolysin sensitised sheep red blood cells (SRBC) for 1 h at 37 °C and then stained with 
May-Grunwald and Giemsa dyes and visualised by light microscopy, or processed as 
described above for TEM. The percentage of MTHC-D2 cells undergoing phagocytosis, and 
the nun1ber of phagocytosed SRBCs per cell, were deten11ined by light uiicroscopy by the 
analysis of 50 randomly selected cells in each sample. 
Mixed Lymphocyte Reactions (MLRs) 
MLR reactions were performed using a cell proliferation assay that enables 
proliferation of pa11icular cell types to be monitored simultaneously by FACS analysis of 
CFSE-dye labeled cells [ 16]. Briefly, the cell division of cytokine plus CD40Ab stimulated 
and un-stimulated MTHC-D2 cell samples (5 X 107 cells/mL) was blocked with 50 µg/mL 
Mitomycin C (Sigma) for 20 min, 37°C in the dark and washed four times with media. 
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Splenocytes were prepared from six week old female BALB/c nuce by passing spleens 
through a sieve and lysing the red blood cells using 5 mL Tris NH4Cl / spleen as well as wool 
column purification to remove adherent monocyte cells. Splenocytes were then loaded with 
CFSE dye (10 µM CFSE in 4 mL media) (Molecular Probes) for 8 min at room temperature 
then washed three times with fresh media. The ratio of stimulator MTH C-D2 cells to 
splenocytes in MLRs was 1 :40. Cells were co-cultured for seven days at 37°C. T cell 
proliferation was monitored periodically over the culture period by FACS detecting the 
sequential loss of CFSE dye in proliferating CD90 (Cy-chrome-conjugated, Caltag), CD8a 
(Cy-Chrome-conjugated, Pharmingen) or CD4 (PE-conjugated, Pharmingen) positively 
stained cells. 5470 fluorospheres (Coulter Corporation) were added to each sample to enable 
accurate counting of proliferating cells and cross comparison between MLR samples. Data 
was analysed using Becton-Dickinson Cell Quest™ software and experiments representative 
of those performed were presented as the number of positively stained proliferating cells on a 
given day of the MLR. 
cDNA subtraction libraries 
Four cDNA subtracted libraries were prepared comparing MTHC-D2 cells cultured in 
,-,,I! ,-,r;T""" •,1 ~ff,.,,''0 ~n 11 ...._ · 1 1 ...... /"'...... .. -1--· • .c · ........ ,_, ..... T .,,...,,. ~ · 
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the presence of TNF-a and GM-CSF. rnRNA (2 µg) was extracted from the different cell 
preparations (QuickPrep Micro mRNA purification system, Pharmacia Biotech) and used for 
cDNA subtraction (PCR-Select cDNA subtraction kit; Clontech, USA). Plasmid libraries 
were prepared from subtracted cDNAs using the UDG pAMPl0 cloning system (GIBCO 
BRL). One to two thousand plasmid clones from each subtracted library were screened for 
differentially expressed cDNAs (PCR-Select Differential Screening Kit, Clontech, USA). The 
differentially expressed cDNA clones were sequenced using Big Dye Terminator automated 
sequencing (ABI sequencer, Biomolecular Resource Facility, JCSNIR). I'.Jucleotide sequences 
were screened against nucleotide databases at NCBI using the BLASTn programme. Selected 
cDNA sequences with homology to known genes were sorted into gene categories. 
Northern analysis of selected differentially expressed cDNAs 
Isolated mRNA (2 µg) from cytokine-stimulated and un-stimulated MTHC-D2 cell 
samples were separated by forn1aldehyde agarose gel electrophoresis, transferred onto nylon 
membrane (BrightStar-Plus, Ambion) and probed with 32P-labeled cDNA from selected 
plasmid clones (Strip-EZ DNA system, Ambion). Positively hybridised bands on northerns 
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were quantified on a Phosphorimager using ImageQuant software. Band intensity values for 
each northern were normalised to murine GAPDH and scaled such that the highest band value 
on all northerns was 10. 
Semiquantitative RT-PCR analysis of IL-12 p40, p35, IL-10, and IFN-y/ IL-4 induced genes 
Isolated rnRNA (2 µg) (QuickPrep Micro mRNA purification system, 
Pharmacia/Biotech) from cytokine plus CD40Ab-stimulated and un-stimulated MTHC-D2 
cell samples was used to prepare first strand cDNA (Ready-To-Go cDNA synthesis kit, 
Amersham, Pharmacia, Biotech, Inc). Expression of MMR, crg-2, IL-10, I-TAC, MHC class 
II, IL-12 p35 and p40 were standardised against GAPDH expression using hot-start semi-
quantitative RT-PCR analysis. PCR parameters were optimised to insure the PCR products 
obtained did not proceed past the linear phase of the reaction that would exceed the analysis 
limits. Experimental findings were repeated three times. Primer pairs and resu~ting fragments 
sizes were as follows: MMR AGACGAAATCCCTGCT ACTG / CTGGACTCAGCAGCAG 
TCTC 195 bp, crg-2 ATGAACCCAAGTGCTGCCGTC I CTTGAGTGAGGACTCAGACC 
538 bp, IL-10 TAGAGCTGCGGACTGCCTTCA / TCATGGCCTTGTAGACACCTTG 350 
bp, I-TAC GAACAGGAAGGTCACAGCCATAGC I ATGAGGCGAGCCTGCTTGGATC 
TG, MHC class II AGTCTTCCCAGCCTTCACCTCAGAGGTAC I CATAGCCCCA_A._AT 
GTCTGACCTCTGGAGAG 250 bp, IL-12 p35 GGCTACTAGAGAGACTTCTTCC / GT 
GAAGCAGGATGCAGAGCTTC 309 bp, IL-12 p40 CGTGCTCATGGCTGGTGCAAAG / 
CTTCATCTGCAAGTTCTTGGGC 313 bp and GAPDH TCCACCACCCTGTTGCTGTA 
and ACCACAGTCCATGCCATC AC 432 bp. Advantage-2 polymerase (0.5units)(Clontech, 
USA) was added at 94°C (hot start). I-TAC and GAPDH were amplified for 30 cycles 
whereas IL-10, IL-12 p35 and IL-12 p40 were amplified for 34 cycles using the thermal 
program: 94°C 20 sec, 64 °c 20 sec, 72 °C 30 sec. MHC class II was amplified for 32 cycles 
using 94°C 20 sec, 60 °C 20 sec, 72 °C 20 sec. !v1lv1R and crg-2 were a111plified for 33 cycles 
of 94°C 20 sec, 62 °C 20 sec, 72 °C 20 sec. 
Results 
Morphological analysis of cytokine and CD40 Ab stimulated MTHC-D2 cells 
During maturation of DCs from progenitor cells a morphological change is evident. 
Progenitor cells are round and non-adherent whereas mature DCs develop longer dendrites, 
become adherent, and are often described as irregular or star shaped [9]. To examine the 
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morphological changes induced by cytokine exposure, the MTHC-D2 cells were stimulated 
for 48 h, then examined by light microscopy that detects shape and adherence state ( data not 
shown), and transmission electron microscopy (TEM) that detects intracellular changes (Fig. 
1 ). As TEM required processing of the cells in a non-adherent state the shape differences 
were not as evident. The morphology of un-stimulated GM-CSF cultured cells was most like 
the phenotype of progenitor myeloid cells being round, and non-adherent by light microscopy 
analysis, and having a large irregular nucleus (Fig. IA). The IFN-y+ TNF-a stimulated cells 
tended to develop a morphology similar to mature DCs being irregular or star shaped with 
longer dendrites when assessed by light microscopy. TEM analysis however, found the 
intracellular structure of these cells to be similar to the progenitor GM-CSF cultured cells 
although exosome release, a property of ex vivo DC's [17], was visible at the cell surface (Fig. 
lB). The IL-4+ TNF-a cultured cells appeared more immature, with many cells remaining 
non-adherent, and TEM detected an assortment of larger intracellular vacuoles (Fig. 1 C) not 
evident in the IFN-y+ TNF-a or un-stimulated cells. The cytokine combination IFN-y+ IL-
4+ TNF-a induced dramatic changes to both the intracellular and extracellular morphology of 
the MTHC-D2 cells. Similar to mature DCs these cells became adherent and developed longer 
dendrites. These cells were different however, to the other cytokine stimulated MTHC-D2 
cells being generally larger, round and contained a substantially greater number of intracellular 
vacuoles (Fig. 1 D). Interestingly these vacuoles were often found to contain phagocytosed 
cell debris or apoptotic bodies. Surprisingly, this morphology could also be obtained rapidly, 
within 6 h, by the sequential addition of IL-4 to IFN-y+ TNF-a stimulated cells or IFN-y to 
IL-4+ TNF-a stimulated cells, suggesting the cells were capable of transdifferentiation. 
Further experiments using a CD40 Ab co-stimulus found that, like ex vivo DCs, this stimulus 
enhanced the maturation state by increasing cellular adherence. 
Cytokine stimulus and CD40 activation of the MTHC-D2 cells differentially regulates the 
expression of cell surface markers associated with DC rnaturation and subtype 
The maturation and activation state of DCs affects their ability to stimulate T cells and 
1s often characterised by differences in the expr~ssion levels of key cell surface markers. 
CD40 co-stimulation of DC's usually enhances the maturation and activation state of the cells 
as indicated by increased expression of these markers. In this study, the cytokine and 
activation stimulus were found to induce different expression patterns of these cell surface 
markers in the MTHC-D2 cells, suggesting various levels of cellular maturation were 
obtained. Sinlilar to progenitor DCs [9], little expression of co-stimulatory molecules CD40, 
CD80 and CD86 were detected on the GM-CSF un-stimulated cells and CD40 activation did 
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not enhance the expression of these molecules (Table 1). Like mature ex vivo DCs, exposure 
to IFN-y+ TNF-cx and IFN-y+IL-4+ TNF-cx increased expression of these costimulatory 
molecules and this was further enhanced by exposure to CD40 Ab. Activation of these cells 
was evident by increased expression of the activation marker CD69. IL-4+ TNF-cx also 
induced the MTHC-D2 cells to express CD40, CD80 and CD69 but unlike the cells exposed 
to IFN-y, these cells had a lower level of CD86 expression, and CD40 activation did not 
enhance the expression of these molecules. 
DC-subtype and macrophage markers CD8cx, CDl lc, CDl lb, DEC-205, and CD44 
are frequently used to characterise cells with DC morphology. These markers were also 
differentially induced in response to the combinations of cytokine stimulation. In particular, 
the combined IFN-y+IL-4+ TNF-cx stimulus had the greatest effect on the expression of most 
of these molecules, except for CD8cx expression where IL-4+ TNF-cx also induced high levels 
of expression of this molecule. The effect of CD40 co-stimulation on the expression of these 
molecules was more variable in the IFN-y+ TNF-cx and IFN-y+IL-4+ TNF-cx stimulated cells 
compared with the co-stimulatory/activation markers, and once again had no effect on the IL-
4+ TNF-cx stimulated cells suggesting a CD40 signaling block. 
Other markers including CD4, a DC subtyping marker, CDS~, a marker of a specific 
DC subset in rats, B cell marker CD45R, and the T cell marker CD90.2, showed very low 
levels of expression in all IvITHL-U2 cells (data not shown). 
The level of phagocytic activity directly corresponds with the type of cytokine stimulus of 
MTHC-D2 cells 
The phagocytic potential of DCs usually changes during maturation where cells are generally 
more phagocytic in an immature state and, as they mature and become activated, the level of 
phagocytic activity declines and the cell directs antigen for presentation on the cell surface [9]. 
However, there are now sorne reports of rnature cross-presenting DCs that are highly 
phagocytic at the site of inflammation [ 18]. To establish whether cytokines differentially 
regulate phagocytosis, Fe receptor mediated uptake of SRBC's was examined for each 
cytokine stimulated MTHC-D2 cell type. Intracellular staining, visualised by light microscopy 
was used to establish the percentage of MTHC-D2 cells undergoing phagocytosis and 
estimate the number of SRBCs within each cell (Fig. 2). Substantial differences in phagocytic 
activity were found in association with the cytokine induced maturation/activation state of 
these cells. This analysis found the IFN--y+IL-4+ TNF-cx stimulated MTHC-D2 cells were 
twice as phagocytic as the cells stimulated with IL-4+ TNF-cx, followed by the IFN-y+ TNF-cx, 
and the un-stimulated GM-CSF cultured cells. CD40 co-stimulation, which enhances 
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maturation of DC 1s, down-regulated the level of phagocytosis of the IL-4+ TNF-a and IFN-
y+ TNF-a stimulated cells. This however, had no effect on the IFN-y+IL-4+ TNF-a 
stimulated cells suggesting these cells, like mature cross-presenting DCs, retain their 
phagocytic ability in a mature state. 
TEM enabled detailed analysis of the intracellular structure of the MTHC-D2 cells 
undergoing phagocytosis (Fig. 3). The morphology of the GM-CSF un-stimulated cells, that 
had little phagocytic activity, were not affected by the presence of SRBC's after 1 h of co-
culturing (Fig. 3aA). However, the presence of SRBC 1s caused the IFN-)', IL-4 and TNF-a 
stimulated DCs to extend the length of their dendritic protrusions (Fig. 3aB,C,D) compared 
with these cell types in Figure 1. Often these protrusions were found to be reaching out for, 
and encompassing, the SRBC's (Fig. 3aC,D). Interestingly, those cells degrading the SRBC's 
had relatively smooth cell surfaces with shorter dendritic protrusions (Fig. 3b ). These 
observations support the findings of phagocytic activity observed by light microscopy, and 
indicate the presence of extracellular antigen (SRBC' s) induces these cells to alter their 
morphology to enable engulfment of the antigen. These changes are supported by other 
studies where the surface area of phagocytic cells increased [19], and the surface folds were 
found to disappear during phagocytosis [20]. 
JL-4 and JFN-y differentially affect the ability of lvITHC-D2 ceiLs to stiniulate mixed 
lyn1phocyte reactions ( MLR) 
One of the most important features of a DC that supports the development of adaptive 
immunity is the ability to stimulate T cell proliferation [9]. This function distinguishes DCs 
from other APC's such as macrophages. The ability of a DC to induce T cell proliferation is 
also associated with maturation/activated state of the cell, where immature DCs are unable to 
stimulate high levels of T cell proliferation [9]. To assess whether particular cytokines affect 
the abiiity of MTHC-D2 cells to stimulate T cell proliferation, IvILR!s were performed and 
analysed using a CFSE cell proliferation F ACS assay [ 16]. This approach enabled the 
proliferation of both CD4 and CDS T cells to be monitored simultaneously, a procedure that 
the traditional c3H)-Thymidine uptake MLR assay is unable to do. 
In this study, initially MLR' s were performed using cytokine stimulated MTH C-D2 
cells (not activated by CD40 Ab cross-linking), and proliferating T cells were monitored with 
the CD90 antibody to detect both CD4 and CDS T cells (Fig. 4, MLR 1). This analysis found 
the IFN-y+ TNF-a stimulated MTHC-D2 cells induced the highest level of T cell 
proliferation, followed by IFN-y+IL-4+ TNF-a, IL-4+ TNF-a, and un-stimulated GM-CSF 
cultured MTHC-D2 cells. When these cells were activated with CD40 Ab and assessed for 
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the ability to stimulate T cell proliferation using CD8 and CD4 specific antibodies (Fig.4, 
MLR 2, MLR 3), these cells induced T cell proliferation faster (1 day earlier) than the un-
activated cells. This response is similar to the effects of CD40 activation on the T cell 
stimulatory capacity of ex vivo DCs. Interestingly , each MTHC-D2 cell type induced a greater 
proportion of CD8 (Fig.4, MLR 2) compared with CD4 (Fig.4, MLR 3) T cell proliferation. 
This result was not un-expected as induction of CD8 T cell proliferation is a common feature 
of MLR's [9]. The IFN-y+ TNF-cx stimulated MTHC-D2 cells were the most potent at 
stimulating CDS T cells, followed by the IFN-y+ IL-4+ TNF-cx stimulated cells. Whereas, the 
IL-4+ TNF-cx stimulated and un-stimulated GM-CSF cultured cells were weak inducers of 
CD8 T cell proliferation. Both IFN-y+ TNF-cx and IFN-y+IL-4+ TNF-cx stimulated MTHC-
D2 cells induced CD4 T cell .proliferation, whereas the IL-4+ TNF-cx and un-stimulated GM-
CSF cultured MTHC-D2 cells were weak inducers of CD4 T cells. These results are similar 
to studies of monocyte derived DCs, where the best stimulators of T cell proliferation had the 
highest levels of maturation, and this was further enhanced by CD40 co-stimulation [9] [21]. 
These results also suggest that, as the IFN-y and IL-4 cytokine microenvironment in vzvo 
changes, it is likely to affect the ability of DCs to stimulate T cell proliferation. 
Genes induced by IFN-y+TNF-a and IL-4+TNF-a stimulation of MTHC-D2 cells 
Biological analysis of the ?vITHC-D2 cells morphology, cell surface marker phenotype, 
phagocytic ability, and T cell stimulatory capacity, identified distinct changes to maturation, 
activation and functional state of these cells in association with specific cytokines and CD40 
co-stimulation. To examine whether particular gene expression profiles were also associated 
with specific cytokine stimulation, molecular analysis using cDNA subtraction was 
performed. This analysis targeted genes that were induced early (6 h) after cytokine 
stimulation. Four cDNA subtraction libraries were prepared, including 1 IFN-y+ TNF-cx 
subtracted from IL-4+ TNF-cx stimulated MTHC-D2 cells; 2 IL-4+ TNF-a subtracted from 
IF1~-y+ T:i~F-a stimulated iv1THC-D2 cells; 3 un-stirnulated Gtv1-CSF subtracted from IF:t"-J-
y+ TNF-a stimulated MTHC-D2 cells; 4 un-stimulated GM-CSF subtracted from IL-
4+ TNF-a stimulated MTHC-D2 cells. Differentially expressed cDNA clones from these 
libraries were sequenced and screened against the NCBI nucleotide database using a BLASTn 
programme. Those sequences sharing homology of greater than 95% over more than 100 bp 
with known gene sequences were sorted into gene categories. Selected cDNAs having 
homology to genes with an imn1une function, or association with DCs and macrophages, as 
well as the frequency of these clones in each library, are listed in Table 2. To establish the 
level of differential expression, some of these clones were also screened by northern analysis 
of mRNA from the cytokine stimulated MTHC-D2 cells (Table 2). This comprehensive study 
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enabled a genetic profile to be developed that identifies unique and comn1on features between 
IFN-r+ TNF-cx verses IL-4+ TNF-cx stimulation of the MTHC-D2 cells. Overall the cytokine 
stimulus affected the expression of genes involved in many levels of cellular organisation and 
function including signaling, transcription and cytoskeletal genes, cell surface receptors, 
secreted molecules, as well as genes associated with cell migration and immune responses. 
The profile of genes from IFN-r+ TNF-cx specific libraries (2 and 3) suggested a 
more mature DC, with anti-viral and CMI potential. This included a range of chemoattractants 
such as MIG, crg-2, I-TAC, and RANTES that attract activated and memory Thl cells [22] 
[23]. Also, Cathepsin C was identified, which is required for activation of granzymes and is 
thought to play a role in the expansion and differentiation of CD8 T cell cytolytic activity [24] 
[25]. Mouse fibrinogen-like protein, which is up regulated in response to mouse hepatitis 
strain 3 infection [26] was also identified. In addition, IFN-r inducible protein Mag-1 was up 
regulated and has been shown to accompany an increase in Th 1 cytokine expression in mice 
infected with Toxoplasma Gondi and undergoing progressive encephalitis [27]. IFN-y+ TNF-
cx stimulation also induced expression of activation marker CD69, as was detected by F ACS 
analysis, and MHC II, which is a marker of mature DCs and is important for antigen 
presentation. Transcription factor IFN-inducible Sp 100, whose function in early antiviral 
responses has been postulated [28], was also identified. Signaling genes such as numerous 
types of GTP and Gb.P binding proteins were specifically expressed in response to IFN-
y+ TNF-a, as well as interferon inducible IFN regulatory factor 1 and 7 genes. Interestingly, 
Mx 1, a gene associated with inhibiting influenza virus replication [29] [30], contains a GTP 
binding domain that is essential for its anti-influenza activity [30], suggesting the importance 
of GTP molecules in anti-viral immune responses. 
Genes from the IL-4+ TNF-cx specific libraries (1 and 4) were associated with 
receptor-mediated endocytosis of pathogens or tumor cells, such as the macrophage mannose 
receptor (MMR), Mg 1 receptor, and FcyR. In addition, an assortment of genes associated with 
cytoskeletal restructuring and lysosomal processing of antigen, such as gelsolin, cytoplas111.ic 
gamma actin, and cathepsin B, L, G identified. Expression of these genes may be responsible 
for the increased number of intracellular vacuoles detected by TEM of the IL-4+ TNF-cx 
MTHC-D2 cells and may also be associated with the enhanced phagocytic function of these 
cells. Also of interest, was the absence of MHC II in the IL-4+ TNF-cx specific libraries but 
not the IFN-r+ TNF-cx specific libraries, as IL-4 is routinely used to induce expression of this 
gene in maturing monocyte derived ex vivo DCs [31] [32]. These results suggest that instead, 
IFN-r or another stimulus may be responsible for expression of MHC II in the ex vivo DCs. 
Some cDNA clones were identified in libraries that compared the IFN-r+ TNF-cx and 
IL-4+TNF-cx stimulated with the un-stimulated GM-CSF cultured MTHC-D2 cells (3 and 4). 
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This suggests in CMI and HI cytokine microenvironments that DCs may have pai1icular 
cellular activities in common. These included genes associated with DC adhesion (ICAM-1 
and ryudocan core protein), antigen processing and presentation (TAP, B 2M and MHC I), as 
well as T cell co-stimulation (CD40). Northern analysis of these cDNA's however, found 
them to be induced to different levels by the cytokine stimulus, such as CD40 and ICAM-1 
were expressed at much higher levels in the IFN-y+ TNF-cx stimulated cells, whereas MHC I 
was expressed at higher levels in the IL-4+ TNF-cx stimulated cells. The differential 
expression of these molecules in various cytokine microenvironments may affect the 
efficiency of DCs to perform specific immunoregulatory tasks. 
Comparison of the northern results detected a trend in the expression patterns of 
cDNAs isolated from IFN-y+ TNF-cx and IL-4+ TNF-cx specific libraries (Table 2). Generally 
cDNAs isolated from the IFN-y+ TNF-cx libraries were expressed 7 fold higher (using an 
average of 12 selected cDNAs) in the IFN-y+ TNF-a cells when compared to the other 
MTHC-D2 cell types by northern analysis. Whereas, the cDNAs isolated from the IL-
4+ TNF-cx specific libraries were often also quite highly expressed by northern analysis in 
other MTHC-D2 cell types, having only 4 fold greater expression (using an average of 17 
selected cDNAs). This suggests that many of the genes induced by IFN-y+ TNF-cx are 
uniquely important to the function of these cells in this cytokine microenvironment, whereas 
those genes induced by IL-4+ Tr--.JF-cx may also be important to the function of the cell in 
other cytokine microenvironments. For example, the cytokine TGF-~, the Mgl receptor, FcyR, 
and the MAC-2 antigen, are expressed at high levels on both the un-stimulated GM-CSF 
cultured, and IL-4+ TNF-cx stimulated MTHC-D2 cells. This suggests that DCs, in the 
absence of IFN-y, have properties important for the uptake of extracellular pathogens (FcyRII) 
and tumor cells (Mgl), antibody mediated endocytosis (MAC-2), and by the action of TGF-~, 
suppress cytotoxic T cells, influence the activation and differentiation of T cells, and the 
expression of co-stimulatory molecules [33] [34] . 
Effects of combining IFN-yand IL-4 stiniulation on the expression of DC immunoregulatory 
genes 
Combining the effector cytokine stimuli (IFN-y+IL-4) found substantial differential effects 
on the morphology, cell surface marker phenotype, as well as phagocytic and T cell 
stimulatory activity of the MTHC-D2 cells, compared to stimulation with these cytokines 
. 
independently. Whether these cytokines induce a distinct genetic profile, as was found for 
these cytokines independently by cDNA subtraction, requires additional genetic analysis. Of 
the limited number of studies that have examined the combined effect of these cytokines on 
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DCs they have been shown to be more effective at inducing production of the CMI promoting 
bioactive form of IL-12 (p70) [5]. We therefore examined the effect of combining these 
cytokine stimuli on expression of the IL-12 p40 and p35 gene subunits, as well as IL-10, a 
regulator of IL-12 production [35] [36]. We also examined the combined effect of IFN-y+ IL-
4 on genes that were induced by these cytokines independently in cDNA subtraction, 
including MHC II, crg-2 , I-TAC, and MMR (Fig. 5). 
In this study, IL-12 p40 was differentially regulated by cytokine and CD40 Ab 
stimulation of the MTHC-D2 cells (Fig. 5). Unlike IL-4+ TNF-a, IFN-y+ TNF-a stimulation 
induced p40 expression. Combining IL-4+IFN-)'+ TNF-a stimulation also induced p40 
expression but not as strongly as IFN-)'+ TNF-a, suggesting the IL-4 in this cytokine 
combination had an inhibiting effect. CD40 co-stimulation enhanced p40 gene expression, 
especially in the un-stimulated GM-CSF cultured MTHC-D2 cells and those stimulated with 
IL-4+IFN-)'+ TNF-a. In these later cells, CD40 co-stimulation appeared to compensate for 
the inhibiting effect of IL-4. The effect of CD40 co-stimulation was not as strong in those 
cells stimulated with IFN-')'+ TNF-a, where a two-fold increase was detected. The expression 
of p40 is similarly regulated in ex vivo DCs, where IL-4 down regulates, and IFN-y up 
regulates expression [3 7] [ 4], and combining these cytokine stimuli decreases p40 expression 
compared with IFN-y stimulation alone [6]. In ex vivo DC's IFN-y induces the p40 
homodimer form of IL-12 p40 that antagonises p70-induced Civil by competing for the IL-12 
receptor, whereas IFN-y+ IL-4 stimulation induces the p40 monomer that supports bioactive 
IL-12 p70 production [38] [39] [ 40] [6]. The studies on MTHC-D2 suggest that in vivo 
bioactive IL-12 production in an IFN-)'+ IL-4 cytokine microenvironment requires CD40 co-
stimulation. The requirement for T cell-derived or microbial stimulus to induce IL-12 
production has also been reported for ex vivo DCs [6]. Unlike p40, p35 expression was 
detected in all cells, and the level of expression was not as effected by the different 
combinations of cytokine and CD40 co-stimulation. Similar to p40 however, as well as studies 
on ex vivo DCs [41], p35 was up regulated n1arginally by IFI'~-'Y con1pared with the un-
stimulated and IL-4+ TNF-a stimulated cells. In addition, p35 expression was up regulated by 
CD40 co-stimulation in cells stimulated with cytokine combinations containing IL-4, whereas 
co-stimulation had little effect on the IFN-)'+ TNF-a stimulated cells. 
IL-10 expression in the MTHC-D2 cells was also examined by RT-PCR as it is a 
down-regulator of bioactive IL-12 p70 production [35] [36], and important for the 
development of HI [ 42]. This analysis found the greatest levels of IL-10 expression in 
association with IFN-y+ TNF-a stimulation, a feature that may contribute to the inability of 
IFN-)' to induce high levels of IL-12 p70 production. Lower levels of IL-10 expression 
however, were associated with IFN-ry+IL-4+ TNF-a and CD40 Ab stimulation , which likewise 
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may contribute to the ability of these stimulants to induce high levels of IL-12 p70 production. 
Interestingly, a similar level of IL-10 expression was associated with un-stimulated GM-CSF 
cultured cells that had been activated with CD40 Ab. This suggests DCs, in the absence of 
IFN-y and IL-4, but exposed to CD40 co-stimulation, may also support IL-12 p70 
production. In support of this, one study has found that immature DCs stimulated with CD40 
Lor bacteria stimulate more IL-12 p70 production than mature DCs [ 43]. 
MHC II is an important molecule enabling DCs to present antigen to T cells and is 
often used as an indicator of the mature state of DCs [9]. In our study, cDN A subtraction 
identified greater levels of expression of this gene in cells stimulated with IFN-y+ TNF-a 
compared with IL-4+ TNF-a stimulated cells (Table 2). RT-PCR analysis detected similar 
results, and found combining these cytokine stimuli also induced MHC II but not as strongly 
as IFN-y+ TNF-a stimulation. Activation with CD40 Ab, which enhanced the level of many 
mature DC associated markers in the MTHC-D2 cells (Table 1), also enhanced the level of 
MHC II expression in both the IFN-y+ TNF-a and IFN-y+IL-4+ TNF-a stimulated cells. 
The chemokines crg-2 and I-TAC, are important for attracting T cells in CMI and were 
found to be up regulated by IFN-y in the cDNA subtraction studies reported here, and by 
others [44] [45] [23]. Similarly to the effects of combining IL-4 and IFN-y stimulus on the 
expression of MHC II, p40, p35 and IL-10, these cytokines also reduced the level of 
expression of crg-2 and I-TAC in the IVITHC-D2 cells. Interestingly, CD40 activation 
enhanced the level of I-TAC expression but reduced crg-2 expression, suggesting these 
chemokines may be differentially regulated during DC!f cell interactions. 
The MMR is a phagocytic receptor for microorganisms and is known to be down 
regulated by IFN-y [46]. In our study, RT-PCR analysis confirmed the effect of IFN-y on this 
gene, as well as the cDNA subtraction data showing that IL-4+ TNF-a induces greater levels 
of expression of this gene compared with IFN-y+ TNF-a. Combining these cytokine stimuli 
induced slightly lower levels of expression compared with IL-4+ TNF-a stimulation 
suggesting that IFN-·y does have an inhibitory effect in this cytokine combination. CD40 co-
stimulation, that effected the expression of other immunoregulatory genes, did not appear to 
effect the expression of MMR except for the IFN-y+ TNF-a stimulated cells where reduced 
expression was detected. By comparison to the effects of IL-4 on the IFN-y-induced genes, 
the effect of IFN-y on the MMR is marginal, which confirms the observation made by 
northern analysis (Table 2), that IL-4 induced genes are often also expressed at similar levels 
in response to other cytokine stimuli and therefore may be important to the function of the cell 
in various cytokine microenvironments. 
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Discussion 
This study has examined whether CMI and HI associated cytokines regulate the development 
of particular DC associated immunoregulatory properties. This study established that IFN-
y+ TNF-cx can induce the MTHC-D2 cell line to develop characteristics common of mature 
DCs as well as immunoregulatory properties that would likely be supportive of anti-viral 
responses and CMI. This was demonstrated by increased levels of co-stimulatory and MH C 
molecules, increased capacity to stimulate T cell proliferation, as well as IFN-y induced 
expression of genes associated with inhibiting viral replication and that support cytolytic 
activity of CDS T cells. Expression of these types of CMI associated genes may contribute to 
the IFN-y stimulated DC's ability to induce CMI in the absence of IL-12 p70. 
Combining IFN-y+IL-4+ TNF-cx stimulation also induced the MTHC-D2 cells to 
develop irnmunoregulatory properties associated with mature DC' s. However, compared with 
IFN-y+ TNF-cx stimulated cells, genes induced by IFN-y stimulation, that would support CMI, 
such as I-TAC and crg-2, were down regulated, whereas properties associated with the up take 
of extracellular pathogens, such as phagocytosis and . expression of MMR, that were induced 
by IL-4 stimulation, were up regulated in these cells and retained after CD40 co-stimulation. 
Combining these cytokine stimuli also reduced the ability of the celis to stimulate Cu8 T cell 
proliferation con1pared with IFN-y+ TNF-cx stimulation, an effect that has also been detected 
in ex vivo DCs [ 4 7]. Although this combination of cytokines induces bioactive IL-12, that 
supports CMI, our study suggests these cytokines may induce the development of other 
immunoregulatory properties that also support HI. Taken together, this cell type may actually 
facilitate the progressive change between these types of immunity. 
Although DC co-stimulatory molecules and T cell stimulatory capacity were induced 
upon maturation of MTHC-D2 cells by IL-4+ TNF-cx compared to un-stimulated cells, it was 
less than that obtained with IF1~-'Y+ Tt~F-a and IFi~--y+IL-4+ T:NF-a stirnulation. It is 
possible the IL-4+ TNF-cx MTHC-D2 cells have not as yet reached full maturity especially as 
studies on a CD14+ DC-like cell line, XS52 [48], and monocyte derived ex vivo DCs [31] , 
require seven to eleven days to mature these cells with IL-4. Alternatively, the IL-4+ TNF-cx, 
stimulated cells may represent a macrophage although this is unlikely as these cells were 
unable to produce esterase [10], and IL-4 suppresses differentiation along the macrophage 
pathway [ 49]. The 1nost likely possibility, based on the data, is that the IL-4+ TNF-cx cells 
have developed properties that suppo1i HI development. For example, by 48 h of IL-4+ TNF-
cx stimulation the MTH C-D2 cells had enhanced their ability to take up extracellular antigen, 
as demonstrated by increased phagocytic activity, expression of pattern recognition receptors, 
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such as FcyRII and the MMR [ 50] [ 51], as well as increased expression of cytoskeletal genes 
and increased numbers of intracellular vacuoles that support phagocytosis [52] [50]. 
Our studies have detected a number of conelations between ex vivo splenic DCs and 
the MTHC-D2 cells in relation to cytokine stimulation, expression of DC sub-typing markers 
CD8cx, CD4, and DEC-205, as well as IL-12 p40 expression (Table 3). Ex vivo DCs, that 
produce the greatest amounts of IL-12 p70, are either CD8cx+ splenic DCs [53], or CDl lc+ 
splenic DCs stimulated with IFN-y+IL-4 [6]. In our study, the MTHC-D2 cells, that were 
similar to these IL-12 p70 producing spleen DCs, were also stimulated with IFN-y+IL-4, were 
CD8cx high' and had a similar pattern of p40 gene expression as the splenic DCs. Another 
conelation is the ex vivo DCs that produce the least amount of IL-12 p70 but produce the 
most amount of p40 homodimer, are either CD8cx- splenic DCs [53], or CD 1 lc+ splenic DCs 
stimulated with IFN-y [6]. In our study, the MTHC-D2 cells that had a similar pattern of p40 
expression as the splenic DCs, were also stimulated with IFN-y, and were CD8cx 10w. The 
expression of DEC-205 by MTHC-D2 cells also conelates with the splenic DCs, where this 
molecule was marginally greater in the IFN-y+IL-4+ TNF-cx stimulated CD Sex high MTHC-
D2 cells compared with the IFN-y+ TNF-cx CD8cx10w MTHC-D2 cells. This is similar to the 
ex vivo CD8cx+ DCs that also express higher levels of this molecule compared with the 
CD8cx- DCs [54]. A conelation between ex vivo spleen DC subtype, production of IFN-y, 
and MTHC-D2 response to IFr'-J-y is also evident. The splenic DC subtype, which produces 
large amounts of IFN-)' are CD8cx-CD4- [53], whereas the MTHC-D2 cells that are 
CD8cx10wCD4- are stimulated with IFN-y. The data with MTHC-D2 suggest that IFN-y causes 
CD8cx expression to be low, and therefore this cytokine may contribute to the CD8a- DC 
phenotype in vivo. Despite these conelations there are also differences in their cell surface 
phenotype, including the IFN-y+IL-4+ TNF-cx stimulated MTHC-D2 cells that are CD8cx hi gh 
express similar levels of CDllb to the IFN-y+TNF-cx MTHC-D2 cells that are CD8a10w_ 
Whereas, the CD8cx+ ex vivo DCs express lower levels of CD 11 b compared to the CD8cx-
DCs [ 54]. It cannot be ruled out that the differences in expression of CD 11 b rnay be under 
the control of other cytokines or immunostimulatory factors not used in the MTHC-D2 study. 
Other recent studies of the CD8cx+ and CD8cx- splenic DC subtypes have began to 
shed light on the different functions of these cells. There is an association of the CD 8 ex+ 
subtype with cross-presenting antigen on MHC I molecules to CD8 T cells, and the CD8cx-
subtype with MHC II-restricted d~rect antigen presentation to CD4 T cells [55] [56]. 
Interestingly, another con·elation exists between cytokine stimulation, and expression of 
CD8cx, MHC I/II in the MTHC-D2 cells that supports the findings of the ex vivo DCs (Table 
3). The IL-4+ TNF-a stimulated MTHC-D2 cells were CD8cx hi gh and expressed higher levels 
of MHC I than the CD8cx iow IFN-y+ TNF-cx stimulated MTHC-D2 cells by northern 
1 7 
analysis. Also, cDNA subtraction and RT-PCR found higher levels of MHC II gene 
expression in the CD8a low IFN-)'+ TNF-a stimulated MTHC-D2 cells compared with the 
CD8cx hi gh IFN-)'+IL-4+ TNF-cx and IL-4+ TNF-cx stimulated MTHC-D2 cells. Regulation of 
MHC I and MHC II expression in response to these cytokines may enable DC subtypes to 
process and present antigen differently to T cells. It is possible the greater phagocytic ability, 
found in association with the IFN-)'+IL-4+ TNF-cx stimulated CD8cx hi gh MTHC-D2 cells, 
could potentially facilitate a cross-presenting function enabling the cells to more efficiently 
take up antigen contained within cells undergoing apoptosis. Preliminary studies within our 
laboratory support this hypothesis where stimulation of a DC cell line, JAWS II (ATCC 
CRL-11904), with IFN-)'+IL-4+ TNF-cx enhanced their capacity to cross-present SINFEKEL 
antigen from JAWS II cells infected with a recombinant vaccinia expressing this antigen, 
compared with IFN-)'+ TNF-cx stimulation (data not shown). 
A question that does arise when assessing the effects of IFN-)' and IL-4 on the 
development of DC associated irnmunoregulatory properties, is under what circumstances 
during an immune response would the microenvironment have different representation of 
these cytokines. It is easy to visualise that under inflammatory conditions induced by a highly 
virulent pathogen, an abundance of IFN-)' may support maturation of a DC with 
immunoregulatory properties that is more likely to support CMI. It is also possible during HI 
or in response to a pathogen that stimulates IL-4 production from uCs [2], that the cytokine 
microenvironment would support maturation of a DC more likely to support HI development. 
A microenvironment where both IFN-)' and IL-4 may be found in abundance could occur 
either in response to a pathogen that induces expression of these cytokines, or during a 
progressive change between CMI and HI. A number of studies have investigated factors 
associated with a change from CMI to HI. In a kinetic study of DC IL-12 production, the 
DCs were found to support Th 1 cell proliferation as IL-12 production peaked and 
subsequently support Th2 development as IL-12 declined [3]. Also, kinetic studies of 
migrating T helper cells have shown that Th 1 IFr-J-)' producing cells that have rnigrated to the 
site of infection, secrete chemoattractants that later recruit Th2 IL-4 producing cells [57]. This 
cascade of DC and T cell interactions could create a microenvironment containing both IFN-)' 
and IL-4 that would direct maturation of DCs recruited to the site, and also as our study has 
indicated, possibly transdifferentiate the IFN-)' stimulated DCs at the site of infection by the 
sequential addition of IL-4. 
The possibility that DCs may transdifferentiate, and in doing so alter their 
immunoregulatory properties has been suggested [58] but so far has received little attention. 
More recent studies however, are indicating that DCs have a high degree of functional 
plasticity through analysis of ex vivo CD8cx+ and CD8cx- DC subtypes, where their potential 
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to drive Thl and Th2 responses is thought not to be fixed for each subtype [59]. Another 
recent study has discovered that polymorphonuclear neutrophils, considered to be end-
differentiated, were found in vivo and in vitro to transdifferentiate, acquiring functional and 
morphological characteristics of DCs during pathological events or when stimulated with 
IFN-y and GM-CSF [60]. This suggests that mature innate immune cells, such as neutraphils 
and DCs, are capable of changing their functional properties in the presence of pathological 
and cytokine stimulus. In this study the MTHC-D2 cell line retained its sensitivity to cytokine 
stimulation. The addition of IFN-y to IL-4+ TNF-cx stimulated cells or IL-4 to IFN-y+ TNF-cx 
stimulated cells resulted in a morphological and cell surface marker change (data not shown) 
to a cell type with the characteristics generated by stimulation with both IFN-y+IL-4+ TNF-cx. 
This occurred much more rapidly (within 6 h) than was required when these cytokines were 
added together to un-stimulated GM-CSF cultured MTHC-D2 cells (24-48 h). The ability of 
these cells to change their immunoregulatory properties so rapidly may represent an immune 
modulating role of DCs that enables these cells to facilitate progression from one state of 
immunity to another. 
It is interesting to speculate that a transdifferentiation mechanism, at the site of 
infection, may enable DCs to aid progression from CMI to HI as the IFN-y producing Th 1 
cells secrete chemokines that attract IL-4 producing Th2 cells [57]. In support of this 
hypothesis in vivo studies have identified a unique DC type that can only be found at the site 
of inflammation and not in the lymph or spleen tissue [ 18]. This DC type is described as 
large, macrophage-like, often containing apoptotic bodies within intracellular vacuoles, is 
phagocytic, and cross-presents antigen. It is interesting that combining IFN-y and IL-4 
stimulation induced the MTHC-D2 cells to develop similar properties to that described for 
this cross-presenting DC. It is possible that a DC exposed to both IFN-y and IL-4 may 
develop properties that provide an alternative pathway for antigen processing and presentation 
to adaptive T cells. Particularly where a pathogen induces cytopathic effect or apoptosis of the 
DCs at the site of infection, such as viral vaccine agents that cause apoptosis of DCs [61]. 
Unlike the hypothesis presented here, others speculate a role for the IFN-y plus IL-4 
stimulated cross-presenting CD8cx+ spleen DC in switching an immune response from HI to 
CMI [ 6]. Our studies indicate that transdifferentiation to the IFN-y plus IL-4 phenotype can 
be induced by either IFN-y or IL-4 addition to IL-4+ TNF-cx or IFN-y+ TNF-cx stimulated 
MTHC-D2 cells. Therefore, this mechanism may aid progression from CMI to HI or from HI 
to CMI. Others have also speculated that in an environment with high levels of IFN-y, in the 
absence of IL-4, production of the IL-12 p40 homodimer from CD8cx- DCs may prevent an 
exaggerated Th 1 response from occurring. However, considering that once IL-12 peaks in 
DCs these cells then support Th2 cell development [3] suggests this type of mechanism may 
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not be required. In addition, it has now been shown that DCs are still able to induce CMI in 
the absence of IL-12 p70 [8]. Hence it is possible the IFN-y stimulated DC only develops 
during circumstances of an early immune response to a pathogen that stimulates IFN-y 
production from innate immune cells, and this DC stimulates CMI using as yet unidentified 
mechanisms. 
In conclusion, the studies presented here suggest in an IFN-y abundant 
nlicroenvironment, this cytokine stimulates the development of immunoregulatory properties 
associated with mature DCs, potent T cell stimulatory capacity, anti-viral mechanisms, and 
f ea tu res supportive of CMI. It is interesting to speculate that in the absence of inflammatory 
stimuli, and in the presence of IL-4, a DC may develop properties common to a phagocyte 
with little IL-12 production, lower T cell stimulatory capacity, and enhanced ability to take up 
extracellular pathogens, that together support HI. Finally, at a stage of immunity where Thl 
and Th2 cells come together, an environment may exist that enables DCs to enhance 
phagocytosis for cross-presenting antigen and for antibody mediated endocytic clearance of 
CMI lysed cells. It is now important to extend these studies by further exploring the 
immunoregulatory properties induced by IFN-y+ IL-4, and to cross-compare the findings 
reported here with the response of ex vivo DCs to these cytokine combinations. In addition, 
tracing the immunoregulatory phenotype of DCs at the site of infection throughout the course 
of an immune response v✓ill help to clarify the ongoing role of these cells and how they may 
support a changing immune response. 
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Figure Legends 
Figure 1: Morphological analysis of cytokine stimulated MTHC-D2 cells by TEM. MTHC-
D2 cells were stimulated for 48 h with effector cytokine combinations and CD40 Ab then 
processed for TEM analysis. Each cell is shown at SK magnification. An-ows shown in B 
indicate release of exosomes, and in D indicate vacuoles and apoptotic bodies inside a vacuole. 
Figure 2: Ability of cytokine stimulated MTHC-D2 cells to phagocytose SRBC ' s. MTHC-
D2 cells were stimulated with cytokines for 48 h, and where indicated, were activated with 
CD40 Ab for the final 16 h. MTHC-D2 cells were then co-cultured with SRBC's for 1 h then 
stained and analysed by light microscopy. 
Figure 3: Analysis of MTHC-D2 phagocytosis of SRBC's by TEM. MTHC-D2 cells were 
stimulated with effector cytokine combinations for 48 h followed by co-culture with S RB C's 
for 1 hand processing for TEM analysis. Each cell type is shown at SK magnification. Those 
cells shown were 3a A: un-stimulated MTHC-D2 cells; B: IFN-y+ TNF-a stimulated; C: IL-
4+ TNF-a stimulated; D: IFN-y+IL-4+ TNF-a stimulated. 3b: IFN-y+IL-4+ TNF-a 
stimulated cells degrading SRBCs. Arrow heads refer to dendritic processes on the cell 
surface, whereas arrows refer to SRBCs. 
Figure 4. The ability of cytokine stimulated MTHC-D2 cells to induce T cell proliferation. 
Mixed lymphocyte reactions measured by F 1\ CS staining of proliferating T cells \Vere 
performed using CD90 to detect all proliferating T cells in MLR 1, CD8a to detect CD8 T 
cell proliferation in MLR 2, and CD4 to detect CD4 T cell proliferation in MLR 3. Un-
activated MTHC-D2 cells were used in MLR 1, and CD40 Ab activated MTHC-D2 cells 
were used in MLR's 2 and 3. Legend A refers to MLR's using un-stimulated MTHC-D2, B 
refers to IFN-y + TNF-a stimulated MTHC-D2, C refers to IL-4 + TNF-a stimulated 
MTHC-D2 cells, and D refers to IFN-y +IL-4+ TNF-a stimulated MTHC-D2 cells, the 
negative control refers to MLR reactions containing only T cells. 
Figure 5: Differential expression of immunoregulatory genes in response to IFN-y and IL-4 
cytokine stimuli of MTHC-D2. These cells were stimulated with cytokine combinations and 
CD40 Ab followed by rnRNA extraction, first strand cDNA preparation, and semi-quantitative 
RT-PCR analysis. The genes targeted for expression analysis are listed on the right. Cytokine 
and activation stimuli of cells representing 1-8 are as follows. (1) GM-CSF, (2) GM-
CSF+CD40 Ab, (3) IFN-y+TNF-cx+GM-CSF, (4) IFN-y+TNF-cx+GM-CSF+CD40 Ab, 
(5) IL-4+TNF-cx+GM-CSF, (6) IL-4+TNF-cx+GM-CSF+CD40 Ab, (7) IFN-y+IL-
4+ Tl'--JF-- a+GN1-CSF, (8) IFr\J-·y+ IL-4+ Tt-'1F-a+Gfv1-CSF+rD40 Ab. 
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Table 1. FACS analysis of cell surface marker expression in nesponse to cytokine and activation stimuli. 
Group Antibody Geo-Mean fluorescent intensity and SD of cytokine-stimulated MTHC-D2 cells 
A ACD40 B IBCD40 C CCD40 D OCD40 
Control No stain 2 (0.15) 2 / (0 .07) 3 (0 .06) 3 (0.12) 3 (0.11) 3 (0.06) 4 (0.14) 3 (0.14) 
Co-stimulatory/ CD40 5 (0.29) 6 (0.48) 15 (0.53) 25 (0.98) 17 (2.64) 14 (1 .04) 26 (2.42) 36 (1 .27) 
Activation COBO 7 (0.66) 8 (0 .58) 44 ( 1.58) 66 (1 .68) 29 (0.60) 19 (0.40) 43 (2 .07) B9 ( 1.83) 
CD86 3 (0.05) 3 (0 .06) 10 (0.35) 18 (0.28) 4 (0.23) 6 (0.94) 7 (0.51) 13 (0 .30) 
CD69 13 (0.89) 14 (0.21) 60 (2. 04) 123 (1.07) 43 (0.52) 42 (2.42) 58 (0.4 7) 99 (2.69) 
DC and CD8cx 7 (0.43) 7 (0.14) 11 (0.50) 13 (0.81) 39 (2.70) 29 (2.09) 35 (2.10) 30 (1.52) 
macrophage CD11c 2 (0 .07) 2 (0 .13) 4 (0.02) 5 (0.22) 10 (0 .68) 6 (0.13) 8 (0.04) 18 (0.13) 
markers CD11b 7 (0.51) 8 (0 .27) 17 (0.35) 19 (0.00) 16 (0.00) 13 (0.00) 21 (0.00) 22 (0.45) 
DEC-205 3 (0 .25) 3 (0 .00) 7 (0. 14) 8 (0.16) 8 (0.51) 9 (0.00) 10 (0.38) 14 (0.29) 
CD44 202 (5.13) 225 (5.72) 274 (0.00) :322 (8 .19) 340 (0.01) 340 (0.00) 407 (0.00) 505 (0.00) 
MTHC-D2 cells were stimulated with the following cytokine combinations for 48 h and activated with CD40 Ab for the final 
16 h followed by antibody staining and FACS analysis. A GM-CSF, B GM-CSF+TNF-cx+IFN-y, C GM-CSF+ TNF-cx+IL-4 
D GM-CSF+ TNF- cx+IFN-y+IL-4. SD - Standard Deviation shown in b·rackets. 
TABLE 2. Frequency and Northern analysis of selected known genes up-regulated in cDNA subtracted libraries from cytokine-stimulated MTHC-02 cells. 
Accession/ cDNA Gene Category Subtracted library Expression in MTHC-02 cells 
Medline un-stimulated IFN-y/ IL-4/ 
2 3 4 TNF-a TNF-a 
cDNA clones isolated from IFN-y+ TNF-a specific libraries Clone Frequency 
Chemokines 
M86829/90368683 Crg-2 IFN-y inducible chemokine 65 69 
S37648/92289805 RANTES monocyte chemoattractant 2 4 
M34815/90319087 MIG monkine induced by IFN-y 50 28 
NMD19494/20302783 I-TAC IFN-y induced. T cell chemoattractant 3 0 10 0 
IFN-inducible 
NM011940/99425269 lfi202b IFN activatable protein 3 3 
AF022371/98028407 lfi203 IFN-activatable protein 2 5 
NM008329/90008876 lfi 204 IFN-activatable protein 8 5 
NM008390/ 88311092 IFN regulatory factor 1 Induces IFN genes with anti-viral activity 8 4 
NMD16850 IFN regulatory factor 7 Induces IFN-a+~ in virally infected cells, and RANTES 8 6 
S77713/95203869 lfi54 IFN-alpha regulated gene 8 5 
S77715/ 95203869 lfi56 Viral infection or IFN-y induced 2 12 
S62227/93274206 LPS-inducible gene New member of an IFN-inducible gene cluster in macrophages 5 4 
M21117/89096892 Mx1 IFN-induced nuclear protein that inhibits influenza virus repl ication 7 8 
U15635/95190404 Mg11 IFN-y induced. Contains GTP binding motif 5 8 
M63961/92091752 Mag-1 IFN-y inducible protein . Accompanies Th 1 cytokine expression. 22 15 
NM013673/97422606 Sp100 IFN-inducible transcription factor. Role in early anti-viral response. 5 
Immune response 
M57890/91035430 Factor B Alternative complement pathway 8 5 
NM009982/97276897 Cathepsin C Activation of granzymes and COB T cell cytolytic activity 2 
L38281 /95237894 lrg-1 Immune responsive gene 9 21 
AJ007971/99077537 IIGP protein GTPase, infection induced 1 10 
M 16238/87175527 Fibrinogen-like protein In cytotoxic T lymphocytes but not helper Tor B lymphocytes. 3 2 
BC004059 Pre-8 cell colony-enhancing factor cytokine acts on early 8-lineage precursor cells 3 10 7 
Cell surface proteins 
L23638/933 14711 CD69 Early activation antigen. 3 2 10 3 
NM010387/92018224 MHC II Antigen presenting Major Histocompatability Complex Class II 7 
M63286/91244839 Mannose-6-phosphate receptor Sorts enzymes to lysosomes and association with phagocytosis 5 10 9 
Signalling 
GTP binding proteins (13 types) IFN-inducible GTP binding proteins 52 45 
GBP binding protein (12 types) IFN-y regulated genes in macrophage activation 83 64 
NM010260/99074031 GBP-2 Example of GBP protein 4 3 0 10 0 
BC010229 Similar to GBP-3 Example of GBP protein 2 10 10 1 
AF349678 STAT-1 Signal transducer 10 12 2 10 3 
BC004808 Similar to STAT-1 Signal transducer 4 5 10 5 
NM019963 STAT-2 Signal transducer 3 2 10 3 
Others 
AF020772/980341601 lmportin alpha 02 Nuclear Transport 9 10 6 
NM011909/99182491 Ubiquitin specific protease, Usp18 Protein degradation 4 3 10 3 
AF068835/99323969 M1204 Oligoadenylate synthetase induced in maturation of dendritic cells 2 
TABLE 2 cont. Frequency and Northern analysis of selected known genes up-regulated in cDNA subtracted libraries from cytokine stimulated MTHC-D2 cells . 
Accession/ cDNA Gene Category 
Medline 
cDNA clones isolated from IL-4+ TNF-a specific libraries 
Cytokines and Chemokines 
M13177/86168129 TGF-p Transforming growth factor. Mitogenic factor 
X06086/88076849 MEP Major excreted protein A remodelling of ext racellular matrix secreted cathepsin 
L 11237/94030619 C10 Related to macrophage inflammatory prolein 
X 12531 /88258380 MIP Macrophage inflammatory protein 
S71251 /94271193 Chemotactic protein-3 Monocytic chemotatic protein from macrophages 
Cell surface proteins 
NM01 0796/92268032 Mg1 receptor On surface of macrophages involved in binding to tumor cells 
NM010188/87042761 FcyR Binds Fe portion of lgG. Mediates endocytosis Ab/Ag complex. 
AF272948/2 11 72992 G-protein-coupled Receptor 84 Chemokine receptor and enhances endocytos is 
D87967 /97223399 SHPS1 Cellular adherence and outgrowth 
X66532/923471 74 L-14 Lectin involved in cell differentiation 
NM008625/93043353 Macrophage mannose receptor Phagocytic receptor for micro-organisms. IFN-y down regulated 
X 13335/91197896 MS2 macrophage-specific cysteine-rich transmembrane glycoprotein 
X16834/90063462 Mac-2/L-34 galactoside binding lectin galactose-specific lectin that binds lgE 
NM011027 Purinergic receptor, P2X ligand-gated ion channel 
S36676/92268032 galactose/N-acetylgalactosamine lectin Expressed on tumoricidal macrophages 
Cytoskeleton 
AC091473/90361737 Actin binding protein Actin cross-linking phosphoprotein of peripheral cytoplasm 
Z31399/95041331 Cclh Cytosolic protein involved in folding actin and tubulin 
X60671/93055012 Ezrin Associates short actin filaments with the plasma membrane 
NM010354/89327303 Gelsolin gene Restructures actin filaments inducing cell shape change 
U16740/97470757 Capping protein alpha 1 subunit Aclin assembly and cell motility 
NM011655/87057644 Bela tubulin Cytoskeleton re-structuring 
NM009609/89127235 Cytoplasmic gamma aclin Supports morphological changes, dendrities and cell motil ity 
AF301152/21448996 CAS Associates with microtubules in proliferating cells 
Lysosomal 
U49351 Lysosomal alpha-glucosidase carbohydrate- hydrolases 
M28541 /8938464 1 Beta-glucoronidase Lysosomal hydrolase 
NM007798/9 1190267 Cathepsin B Lysosomal thiol proteinase . Involved in processing of antigen 
NM009984/8627 17 44 Cathepsin-L MHC II antigen processing 
NM007800/97362044 Cathepsin-G MHC II antigen processing 
NM010686/96299782 LAPTm5 Lysosomal-associated multitransmembrane protein 
M32017/90307738 Lgp-B Lysosomal membrane glycoprolein 
M21050/88320416 Lysozyme M Expressed strongly in macrophages 
Cell migration 
AF026124/99030428 SAM9 Involved in post-migration of neurons 
X85991/95267431 Semaphorin B Acts as growth cone guidance signals, axonal pathfinding 
Immune response 
K02782/85038854 Complement C3 Binds Ag/Ab complexes and tagets to phagocytes for clearance 
X12905/88318954 Complement properdin Alternative pathway. Enhances complement mediated clearance 
Signalling 
X99644/97133299 TIF1 Reacts with nuclear receptors and transcription factors 
X17400/90016295 TIS? Autocrine factor that amplifies initial ligand induced signal 
NM009811 /97 190206 Caspase-6 Nuclear events of apoptosis 
U36277/96235048 I-Kappa 8 alpha chain Inhibitor of transcription factor NF- 1eB 
AF232716/20307889 Protein arginine N-methyltransferase 1 Signal transduction 
NM021420/97304522 serine/ threonine kinase 4, Stk4 Signal transduction 
NM019744 Nuclear receptor co-activato r 4 Transcri ption regulation 
Others 
NM01 1456/97326124 serine protease inhibitor 14 Regul ators of extracellular proteolysis 
NM033075/97124840 G7e Resembles a vi ral envelope gene in MHC class Ill gene region 
cDNA clones isolated from both the IFN-y+ TNF-a and IL-4+ TNF-a specific libraries 
D89572/97420681 
M83312/92105763 
X52264/89345188 
M 18466/88088825 
U4 7327 /99086740 
NM009735/840285 77 
NM011530/91102550 
M 1344 6/87064538 
Ryudocan core protein 
CD40 
ICAM-1 
Ly-6C.2 
Alpha-tubulin isotype M-alpha-2 
NM007807/96202527 gp91 phox 
Cell surface proteins 
Cell adhesian, neurite growth promotion, anticoagulation 
Co-stimulatory molecule 
lntercellular adhesian molecule 
Lymphocyte differentiation antigen 
Antigen processing 
Antigen presenting major histocompatabitility complex class I 
Complexes with MHC molecules on the cell su riace 
Transporter gene 
Cytoskeleton 
Microtubule formation 
Phagocytosis 
Transfers electrons from NADPH in respiratory burst oxidase 
Subtracted library 
1 2 3 4 
Clone Frequency 
2 
6 
8 
3 
2 
2 
2 
2 
4 
4 
3 
3 
2 
2 
6 
8 
3 
1 
1 
1 
2 
4 
4 
1 
2 
3 
2 
4 
1 
2 
1 
3 
10 
2 4 
5 3 
2 2 
3 
7 2 
1 4 3 
3 15 
5 
2 2 
Expression in MTHC-D2 cells 
un-stimulated IFN-y/ 
10 
6 
8 
3 
8 
10 
0 
2 
8 
9 
7 
10 
10 
7 
2 
2 
7 
5 
3 
8 
9 
5 
2 
TNF-a 
7 
6 
10 
9 
3 
6 
10 
3 
7 
7 
10 
5 
6 
7 
7 
2 
10 
9 
10 
10 
10 
7 
10 
9 
10 
10 
10 
10 
9 
6 
10 
10 
10 
10 
9 
9 
iO 
10 
10 
7 
10 
3 
3 
9 
10 
9 
IL-4/ 
TNF-a 
Selected cDNA subtracted clones from cytokine-stimulated MTHC-D2 cells having >95% over> 100 bp homology with known genes associated with cytokine stimulation, dendritic and 
macrophage maturation/function , and the immune system are shown in this table . cDNA's are clustered according to which subtracted libraries they were isolated from. Subtracted library 
1 : IFN-y+ TNF-o. subtracted from IL-4+ TNF-o. stimulated MTHC-D2 cells; 2 : IL-4+ TNF-o. subtracted from IFN-y+ TNF-o. stimulated MTHC-D2 cells; 3: Un-stimulated MTHC-D2 cells 
subtracted from IFN-y+ TNF-o. stimulated cells; 4: Un-stimulated MTHC-D2 cells subtracted from IL-4+ TNF-a stimulated cells. The frequency of each clone from the respective libraries is 
given . Selecled cDNA clones were further analysed by northern blot screening to establish the comparative expression levels in each cytokine-stimulated MTHC-D2 cell type. For northern 
analysis the MTHC-D2 cells were stimulated with cytokines for 6 h followed by mRNA extraction and northern blotting. cDNA clones were radioactively labelled and hybridised to the 
northerns . Phosphorlmager us ing lmageOuant software was used to quantitate the differential expression. Band intensity values for each northern were normalised to GAPDH and 
scaled such that lhe highest band value on all northerns was 10. 
Table 3. Similarities between splenic ex vivo DCs and cytokine stimulated IVITHC-O2 cells. 
Cell property , 
Similar pattern of p40 gene expression 
as DCs that produce high levels IL-12 p70 
Similar pattern of p40 gene expression 
as DCs that produce low levels IL-12 p70 
Greater levels of DEC-205 
expression 
Expression of CD8cx and CD4 in 
the pres·ence/production of IFN-y 
MHC I expression/function 
MHC II expression/function 
Correlat ion 
Ex vivo DCs 
CDBcx+ 
IFN-y+IL-4 stimulated 
coscx-
lFN-y stimulated 
CDBcx+ 
coscx- co4-
CDScx+ DCs are more efficient than 
CDscx- DCs at cross-presenting antigen 
on MHC I to CDS T cells 
CDscx- DCs are more efficient than 
CDBcx+ DCs at directly presenting antigen 
on MHC II to CD4 T cells 
MTHC-O2 
CD8cx high 
IFN-y+IL-4 stimulated 
CD8cx low 
IFN-y stimulated 
CD8cx high 
IFN-y+IL-4 stimulated 
CD8cx low co4-
CD8cx high, IL-4 stimulated cells 
express greater levels of MHC I 
than CD8cx10w IFN-y stimulated cells 
CD8cx low, IFN-y stimulated cells 
express greater levels of MHC II 
than CDScxhigh IL-4 stimulated cells 
